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Chapter 1
General introduction
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1.1	 Inflammatory	Bowel	Disease
The two major forms of inflammatory bowel disease (IBD), Crohn’s disease (CD) and 
ulcerative colitis (UC) are characterized by chronic relapsing intestinal inflammation [1]. 
This life-long disorder may occur at any time, although 80% of the cases are diagnosed in 
early adult life. The incidence and prevalence of IBD are increasing with time and affects 
nowadays approximately 3.6 million people in the USA and Europe [2]. UC is limited to the 
colon, and microscopical features include superficial inflammation infiltration in the mucosa 
and submucosa with cryptitis and crypt abscesses. By contrast, CD involves any part of 
the GI-tract in a non-continuous fashion. Histologically, CD is characterized by thickened 
submucosa, transmural inflammation and tissue ulcerations [1]. The exact etiology of IBD 
is largely unknown but genetic, environmental and intestinal microbial factors have been 
reported to play a role [3]. Moreover, these inflammatory diseases result in an inadequate 
balance between T regulator (Treg) and T effector responses, in particular Th1/Th17 cells in 
CD and Th2 cells in UC [4].
1.1.2	 IBD	genetics
Genome wide association studies (GWAS) have identified 163 genetic risk loci underlying 
IBD susceptibility [5,6]. 30% of these genetic loci are shared between CD and UC, suggesting 
similar genetic predispositions and pathological pathways. IBD susceptibility genes are 
linked to pathways/processes involved in intestinal homeostasis, including barrier function, 
innate immune function, reactive oxygen species generation, endoplasmic reticulum stress 
and metabolic pathways associated with cellular homeostasis [7]. Susceptibility genes 
related to the innate immune response include a repertoire of innate immune receptors like 
NLRP3, RIG-1, TLR3, TLR5 and NOD2 [8-11]. Mutations in NOD2 impairs activation of NF-
κB in response to peptidoglycan through the recognition of muramyl dipeptide(MDP), thereby 
modulating both innate and adaptive immune responses [12]. Also expression profiles of 
adaptor molecules involved in TLR/NOD signaling pathways are affected in IBD patients 
e.g. CARD9. Depending on the stimulus, CARD9 interacts with distinct signaling complexes 
and activates different pathways to modulate cytokine environments properly [4]. Defective 
CARD9 function results in failure to promote an adequate Th17 immune response against 
intracellular pathogens [13]. Other genetic associations in the innate arm of the immune 
system comprise the autophagy related genes ATG16L1 and IRGM [14,15]. Autophagy 
represents the self-digestion of organelles and ingested extracellular bacteria and other 
types of pathogens via lysosomal degradation, and defects are implicated in the immuno 
pathogenesis of IBD [16,17]. GWAS also identified susceptibility genes related to the adaptive 
arm of the immune system, and includes TNFR15, IL-2, JAK2, TYK2, STAT3, CCR6, and IL-
23R [18]. IL-23R is a key differentiation feature of CD4+Th17 cells that are critical in mediating 
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antimicrobial defenses [19]. Balancing between IL-17/Treg responses is critical for optimizing 
defenses to microbes while simultaneously avoiding chronic tissue inflammation. Another 
IBD linked locus involves genes linked to anti-inflammatory responses like IL-10, IL-27 and 
IL-10Rα, demonstrating the importance of a proper balance of pro and anti-inflammatory 
regulators. However, the heterogeneity of IBD and the low disease penetrance in individuals 
carrying disease-susceptibility alleles suggest that several host and environmental factors 
interact to cause IBD [20]. Therefore, the so-called multi-hit hypothesis was proposed, were 
the induction and perpetuation of chronic intestinal pathology requires at least two triggers 






To study the pathogenesis of IBD, many animal models have been developed reflecting 
different aspects of disease, but no model completely recapitulates the characteristics of 
human disease [21]. Most IBD models result from exogenous manipulation; they can be 
categorized based on induction by chemicals, pathogens, immune cell transfer, or gene 
targeting [22].
Spontaneous development of colitis occurs in mice with particular genetic defects produced 
by either gene targeting or the introduction of a transgene, including IL-10 knockout mice and 
TNF(Δare) transgenic mice. Also transfer of CD45RB+ T cells to immune-deficient mice results 
in the development of colitis [23]. One notable disadvantage of these models is that they are 
established in immune-compromised mice in contrast to chemically induced models.
Most widely chemical induced models used for preclinical efficacy studies are dextran 
sulfate sodium induced (DSS) and trinitrobenzene sulfonic acid (TNBS) colitis. In the DSS 
model, the epithelial layer is disrupted resulting in increased permeability and translocation 
of intestinal bacteria. After induction mice develop colonic inflammation, which do not require 
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adaptive immune cells. Therefore, this acute model is suitable to study the effect of new 
compounds on epithelial cell barrier. The TNBS colitis model is a hapten-induced colitis 
model, based on the intrarectal administration of TNBS in ethanol. Inflammation is induced 
by a two-step process; first the ethanol impairs the epithelial barrier. Subsequently, TNBS 
haptenizes autologous antigens and microbial proteins rendering them immunogenic to the 
host [24]. Notably, all models for intestinal inflammation are driven by the resident microbiota, 
since inflammation fails to develop in germ-free mice [25,26].
1.2.1	 Crosstalk	between	the	intestinal	microbiota	and	the	immune	system
As indicated in the previous paragraph, disturbance of the dynamic balance between 
microbes, particularly commensal flora, and host defensive responses at the mucosal frontier 
plays a pivotal role in the initiation and pathogenesis of chronic IBD. Immediately after birth, 
the mammalian gastro-intestinal tract (GI-tract) is colonized by a dynamic community of 
microorganisms, referred to as the gut microbiota [27]. The human microbiota consists of 
1014microbial cells, with highest densities in the distal colon with up to 1011-1012 organisms per 
gram of luminal content [28]. This microbiota community establishes a symbiotic relationship 
with its host. They supply essential nutrients and metabolize indigestible compounds, and 
defend against the colonization by pathogenic bacteria, while occupying a protected nutrient 
rich environment [29]. The intestinal immune system, which is exposed to an enormous 
bacterial load, has a critical role in limiting tissue invasion by these resident bacteria. Host-
microbiota homeostasis is achieved by various immunological barriers. The first barrier is 
the limitation in exposure of the epithelial layer to luminal content by secretion of mucus, 
anti-microbial peptides and IgA, thereby creating a physical barrier. Bacteria that penetrate 
this semi-sterile layer and breach the epithelial barrier are recognized by innate immune cells 
and undergo rapid phagocytosis followed by the induction of various T cell responses [30].
Interactions between microbes and the host are of critical importance in orchestrating the 
immune system, as shown in studies with germ-free mice. Germ-free mice are sterile mice 
and show defects in the development of gut associated lymphoid tissue (GALT)[31] reflected 
by reduced antibody production by IgA plasma cells [32], fewer Peyer’s Patches (PP) and 
mesenteric lymph nodes(MLN) as well as impaired development of isolated lymphoid follicles 
[29]. In these mice, the structure and function of epithelial cells is also impaired, which is 
reflected by decreased rates in cell turnover and altered microvilli structures. Moreover, 
absence of microbiota impairs proper balance of chemokine, cytokine and defensin production 
by intestinal epithelial cells (IEC) and immune cells. Altogether, these defects make germ-
free mice more susceptible to infection by pathogenic bacteria, viruses and parasites. Host-
microbiota interactions not only shape the immune system, but in turn the immune system 
also shapes the composition of the microbiota. This was demonstrated in a study with TLR5 
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deficient mice that lack the receptor for bacterial flagellin [33]. Absence of TLR5 results in 
changes in the composition of the microbiota and symptoms of the metabolic syndrome.
1.2.2	 Dysbiosis	of	the	microbiota	and	disease
Dysbiosis refers to the imbalance in the composition of the microbiota, which includes the 
outgrowth of potentially pathogenic bacteria and a decrease in bacterial diversity and bacteria 
beneficial to the host [34]. Factors contributing to dysbiosis include host genetics, altered 
microbes exposure, and medical practice like vaccination and use of antibiotics. Moreover, 
lifestyle which includes diet, stress and hygiene could also contribute to dysbiosis. Resultant 
changes in host-microbiota interactions might underlie the large increase in the incidence of 
several immune related disorders such as atopic dermatitis, IBD, asthma, rheumatoid artitis 
and multiple sclerosis [35]. Data supporting this ‘altered microbiota’ interpretation include 
the correlation between asthma/allergies and use of antibiotic in industrialized countries 
[36], and the correlation between GI-microbiota of newborns and the development of allergic 
diseases [37].
In the context of intestinal disorders, an altered gut microbiota has been observed in 
patients with inflammatory bowel disease compared to healthy individuals [38,39]. However, 
no pathogenic species have been identified so far. It might be that in normal conditions 
commensal bacteria do not elicit an immune response but have the potential to become 
pathogenic only when genetic or environmental conditions are altered in the host [28]. These 
species are reflected to pathobionts which cause an immunological disequilibrium under 
conditions of dysbiosis.
1.2.3	 Immune	modulation	by	probiotics
Since the microbiota is of critical importance in shaping the intestinal immune system, 
modulation of the microbiota with pre-or probiotics might be a useful strategy to prevent 
immunological disorders. Probiotic have been defined by the WHO as “live micro-organisms 
which when administered in adequate amounts confer a health benefit for the host” [40]. 
Most probiotics are gram positive lactic acid bacteria, mainly consisting of Lactobacillus and 
Bifidobacterium species [41], but also the gram negative Escherichia coli strNissle 1917 has 
been shown to exert beneficial effects [42].
Several mechanisms of action have been proposed in which probiotics assert these 
beneficial effects. First, they can interfere with the ability of pathogens to colonize and infect 
the mucosa [43]. This can be achieved by either direct inhibitory effect on pathogens, by 
competitive exclusion, or through the influence of probiotic bacteria on the composition of 
the endogenous commensal flora [44]. Secondly, probiotics have been shown to stabilize 
and maintain the intestinal barrier. Enhancement of epithelial barrier function can be 
achieved through general antimicrobial effects like the secretion of mucus or defensins 
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[45], effects on epithelial cell survival [46], and modulation of tight-junction function [47,48]. 
Furthermore, probiotics may modulate enzymatic activity in the intestine, for example by 
inhibition of pro-carcinogenic enzymes or the induction enzymatic activity that favors food 
nutrition [49]. Probiotics may also directly modulate local en systemic immune responses of 
the host [50,51]. Direct modulation occurs after interaction of these bacteria with epithelial 
and (innate) immune cells in the intestinal mucosa, which contains the largest reservoir of 
immune cells in the body. Compared to the colon, endogenous bacteria load is relative low in 
the small intestine, and thereby the most likely target site for probiotics in the modulation of 
innate and adaptive immune responses [52].
1.3.1	 Microbial	sensing	via	pattern	recognition	receptors
Pattern recognition receptors (PRR) include Toll-like receptors (TLR), nucleotide binding 
oligomerization domain receptors (NOD-like receptors), and C-type lectin receptors [53]. 
These receptors recognize a variety of microbial components and allow (innate) immune 
cells to sense pathogens associated molecular patterns (PAMP) on bacteria, viruses, fungi 
and parasites, but also endogenous danger associated molecular patterns.
In the intestine, these receptors are expressed on IEC and antigen presenting cells (APC) and 
play a central role in governing the interface between host and microbiota [54]. Cell surface 
TLR recognize mainly bacterial surface products such as lipopeptides and peptidoglycan 
(TLR 1, -2, -6), lipopolysaccharide (LPS) – a major component of gram negative bacteria 
(TLR4), and flagellin (TLR5). TLR 3, -7, -8 and 9 reside in the intracellular organelles and 
sense microbial nucleic acids [55]. NOD-like receptors detect peptidoglycan components 
of the bacterial cell wall [56]. In contrast, C-type lectin receptors recognize specific 
carbohydrate structures on self-antigens or cell wall components of pathogens. Their main 
function is to internalize antigens for degradation in lysosomal compartments to enhance 
antigen presentation [57,58].
Despite various physical barriers, PRR in the gut are exposed to an enormous microbial 
load. To prevent excessive activation of these receptors, the host has developed a set of 
redundant overlapping processes to prevent disproportionate immune activation in steady-
state conditions, while maintaining the ability to be activated upon infection [59]. These 
strategies to avoid excessive activation of immune cells include the expression of negative 
regulators of TLR signaling upon activation, like IL-10, Tollip and IL-1Ra [60,61] or the co-
stimulation of receptors like DC-SIGN that interfere with TLR signaling [62]. Selective 
expression of PRR on innate immune cells also prevents aberrant receptor activation. 
Under homeostatic conditions for example, TLR2 and TLR4 and several co-factors required 
for signal transduction are barely expressed, but these receptors become up-regulated 
upon inflammation [63]. Selective TLR5 expression on the basal site of IEC is also such 
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a mechanism in which the host only responds to flagellin-bearing bacteria that invade the 
epithelium layer[64].
1.3.2	 Dendritic	Cells	in	the	gastro-intestinal	tract
Dendritic cells (DC) are professional bone marrow derived antigen presenting cells (APC) 
that migrate from peripheral tissues to secondary lymphoid organs for antigen presentation 
to T cells [65]. In the gut, DC continuously migrate from the mucosa to the MLN, thereby 
inducing tolerance to “self” and food antigens or protective immunity [66]. Antigen-uptake by 
mucosal DC can be facilitated by microfold cells, that are specialized epithelial cells found 
on the surface of the follicle-associated epithelium (FAE) that transfer antigenic material to 
DC beneath the epithelia layer [67]. The process of antigen-uptake can also, although less 
efficient, be facilitated by epithelial cells. Moreover, DC can also sample antigens directly with 
dendrites that stick through the epithelium into the lumen [68]. Since the intestinal mucosa 
is an important entry site for pathogens, but also home to a large and diverse commensal 
microflora, intestinal APC have to discriminate between friend and foe. The mechanisms by 
which various intestinal DC subsets respond to environmental triggers, thereby shaping local 
immune responses will be discussed in the following paragraphs.
1.3.3 Intestinal DC subsets
In the gut, APC are found in the lamina propria (LP), isolated lymphoid follicles, PP, and 
the MLN. APC that survey the intestinal mucosa comprise several different phenotypes 
dependent on their anatomical localization. This APC pool includes various subpopulations 
of macrophages, conventional CD11chi DC, and plasmacytoid DC (pDC). All subtypes 
have been adapted to the intestinal environment to prevent the generation of destructive 
inflammatory responses, but ensure protection against enteric pathogens [69]. Classification 
of intestinal DC subsets is often based on the expression of cell surface receptors.
DC found in the PP, which are organized lymphoid structures in the small intestine, are 
mainly consist of CD11chiCD11b+CD8α-, CD11chiCD11b+CD8α+ and CD11chiCD11b-CD8α- 
conventional DC [70]. These DC modulate T-cell skewing, where CD11b+ DC are linked to 
Th2 polarization contrary to CD8α+DC that induce Th1 responses.
Mononuclear phagocytic cells located in the LP can be divided into different subgroups 
with functionally different properties and can be distinguished by the expression of surface 
receptors. Main subtypes include CX3CR1–CD68–CD103+ DCs and a population of 
classical macrophages that are CX3CR1+CD68+F4/80+ [71,72]. CD103+DC subset express 
2,3-dioxgenase (IDO) and drive regulatory T-cell (Treg) development in the MLN via TGF-β 
and retonic acid [73,74]. By contrast mouse CX3CR1
+phagocytes have been shown to drive 
the development of naïve T cells to Th1 and Th17 cells [75,76], presumably via a flagellin or 
ATP-dependent mechanism [77] as shown in figure 2.
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1.4	 	Shaping	intestinal	immune	cell	populations	by	selective	
chemokine expression
As described in the previous section, mucosal DC can elicit effector responses that lead 
to the secretion of distinct patterns of cytokines thereby dictating the skewing of naïve Th 
cells to effector T cells. Likewise, small chemo-attractive cytokines defined as chemokines, 
play a critical role in directing the balance between physiological and pathophysiological 
inflammation in health and IBD [78]. Chemokines secreted by IEC and APC in the intestinal 
mucosa play an important role in shaping immune cell populations, - including B, -T 
lymphocytes, neutrophils and mast cells - by targeting specific receptors on these cells [79].
In conditions of homeostasis, a subfamily of so called homeostatic or constitutively expressed 
chemokines play a key immune-surveillance role in lymphocyte and DC trafficking between 
primary and secondary lymphoid tissue [80].These chemokines include CCL25 and CCL28 
which are produced by epithelial cells of the small intestine and colon, respectively [81]. 
Also CCL9, CCL20 and CXCL16 produced in the FAE are defined as homeostatic since they 
contribute to the organization and shaping of this tissue in steady state conditions.
Another class of chemokines comprises those that are induced upon inflammation, which 
lead to the recruitment of leukocytes, including DC, to the inflamed tissue. Active inflamed 
tissue of inflammatory bowel disease patients showed increased expression levels of 
CXCL8, CCL2, CCL3, CCL4 CCL11 and CCL24 [82], which resulted in increased trafficking 
and localization of monocytes, NK-cells and T lymphocytes in the mucosa. Since leukocyte 
infiltration into the intestine is a fundamental event in disease development and progression, 
modulation of chemokine expression might be a suitable strategy to dampen inflammation.
1.5	 Aim	of	this	thesis
This thesis aimed to provide insight into the role of microbiota-host interactions in the 
regulation of mucosal and systemic immunity in the context of IBD. Regulation of microbiota 
composition (e.g. by probiotics and prebiotics) offers the possibility to modulate immune 
responses and contribute to the prevention and treatment of (autoimmune) - diseases.
By evaluating immune modulation capacities of probiotics with genome-wide gene 
expression profiling in both in vivo and in vitro models, novel mechanisms were identified in 
which probiotic bacteria modulate immune responses under conditions of homeostasis and 
inflammation. These new insights will allow more rational selection and validation of probiotic 
usage in a variety of clinical conditions.
Chapter 2 describes the characteristics of the recurrent TNBS colitis model in BALB/c mice. 
Processes underlying the development of pathology in this model were identified by temporal 
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gene expression profiling of the colon. It is demonstrated that the recurrent TNBS-induced 
colitis model combines histopathological features with aspects of active inflammation and 
chronic processes of cellular infiltration, angiogenesis and tissue remodeling, which are all 
relevant to human IBD. Furthermore, the sensitivity of the model for immunosuppression 
by local treatment with budesonide was evaluated. In chapter 3 this model was used to 
evaluate the efficacy of two probiotic preparations – L.plantarum and VSL#3–in dampening 
intestinal inflammation. To this end, genome wide screening of inflamed colonic tissue was 
applied in order to identify processes and pathways that are modulated by probiotics.
The interaction between the intestinal microbiota and the gut-associated mucosal immune 
system is considered to play a key role in inflammatory diseases in the gut [83], as well 
as at peripheral sites like the skin [84][85,86]. In chapter 4, the association between gut 
inflammation and atopic dermatitis was studied in human ApoC1+/+ transgenic mice that 
display features of atopic dermatitis. Furthermore, the potential suppressive effect of 
probiotic bacteria was evaluated in this model. To further substantiate the observed immune 
modulating effects of probiotic bacteria in mouse models, the modulation of bone-marrow 
derived dendritic cells was studied. To account for the genetic variation among populations, 
DC derived from mice with different genetic backgrounds were studied. Emphasis was 
put on the modulation of TLR and their downstream signaling pathway, since immune-
modulatory effects of commensal and probiotic bacteria may rely on their interaction with 
these receptors. The studies described in chapter 5 refer to the activity of VSL#3 – a mixture 
of 8 probiotic strains – as an approach to the complexity of different types of interaction in 
vivo as opposed to the effects of ultrapure ligands which may only interact with single TLR. 
To facilitate translation of observations with mouse DC to the human setting, the effects of 
probiotic bacteria on human DC were evaluated as well. Chapter 6 describes the effect of 
probiotics on human monocyte derived DC with emphasis on the modulation of cytokine 
and chemokine expression, employing dedicated gene arrays and multiplex protein profiling. 
Furthermore, we aimed to identify pathways accounting for the anti-inflammatory effect of 
probiotics on DC.
The in vivo models employed in this thesis are likely to have compromised intestinal barrier, 
which could facilitate the accessibility of the probiotics to the immune cells and the lymphoid 
tissues. Therefore, studies in the disease state may not reflect and predict the immune- 
modulatory effects of probiotic bacteria in healthy individuals. This issue was addressed 
in chapter 7, where the immune-modulatory effects of probiotic bacteria in healthy, non-
diseased mice were evaluated. Finally, Chapter 8 and Chapter 9 (in Dutch), present the 
general discussion, giving an comprehensive overview of the performed work and elaborate 
on future application of probiotic bacteria in modulating immune responses in health and 
disease.
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Abstract
The recurrent TNBS-colitis model in BALB/c mice has been proposed as a model of 
Inflammatory Bowel Disease with a shifting pattern of local cytokines with the expression 
of Th1 cytokines during the early phase, Th17 cytokines during the intermediate phase 
and Th2 cytokines during late fibrotic stages. In this study, we evaluated the development 
of pathology in time-in conjunction with genome-wide gene expression in the colons-, in 
response to three weekly intrarectal instillations of TNBS. During this time-frame mice 
develop colitis with extensive cellular infiltration of (sub)mucosa and mildly to moderately 
affected crypt architecture. These pathological processes were sensitive to local treatment 
with budesonide. Gene expression profiling confirmed an acute phase response after each 
intrarectal TNBS-challenge. In addition, a chronic inflammatory process developed over time 
particularly evident from a gradual increase in expression of mast cell related genes. The 
changes in pathological hallmarks were consistent with a temporal expression of mRNA 
encoding a selection of chemokines. In conclusion, the early stages of the recurrent TNBS-
colitis model reflect several aspects of inflammatory bowel disease which are sensitive to 
immunomodulation.
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Introduction
Inflammatory Bowel Diseases (IBD), with Ulcerative Colitis (UC) and Crohn’s Disease (CD) 
as major entities, are chronic inflammatory disorders of the gastrointestinal tract, affecting 
an estimated 3.6 million people in Europe and the US [1]. IBD may be chronic or relapsing 
in nature, possibly due to a process of inflammation following an exaggerated immune 
response against enteric microorganisms. These processes affect intestinal function leading 
to diarrhea, cramping, and abdominal pain. Although considerable progress has been 
achieved with regard to the multifactorial nature of IBD [2], current therapies show limited 
efficacy [3].
Although there is a clear medical need to develop novel anti-inflammatory therapy for IBD, 
the evaluation of novel therapeutic strategies is hampered by the availability of suitable 
preclinical efficacy models. Most frequently, acute colitis models such as dextrane sodium 
sulphate (DSS) and the 2,4,6-trinitrobenzene sulfonic acid (TNBS) induced colitis are used 
[4,5].These models are characterized by severe acute inflammation of the colon representing 
histopathological aspects that reflect human IBD. Whereas the DSS-colitis model involves 
activation of the innate immune system in particular, the TNBS model was shown to depend 
on a local Th-1 biased response [6]. The acute chemically induced IBD models have been 
shown of great value for a better understanding of acute inflammatory disease processes in 
IBD. In addition, efficacies of a limited number of relevant treatments have been reported in 
these models [7-9].
As an alternative to chemically induced colitis, several models helped to gain valuable insight 
into the underlying pathology of IBD, such as the model based on transfer of CD45RBHi 
CD4+ T cell to immunodeficient recipients or the development of colitis in IL-10 deficient mice 
[10,11]. These models put emphasis on the role of the intestinal microbiota eliciting a chronic 
inflammatory response in the gut. However, because these models are performed in an 
immunodeficient environment with disturbed immunoregulatory circuits they are not always 
suitable for the evaluation of novel therapeutic strategies.
In recent years, several groups have demonstrated that repeated intrarectal administrations 
of low-dose TNBS to mice and rats result in chronic colitis [12,13]. This colitis model has 
primarily been used to study fibrotic processes as a consequence of chronic intestinal 
inflammation [14,15]. Recently, we have implemented a modified protocol of the chronic 
TNBS colitis model with reduced duration, in which treatment with probiotics was shown to 
prevent the onset of chronic colitis and associated clinical symptoms, suggesting sensitivity 
to immunomodulation [16] .
In this report, we characterize the processes underlying the development of pathology in this 
model by temporal gene expression profiling in the colon with the aim to further substantiate 
the value of this model for both mechanistic and pre-clinical efficacy studies. We show that 
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the recurrent TNBS-induced colitis model combines histopathological features with aspects 
of active inflammation and chronic processes of cellular infiltration, angiogenesis and tissue 
remodeling, which are all relevant to human IBD.
Figure	1.	Disease	characteristics	of	the	recurrent	TNBS	model	and	efficacy	of	budesonide	
treatment. 
The development of colitis induction is evident from periods of loss of body weight following each 
rectal instillation of TNBS (Figure 1A; AUC p<0.005). At end-point, inflamed colons show significantly 
increased weight/length ratios and colon thickness (Figure 1B); both aspects are suppressed by 
budesonide. TNBS colitis induction is associated with a significantly increased histological score 
(Figure 1C); this score is significantly lower in budesonide treated animals. Bars represent group mean 
values of 10-12 mice / group, error bars represent SEM. Mann-Whitney U-test; * p<0.05, ** p<0.01, *** 
p<0.001
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In this study, we evaluated early stages of the recurrent TNBS colitis model and confined 
ourselves to 4 weeks of follow-up after skin sensitization and three weekly intrarectal 
challenges with increasing dosages of TNBS, thereby combining two previously published 
protocols [5,15]. This adapted protocol consistently resulted in mild to moderate colitis, 
reflected by significant growth retardation(p <0.005) (Figure 1A).Each rectal TNBS instillation 
Table 1. Relative circulating cytokine concentrations in TNBS-induced colitisa
 Group
Cytokine Healthy	(n=14) Vehicle	(n=19) Budesonide	(n=15)
Eotaxin 100% ± 5% 102% ± 9% 89% ± 10%
G-CSF 100% ± 10% 114% ± 9% 83% ± 8%c
GM-CSF 100% ± 4% 108% ± 5% 98% ± 7%
IFNγ 100% ± 10% 137% ± 12%b 93% ± 14%c
IL-10 100% ± 25% 194% ± 37% 54% ± 16%
IL-12p40 100% ± 8% 87% ± 7% 28% ± 4%c
IL-12p70 100% ± 15% 117% ± 19% 89% ± 11%
IL-13 100% ± 9% 133% ± 12% 82% ± 10%c
IL-17 100% ± 13% 153% ± 17%b 94% ± 12%c
IL-1α 100% ± 19% 93% ± 12% 87% ± 17%
IL-1β 100% ± 8% 135% ± 12%b 82% ± 9%c
IL-2 100% ± 11% 118% ± 12% 84% ± 12%
IL-3 100% ± 13% 137% ± 14% 104% ± 13%
IL-4 100% ± 15% 111% ± 12% 85% ± 14%
IL-5 100% ± 6% 111% ± 12% 72% ± 8%c
IL-6 100% ± 15% 122% ± 9% 82% ± 9%c
IL-9 100% ± 9% 118% ± 8% 84% ± 8%c
KC 100% ± 7% 107% ± 7% 81% ± 4%c
MCP-1 100% ± 9% 131% ± 9%b 86% ± 16%c
MIP-1α 100% ± 8% 95% ± 7% 96% ± 10%
MIP-1β 100% ± 6% 121% ± 6%b 100% ± 10%
Rantes 100% ± 6% 91% ± 5% 80% ± 7%
TNFα 100% ± 10% 106% ± 9% 116% ± 20%
a, In two independent studies, serum concentrations of 23 cytokines were determined by multiplex 
technology on day 28. In supportive table 2 concentrations are presented as pg/ml ± SEM. In each 
study, values were normalized and expressed as a percentage of the mean concentration of the 
corresponding healthy control mice. Relative concentrations and shown as % ±SEM.
b, significantly (p<0.05) different relative serum concentration from that in healthy mice
c, significantly (p<0.05) different relative serum concentration from that in vehicle treated mice.
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induced transient loss of body weight of 5 to 15%. Average mortality was less than 15 % and 
in particular associated with the first rectal challenge. At endpoint, colitis was evident from 
an increased colon weight/length ratio and increased thickening of the colon(Figure 1B).
These macroscopic changes were associated with increased histology scores in the distal 
part of the colon (Figure 1C). Infiltration of mucosa and submucosa by CD4+ and CD8+ T 
cells, CD11b+ cells (Figure 2A), confirmed as macrophages by F4/80 staining (Figure 2B) was 
associated with mild to moderate damage of the mucosal architecture.
All of these aspects were suppressed in mice treated by intrarectal administration of 
budesonide. Besides, budesonide treatment was associated with weight loss, typical for 
chronic exposure to corticosteroids in mice.
Multiplex analysis of 23 different cytokines and chemokines in serum collected at endpoint 
revealed significantly increased levels of IFN-γ, IL-1β, IL-17, MCP-1 and MIP-1β in mice with 
colitis, but not in mice treated with budesonide. Furthermore, budesonide suppressed IL-
12p40 levels even compared to the serum concentrations in healthy control mice (Table 1).
Altogether, several inflammatory characteristics relevant to IBD are represented in this model 
and shown to be sensitive to corticosteroid treatment.
Figure	2.	Colitis	induction	is	associated	with	increased	numbers	of	innate	and	adaptive	
immune cells. 
The composition of the cellular infiltrate and the effect of budesonide treatment were analyzed by 
immunohistochemistry. (A) Enumeration of the cells showed significantly increased cell numbers per 
mm2 tissue due to TNBS colitis induction. Budesonide treatment significantly reduced the number of 
these infiltrating cells. Bars represent group mean values of 10-12 mice / group, error bars represent 
SEM. Mann-Whitney U-test; * p<0.05, ** p<0.01, *** p<0.001. (B) Double staining of CD11b+ and 
F480+ cells using fluorescence microscopy confirmed co-expression of these two cell surface 
markers. 
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Figure	3.	Disease	characteristics	of	the	recurrent	TNBS	model	in	time.	
Results of the time-course study in the recurrent TNBS colitis model. At each time-point indicated 
in Figure 8, 8 animals were sacrificed and colon length (A) and weight (B) was determined. Colitis is 
associated with a gradual increase in colon weight whereas the colon length is severely affected by 
each TNBS administration followed by a gradual relaxation.
Alterations	in	gene	expression	during	the	development	of	recurrent	TNBS	colitis.
Because the adapted recurrent TNBS colitis model showed involvement of relevant 
pathological processes and sensitivity to treatment, we sought to gain more insight into 
processes involved in the early development of colitis in this model. Therefore, we evaluated 
gene expression in colons of mice sacrificed at different time-points, i.e. before the first and 
2 or 7 days after each rectal TNBS instillation. Evaluation of colon macroscopy at each of 
these time-points showed that TNBS administration was associated with transient shortening 
of the colons, whereas colon weight increased gradually in time (Figure 3). Histological 
evaluation of the colons revealed marked areas of hemorrhages and complete destruction of 
crypt architecture two days after each TNBS instillation; this mucosal damage had partially 
recovered seven days after each instillation (data not shown).
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Figure	4.	Transcriptome	analysis	in	the	recurrent	TNBS-induced	colitis	model.
To determine temporal patterns of gene expression levels that were affected by the repeated TNBS 
instillations, microarray analysis was performed on RNA isolated from colon tissue of colitic mice at 
day 9, 14, 16, 21, 23, and 28 (n = 5 / group) (A) A heat-map of the genes with significantly modified 
gene expression revealed multiple clusters with different temporal expression patterns. (B) Bar graph 
indicates the number of up regulated (red) and down-regulated genes during colitis development at 
each time point. Genes were considered significant with a False discovery rate (FDR) p value <0.05. 
FDR was used to correct for multiple comparisons
Genome wide expression profiling was performed on RNA isolated from distal colon tissue of 
five TNBS-treated mice at each selected time-point. Based on False Discovery Rate (FDR) 
correction, a total of 2074 genes of the 14285 transcripts that passed the filtering procedure, 
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showed significantly different levels of mRNA at one or more time-points in comparison to 
mRNA from healthy mice. Differentially expressed genes that showed similar expression 
profiles are clustered in a heatmap (Figure 4A). The first TNBS challenge was associated 
with enhanced expression of a limited number of genes, whereas enhanced expression of 
a large number of genes occurred shortly after the second challenge on day 16 (Figure 4B). 
These patterns were largely normalized on day 21. Importantly, the third challenge resulted 
in extensive changes in gene expression on days 23 and 28. Forty-two % of the genes that 
showed increased expression on day 28 were also enhanced on day 23 and therefore not 
normalized. Furthermore, 27% of the genes differentially expressed on day 28, were not 
different from healthy on any of the earlier time-points, suggesting developing pathology 
upon multiple TNBS instillations.
To further elucidate the cellular processes associated with the induction of colitis by repeated 
TNBS instillations, we performed gene ontology analysis on the FDR filtered gene data set 
using MetaCoreTM software. Enriched processes with more than 15 genes and p-values below 
10-5 were considered to be significant (Supportive Table 1), which include general terms like 
“inflammation”, but also detailed underlying subcategories. Five major processes important 
for human pathogenesis of IBD were identified in this model, i.e. I) tissue morphogenesis, 
II) the response to wounding, III) immune/inflammatory responses, IV) cell adhesion and 
V) angiogenesis. Gene expression associated with immune/inflammatory responses was 
particularly evident 2 days after each TNBS challenge. Furthermore, several processes 
gradually developed in time, in particular processes associated with epithelial cell growth 
Table 2. Master regulators in colitis development 
Transcription factor Central	regulator	of	 Time-point
9 14 16 21 23 28
SP1 Lipid metabolism, inflammation  ++ ++  ++ ++
HNF4α Endodermal development ++ ++
c-myc cell proliferation + + + + +
CREB1 Inflammation + + +
p53 Apoptosis, cell cycle + + + + +
NF-κB Inflammation + + + + +
AP1 Inflammation + + +
C/EBP-β Lipid metabolism, inflammation + +
ESR1 Metabolism, inflammation     + +
a Transcription factors were identified in biological networks generated using MetaCoreTM software. 
Transcription factors represented in this table were identified in significant networks containing a 
minimal of 8 nodes.
b Level of significance of the transcription factor network is classified based on z-scores: +, z-score 
between 50 and 100; ++, z-score above 100. No score means that the networks for these transcription 
factors were not identified at the time-point or had a z-score below 50.
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and tissue repair/wound healing (Supportive Table 1). Altogether, several processes found 
in human IBD are reflected in this recurrent TNBS model and these will be discussed more 
detailed in the next paragraphs. The key transcription factors involved in the processes 
underlying the development of colitis in this model were identified by MetaCoreTM analysis. 
As shown in Table 2, Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), activator protein 1 (AP-1), CAMP responsive element binding protein 1 (CREB1), were 
central to the process at most time-points, in accordance with an inflammatory process. 
Figure	5.	Effect	of	recurrent	TNBS	administrations	on	cell	adhesion	molecules	and	
chemokines.
(A) Local mRNA expression of cell adhesion molecules and chemokines was determined within the 
time-course microarray experiment. The size of the effect of TNBS-induced colitis on gene expression 
in comparison to healthy colons is indicated in a heatmap. These differences are based on mean 
expression levels of 5 individual animals per time-point. (B) Circulating serum chemokines were 
analyzed by multiplex technology. Relative serum concentrations of concentrations of GM-CSF, MCP-
1 (CCL2), MIP-1α (CCL3), and MIP-1β (CCL4) are graphically depicted; significant differences are 
indicated by #.
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Networks involving Hepatocyte-Nuclear Factor-4α (hnf4α) were only observed on day 16 and 
23, consistent with its role in the acute phase response.
Chemokines,	cytokines	and	cell-adhesion	molecules	in	recurrent	TNBS-colitis
Each of the repeated challenges with TNBS was followed by increased expression of genes 
encoding mediators of acute inflammation such TNF-α, IL-1β, CHI3L1, as well as calprotectin 
or calgranulin C (S100a8 -a9). These S100-proteins are relevant to the pathogenesis, 
disease activity, diagnosis, and therapeutic management of IBD [17].Apart from this acute 
response towards TNBS instillations, the adaptive arm of the immune system appeared to 
be of importance from day 23 onwards as shown by gene ontology analysis in MetacoreTM. 
This analysis also revealed a role for cell adhesion molecules and chemokines. The KEGG 
list of 69 cell adhesion molecules (CAMs), chemokines and chemokine receptors, that was 
previously applied to illustrate an important role of these molecules in mucosal biopsies of 
UC and CD patients [18], was used to evaluate their expression during the development of 
recurrent TNBS-colitis. A heat-map of the molecules on this list that showed significantly 
altered expression at one or more time points is presented in Figure 5A. Several endothelial 
and leukocyte CAMs that were increased in patients with colonic IBD were also enhanced 
in the mouse model, e.g. CD62L, ICAM1, MADCAM1, SELE, THY1, JAM3, and PECAM1. 
Moreover, several chemokines involved in the recruitment of leukocytes, i.e., CCL2 (MCP-1), 
CCL3 (MIP-1α), CCL4 (MIP-1β), CCL7 (MCP-3), CCL9 (MIP-1γ), CCL24 (eotaxin-2), CXCL-
1 (KC), and CXCL-2 (MIP-2α) were induced as well. Not all transcripts related to immune 
responses were up-regulated. Several genes encoding chemokines, including CCL21, 
and 25, and CXCL12, 14, and 15, showed gradually decreased expression during the 
development of colitis, indicative of a changing chemotactic profile during the progression 
of colon inflammation. Multiplex analysis on serum samples revealed that concentrations 
of GM-CSF, MCP-1, MIP-1α, and MIP-1β were significantly increased at one or more time-
points during the experiment, although they did not reflect colon tissue gene expression 
profiles for these chemokines (Figure 5B).
As reported previously, repeated challenges with TNBS are associated with a changing 
cytokine profile in colon, suggesting for a shift from Th1 to a Th17 profile, and eventually 
Th2 cells with fibrosis [15]. In line with this study, IFN-γ gene expression was increased in 
our study, with a maximum on day 16, whereas IL-4 gene expression remained unchanged 
until the third TNBS challenge, after which a significant increase was observed (Figure 6A). 
However, mRNA expression profiles of cytokines considered significant for IBD or colitis, 
such IL-12p40, IL-23p19, IL-12p35, IL-17 did not differ from those in healthy tissue (data not 
shown).
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To establish whether these IBD-related cytokines were reflected in the periphery, serum 
samples were subjected to cytokine analysis employing multiplex technology. A shown in 
Figure 6B, we did not obtain evidence for a biased cytokine profile at any time-point.
Involvement	of	mast	cells	and	α-defensins	in	TNBS-colitis
A small subset of genes showed gradually increasing expression levels in time. This cluster 
mainly comprised mast cell specific genes (Figure7A), including mast cell protease 1, 4, 
and 6 (mcpt1, 4, 6), mast cell chymase (cma2,), carboxypeptidase A3 (cpa3), tryptase α/β1 
(tpsab), and high-affinity IgE Fc receptor (fcer1a).Gene expression was induced up to 233-
fold (mcpt1, day 28). The highest expression levels of these genes were observed during the 
later stages of this model, i.e. on days 23 and 28. Immunohistochemical staining of FcεRI+ 
confirmed the presence of large numbers of mast cells in the lamina propria of affected colon 
tissue (data not shown). This was in line with increased numbers of mast cells stained by 
toluidine blue in affected colon tissue (Figure 7B).These results suggest a gradual increase 
of mast cells associated with the development of chronic colitis in this model.
Figure	6.	Effect	of	recurrent	TNBS	administrations	on	local	and	circulating	cytokine	profiles.
(A) Local mRNA expression of cytokines was determined within the time-course microarray 
experiment. The size of the effect of TNBS-induced colitis on gene expression in comparison to 
healthy colons is indicated in a heatmap. These differences are based on mean expression levels 
of 5 individual animals per time-point. (B) Relative serum concentrations of Th1/Th2/Th17 hallmark 
cytokines at different time-points during the development of colitis. Concentrations of IFN-γ and IL-
12p70, IL-4 and IL-13, and IL-17 are graphically depicted; significant differences are indicated by #.
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Figure	7.	TNBS	–induced	colitis	is	associated	with	increased	numbers	of	mast	cells	and	
α-defensins.
(A) mRNA expression of selected mast cell specific genes in affected colon tissue (n = 5 / group). 
Heatmap represents fold changes in TNBS colitis mice as compared to healthy control mice. 
(B) Quantification of toluidine blue positive cells confirmed TNBS induced up-regulation of mast cells.
(C) mRNA expression of α- and β-defensin genes in affected colon tissue.
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Another set of genes that showed strongly affected expression levels encoded for antimicrobial 
peptides. Expression of many members of the α-defensin family was transiently increased 
on day 9, immediately following the first intrarectal TNBS instillation (Figure 7C).A subset of 
these defensins, including α-defensin 1 (defa1) and four α-defensin-related cryptidins (defcr5, 
6, 20 and 21 and defcr-rs1) also showed increased expression on day 28. These genes were 
induced up to 132-fold (defcr-rs1, day 28).This modulation was restricted to α-defensins, as 
the level β-defensin gene expression remained unchanged.
Discussion
To gain insight into the pathogenesis of IBD, a variety of animal models reflecting different 
aspects of the disease are used [10,11,19]. Most IBD models result from exogenous 
manipulation; they can be categorized based on induction by chemicals, immune cell transfer, 
or gene targeting [19]. Models based on immune cell transfer, such as the CD45RBHi T-cell 
transfer model, and models based on gene targeting, such as the IL-10 knockout mouse 
model, present excellent models to study mechanisms involved in the pathogenesis IBD [20]. 
Nonetheless, these models have the disadvantage of lacking a fully functional immune system. 
These limitations do not apply for models of colitis induced by DSS or TNBS. However, these 
models usually have the disadvantage of being mediated by damage and being relatively 
insensitive to anti-inflammatory drugs. In this respect the recurrent TNBS colitis model is 
more promising. This model has been proposed because the induced pathology reflects the 
chronic and relapsing immune activation processes underlying human IBD resulting in late 
onset of fibrosis [13,15]. In this report, we show results obtained in a modified version of this 
model, limiting the duration to first three weeks of colitis development. We show its sensitivity 
to immunosuppression by local corticosteroid treatment with budesonide which is a relevant 
compound in clinical treatment of patients with CD. Moreover, we recently showed that the 
model is sensitive to pretreatment with probiotic bacteria [16].
Our initial work to develop a model for colitis was largely inspired by the work of Neurath et al. 
who showed that TNBS-induced colitis is mediated by Th1 cells [21]. However, in our hands 
this model showed in SJL mice substantial mortality and variation, which was partly explained 
by the source of the animals and the type of chow diet (data not shown). Modifications to the 
protocol, as indicated by Wirtz et al [5], i.e. skin sensitization with TNBS prior to intrarectal 
challenges with TNBS, decreased the mortality rate in this model. Nevertheless, the limited 
therapeutic window of 2 days in the acute model prompted us to evaluate the characteristics 
of a recurrent TNBS-colitis model described by Fichtner-Feigl et al [15], allowing for prolonged 
treatment during a period of several weeks.
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Our study further characterizes the processes underlying or associated with the early stage 
development of colitis in this model, i.e. a time frame of 3 weeks, by performing genome 
wide transcriptome analysis on colon tissue. This approach revealed that each intrarectal 
TNBS challenge induced a complex set of genes encoding molecules that are generally 
associated with an acute phase inflammatory response, such as TNFα, IL-6, calgranulins 
S100a8 and 9, and reg3γ.In addition, each intrarectal TNBS challenge was associated with 
an enhanced expression of genes encoding a set of chemokines; MCP-1 (CCL-2), MIP-
1α (CCL3) and MIP-1β (CCL4), CCL7, CCL9, CCL11, CCL24,CXCL2 and CXCL4, showed 
a similar acute phase expression pattern, consistent with the influx of inflammatory cells. 
Moreover, serum concentrations of GM-CSF, MCP-1, MIP-1α, and MIP-1β were significantly 
increased in particular two days after each TNBS challenge. These data suggest that each 
TNBS challenge induces transient chemokine production in the colon, which likely drives the 
attraction of innate and adaptive immune cells to the site of TNBS-induced tissue damage. 
The involvement of these chemokines is relevant for human IBD since the majority is also 
elevated in tissues of UC and CD patients [22-24].
In addition, CXCL1 and CXCL2, which are chemokines with strong angiogenic effects, 
were strongly induced by the first intrarectal TNBS challenge and this was followed by the 
enrichment of a large cluster of genes encoding factors that are involved in angiogenesis, 
including FGF, endothelin-1, and VEGF-D. These data are suggestive for a link between the 
process of inflammation and angiogenesis in this model. Importantly, angiogenesis has been 
described as an important component in the pathogenesis and potential target for treatment 
of IBD [25].
Interestingly, the expression of a set of genes encoding chemokines involved in homeostatic 
processes, including CCL21, CCL25, CCL27 and CCL28, was gradually down-regulated in 
our TNBS colitis model. As these chemokines are involved in mucosal lymphoid structure 
development [26], our findings suggest that normal lymphatic tissue regeneration is affected 
in the model. This was substantiated by the observation that colitic tissue contained lower 
levels of transcripts associated with B cells (Cd19, Cxcr5, Tnfrsf13c, and Pou2af1)and 
intraepithelial lymphocytes [27] (IL-15, IL-7, andCD3γ).
Many genes that showed reduced expression upon TNBS colitis induction were related to 
metabolic processes. These main affected metabolic functions based on gene expression 
shifts comprise of changes in oxidative stress response processes, methylation, lipid 
biosynthesis, and small molecule metabolism. These observations reflect the strong 
connection between immune and metabolic response systems in the gut, as described 
Shulzhenko et al [28].
Mast cell influx is one of the key features of the model presented in this paper, as observed 
by microarray and histological examination. The transcriptomics data revealed progressively 
elevated mRNA levels of genes encoding mast cell specific products such as proteases 1, 
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4 and 6 (mcpt-1, -4, -6), carboxypeptidase 3 (cpa3), and high affinity Fc receptor for IgE 
(FcεRI). Mast cell infiltration was confirmed by increased numbers of toluidine blue positive 
mast cells as well as increases in FcεRI+ cells in the affected lamina propria. The attraction 
of mast cell progenitors from the blood depends on several factors, in particular local 
chemokine expression. These include, CCL2, CCXL4, CCL3, CCL24, and CCL11 [26,29]. 
These chemokines were up-regulated during acute inflammation phases of the model and 
may therefore contribute to the temporal migration/recruitment of these cells to the inflamed 
mucosa. Interestingly, protective effects of probiotics in this model were associated with 
reduced expression of these chemokines [16].Also in biopsies of CD and UC patients 
mucosal accumulation of mast cells has been observed [30-33];however, the causative 
relationship between the development of IBD and numbers or activation state of mast cells 
has not been established. As mast cells are known to produce and release a plethora of 
mediators involved in pro-inflammatory as well as regulatory and active tissue repair 
processes [32,34,35], we hypothesize that they may exert differential effects depending on 
the stage of the inflammation processes.
The induction of colitis was associated with an increased expression of a cluster α-defensins 
together with the expression of other antimicrobial peptides, such as angiogenin 4 (ang4), 
regenerating islet derived antimicrobial peptides RegIIIγ and RegIV (reg3g and reg4, 
respectively), and secretory phospholipase A2 type IIA (pla2a2a/pla2g2a). Although all of 
these anti-microbial peptides have been described as products of Paneth cells in the small 
intestine, we have not been able to demonstrate the origin of these transcripts in the colon. 
Staining with Lendrum’sphloxine-tartrazine or immunohistochemical staining for lysozyme P 
did not confirm the presence of Paneth cells in the affected colon tissue(data not shown). It is 
tempting to speculate that these genes are indicative of the presence of metaplastic Paneth 
cells, which have been reported in both colonic CD and UC biopsies [36-38], whereas 
they are not found in healthy colon tissue[39,40].In patients these cells showed increased 
expression of human α-defensins DEFA5 and DEFA6 in the colon [22,38,41,42]. Additional 
studies are needed to establish the origin of the antimicrobial peptide gene expression in 
affected colon tissue.
In conclusion, this recurrent TNBS-colitis model, adapted to comprise both transient acute 
inflammatory processes and gradually developing chronic inflammation, reflects several 
clinical and histopathological features of human IBD. The temporal gene expression profiles 
generated in this study revealed distinct processes involved in the onset and progression of 
disease in this model, and this knowledge may help to identify novel targets and therapeutic 
approaches for IBD.
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Materials and Methods
Mouse colitis model
All experiments were performed with female BALB/c mice (8wk old, 18-22 g) obtained from 
Janvier (St. Berthevin, France). Mice were conventionally housed under controlled temperature 
(22-24°C) and photoperiod (12hlight-dark cycle), and had free access to standard mouse 
chow (SSNIFF R/M-H, BioServices B.V., Uden, The Netherlands) and acidified tap water. 
Animal experiments were approved by the Institutional Animal Care and Use Committee 
of The Netherlands Organization for Applied Scientific Research (TNO), approval number 
DEC2982 and were in compliance with European Community specifications regarding the 
use of laboratory animals.
To induce colitis, mice were exposed to intracolonic administration of step-wise increasing 
doses of TNBS (Figure 8).Seven days prior to the first intracolonic TNBS administration, mice 
were sensitized by a single application of 3.75 mg of TNBS (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) in 48% (v/v) ethanol on the shaved dorsal skin. On days 7, 14 and 21, mice 
were lightly anaesthesized with isoflurane and subsequently 0.75, 1.5 and 2.25 mgTNBS in 
40% (v/v) ethanol was administered per rectum via a 2.0 mm tube (Unomedical A/S,Birkerød, 
Denmark) connected with a 1.0 ml syringe, which was advanced into the rectum for 
Figure	8.	Schematic	representation	of	the	colitis	induction	protocol.
Induction of colitis is achieved by dorsal skin application of TNBS in ethanol on day 0, followed by 
rectal TNBS/ethanol instillations on day 7, 14, and 21. The necropsy time-points for study 1, i.e. 
TNBS disease induction and corticosteroid treatment, and study 2, i.e. the time-course experiment, 
are presented in the upper part of the schematic. Severity of colitis induction was assessed by 
measurement of colon weight, length and thickness and by histopathological evaluation of the distal 
part of the colon. At each necropsy, serum was collected for cytokine profiling and colon tissue was 
sampled for RNA isolation.
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approximately 3 cm. Upon administration of 150 µl of TNBS solution, mice were held in a 
vertical position for 30seconds to allow for equal distribution.
Study	design
In this report, the results of 2 experiments (Figure8) are discussed in detail. In study 
1, induction of colitis was performed as described above and at day 28 all animals were 
sacrificed for assessment of all relevant parameters. In this study, local budesonide (3 mg/
kg) treatment was included as a positive treatment control. Budesonide was administered 3× 
per week starting one day prior to the first rectal TNBS administration, i.e. day 6. Budesonide 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) was prepared in PBS containing 2.5% (v/v) 
Tween-80 and 2.5% (v/v) ethanol. In study 2, we performed a time-course study to evaluate 
the development of colitis by macroscopy, cytokine profiling and gene expression profiling. 
In this study, one group of animals (n=8) was included for each time-point in the study. The 
selected time-points 2 and 7 days after each TNBS administration, 8 mice were sacrificed, 
as indicated in Figure 8.
Colon	macroscopy
Severity of colitis was assessed by macroscopical analysis directly upon sacrifice. After colon 
length was measured, feces were removed by gentle pressure with forceps. Subsequently, 
colon weight was measured. Finally, colon thickness was measured with a digital caliper at 
1, 2, and 3 cm from the anus.
Histological	assessment	of	colitis
Following measurement of macroscopy parameters, colons were dissected and fragments 
were fixed in 4% buffered formalin and embedded in paraffin. Sections of 5 µm were 
stained by hematoxylin-eosin-saffron. Inflammation was scored in a blinded manner for 3 
non-sequential sections per colon fragment at a 400× magnification, according to a semi 
quantitative (0-4) scoring system, based on number of infiltrating cells and mucosal damage. 
Mast cells were evaluated after staining with toluidine blue[43]at a 400× magnification.
Immunohistochemical	analysis	of	cellular	infiltrates
Dissected colon fragments were immediately immersed in Tissue TekOCT compound (Sakura 
Finetel, Torrance, CA, USA) and cryopreserved in liquid nitrogen. Immunohistochemistry 
was performed on 6 µm sections with primary antibodies specific for CD4 (L3T4.), CD8 (53-
6.7), CD11b (M1/70), and F4/80 (CI-A3-1all obtained from BD Biosciences(San Diego, CA, 
USA). After incubation, biotinylated antibodies were detected by incubation with streptavidin-
HRP (Vector Laboratories, Burlingame, CA, USA) using 3-amino-9-ethylcarbozole (Sigma) 
as a substrate. Immunopositive cells were counted at a 400× magnification and normalized 
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against the colon tissue surface area. For immunofluorescence, primary antibodies and 
according Texas red and fluorescein labeled secondary antibodies were applied. Slides were 
covered with Vectashield (H1000) mounting medium with DAPI Vector).
Cytokine	and	chemokine	quantification	in	serum
Cytokine concentrations in serum obtained at each sacrifice were determined by Multiplex 
analyses. For this purpose, serum was diluted and assayed with the Bio-Plex Pro 23-Plex 
Panel, for IL-1α, -1β, -2, -3, -4, -5,-6, -9, -10, -12(p40), -12(p70), -13, -17, IFN-γ, TNF-α, 
RANTES, MIP-1α and -1β, MCP-1, KC, G-CSF, GM-CSF, and eotaxin protein (Bio-Rad 
Laboratories, Hercules, CA, USA). The beads were read on a LiquiChip 200, (Qiagen, 
Hombrechtikon, Switzerland), and data were analyzed by the five parameter curve fitting in 
Luminex100 IS Software. Cytokine concentrations were corrected for the dilution factor and 
presented in pg/ml or as relative concentrations to the average concentration in healthy mice.
Transcriptome	analysis
Total RNA from frozen intestinal tissue was isolated using TRIzol reagent (Invitrogen, Breda, 
The Netherlands) according to the manufacturer’s instructions. RNA was treated with DNAse 
and purified using Nucleospin RNAII Total RNA Isolation kit (Macherey-Nagel, Düren, 
Germany), according to manufacturer’s protocol.
The quality control of RNA samples, RNA labeling and hybridization were performed at 
ServiceXS (Leiden, The Netherlands). RNA concentration was assessed using a Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, U.S.A). The RNA 
quality and integrity was determined using Lab-on-Chip analysis on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, U.S.A.). The RNA integrity numbers 
(RIN) of all RNA samples had values above 7.3. BiotinylatedcRNA was prepared using the 
IlluminaTotalPrep RNA Amplification Kit (Ambion, Inc., Austin, TX, U.S.A.) according to the 
manufacturer’s specifications starting with 500 ng total RNA. Per sample, 750ng of cRNA 
was used to hybridize to the Sentrix MouseRef-8 BeadChips (Illumina, Inc., San Diego, 
CA, U.S.A.). Each BeadChip contains eight arrays and each of the arrays harbors 25697 
probes. Hybridization and washing were performed according to the Illumina standard assay 
procedure. Scanning was performed on the IlluminaiScanner (Illumina, Inc., San Diego, CA, 
U.S.A.). Image analysis and extraction of raw and background subtracted expression data 
were performed with IlluminaBeadstudio v3 Gene Expression software using default settings. 
The data discussed in this publication have been deposited in NCBI’s Gene Expression 
Omnibus[44] and are accessible through GEO Series accession number GSE35609(http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35609).GeneSpring GX 11.0 was used 
for quantile normalization of the probe-level, background subtracted expression values. 
After the normalization, unexpressed probes were removed from the further analyses. All 
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expression values below 5 (2.322 on log2 scale) were floored to 5. Differentially expressed 
probes were identified using the limma package of the R/Bioconductor project, applying 
linear models and moderated t-statistics that implement empirical Bayes regularization of 
standard errors[45]. The statistical analyses were performed through The Remote Analysis 
Computation for gene Expression data (RACE) suite athttp://race.unil.ch [46]. False 
Discovery Rate (FDR) corrected p-values of 0.05 was used as threshold for significance of 
the differential expression. Fold changes relative to healthy control mice are presented. GEO 
Processes were identified using Metacore Software V6.11.
RT-qPCR for a set of genes (CCL2, CCL11, CCL24, cldn-1, cldn-4, cldn-11) showed a high 
correlation with data obtained by microarrays, and thereby confirmed the relative gene 
expression presented in the figures (data not shown).
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Abstract
Background
Host-microbiota interactions in the intestinal mucosa play a major role in intestinal immune 
homeostasis and control the threshold of local inflammation. The aim of this study was to 
evaluate the efficacy of probiotics in the recurrent trinitrobenzenesulfonate (TNBS) induced 
colitis model, and gain more insight into protective mechanisms.
Method
Moderate chronic inflammation of the colon was induced in BALB/c mice by repetitive 
intrarectal challenges with TNBS. Administration of probiotics started two weeks before 
colitis induction, and was continued throughout colitis development.
Results
Long-term administration of Lactobacillus plantarumNCIMB8826 or the probiotic mixture 
VSL#3 reduced intestinal inflammation induced by TNBS, evident from improved colon 
morphology and less influx of innate (CD11b+) and adaptive (CD4+/CD8+) immune cells in 
the intestinal mucosa and decreased pro-inflammatory serum cytokines (IFN-γ, IL-17, IL-
1β, MCP-1) in probiotic-treated mice. Genome wide expression analysis of colonic tissues 
using microarrays revealed differences in expression of genes related to inflammation and 
immune processes between untreated and probiotic treated mice. Principal Component 
Analysis revealed that probiotic treatment resulted in a shift of gene expression profiles 
towards those of healthy controls. Effects of probiotics on colonic gene expression were 
most profound during active inflammation, in particular on gene clusters related to mast cells 
and anti-microbial peptides. The results were substantiated by suppression of chemokine 
gene expression.
Conclusions
Our data are in favor of a model in which probiotics down-regulate expression of chemokines 
in the colon, thereby decreasing influx of inflammatory cells and rendering mice resistant to 
the induction of colitis.
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Introduction
Inflammatory bowel disease (IBD) refers to chronic, spontaneously relapsing inflammation 
of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative colitis (UC) as 
two major entities. The exact etiology and pathogenesis of IBD is still unclear, but it includes 
genetic, immunological, and environmental factors (1;2). Standard therapies comprise 
salicylates, corticosteroids, immunomodulating and immunosuppressive drugs (3). However, 
these strategies are not effective in many patients and put the patients at risk to develop 
opportunistic infections or treatment related cancers. Alternative strategies such as altering 
the composition of intestinal microbiota with selected prebiotics, probiotics and/or synbiotics 
have been shown effective in inducing sustained remission of UC patients (4).
Interactions between host and microbiota play a key role in the susceptibility for experimental 
colitis, as germ-free mice do not develop colitis (5). The intestine is home to a complex 
population of trillions of commensal bacteria that participate in the digestive process and 
interact with the mucosal immune system of the host (6). The interaction of commensal 
bacteria with epithelial and immune cells in the intestine may cause both pro-inflammatory 
and regulatory immune responses(7). Therefore, altering the composition of the intestinal 
microbiota with probiotics has been suggested as an alternative approach in either 
maintaining or establishing intestinal homeostasis in IBD patients.
Probiotics are defined as viable, non-pathogenic micro-organisms that if ingested in sufficient 
numbers have a beneficial effect on the host. Different mechanisms have been suggested 
to explain this beneficial effect, such as colonization resistance, enhancing immune function 
by interacting with innate immune cells in the mucosa, and regulation of the intestinal barrier 
integrity (8). Indeed, clinical efficacy of probiotics has been proven in several studies in IBD 
patients and animal models of IBD.
In this study, we examined the effect of two probiotics, L. plantarum NCIMB8826 and 
VSL#3,on intestinal inflammation in the recurrent TNBS colitis model. VSL#3 was selected 
as a clinically validated product to identify pathways leading to a decreased inflammatory 
state. In this respect, we had a particular interest in the modulation of Toll-like receptors 
(TLR)and pathways involved in the recruitment of inflammatory cells. We are the first to 
perform genome wide screening of colonic tissue in this recurrent model of colitis in order to 
identify processes and pathways that are modulated by probiotics. This screening revealed 
that effects of VSL#3 treatment were most abundant during active inflammation, especially 
on gene clusters related to mast cells and anti-microbial peptides, and these effects were 
reflected by decreased influx of inflammatory cells.
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Materials	&	methods
Mice
Eight-week old female BALB/c mice (18-21 gr) were obtained from Janvier (St. Berthevin, 
France) and maintained in the animal facility of TNO under specific pathogen free conditions 
with a 12h light/dark cycle. Mice had free access to standard mouse chow (SSNIFF R/M-H, 
Bioservices B.V., Uden, The Netherlands) and water. Animal experiments were approved by 
the institutional ethical committee on animal care and experimentation.
Probiotic strains
VSL#3 (Ferring Pharmaceuticals, Berkshire, UK) was purchased as a commercially available 
probiotic mixture containing freeze-dried bacteria (Bifidobacterium longum, B. breve,B. 
infantis, Lactobacillus acidophilus, L. plantarum, L. casei,L. bulgaricus, and Streptococcus 
thermophilus).
L. plantarumNCIMB8826wasgrown at 37 oC in Mann-Rogusa Sharpe broth (ScharlauChemie, 
Barcelona, Spain) until mid-exponential growth phase (OD600nm = 1). Bacteria were washed 
twice in phosphate buffered saline (PBS) at pH 7.4, suspended at 2×109 cells/ml in PBS 
containing 25% glycerol, and stored at -80 oC until use. Before use, the bacterial suspensions 
were washed once with PBS. Mice were treated three times a week by oral administration 
of3 x108 CFU L. plantarum or VSL#3 suspended in 200 μl PBS, or 200 μl vehicle (PBS) only, 
starting 14 days before the first intrarectal challenge with TNBS .
Induction of colitis
Colitis induction was performed as described previously(9), with slight modifications. Briefly, 
mice were sensitized by application of 3.75 mg of TNBS (Sigma-Aldrich) in 48% (v/v) ethanol 
to the shaved dorsal skin on day 0. Experimental colitis was induced by administration of 
increasing doses (0.75, 1.0 and 2.5 mg / mouse) of TNBS in 40% ethanol on days 7, 14 and 
21, respectively. Mice were anesthetized with 3 % isoflurane and then administered TNBS in 
ethanol via a sterile 2.0 mm catheter (Unomedical A/S, Birkerǿd, Denmark)inserted 35 mm, 
intrarectally. Mice were kept in a head-down position for an additional 30seconds to ensure 
distribution of TNBS in the colon. On day 28, i.e. 7 days after the third TNBS challenge mice 
were sacrificed and colons were removed. After the removal of feces, colons were subjected 
to macroscopic evaluation before further processing for RNA isolation and histology.
Analysis	of	serum	cytokines
Serum cytokine and chemokine protein levels were quantified using a Mouse Cytokine 
23-PlexPanel (Bio-Rad,Hercules, CA, USA) according to manufacturer’s protocol. The 
assay is based on multiplex technologyand simultaneously measures IL-1α, -1β, -2, -3, -4, 
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-5,-6, -9, -10, -12(p40), -12(p70), -13, -17, IFN-γ, TNF-α, RANTES, MIP-1α and -1β, MCP-
1, KC, G-CSF, GM-CSF, and eotaxin protein. The beads were read on a LiquiChip 200, 
(Qiagen, Hombrechtikon, Switzerland), and data were analyzed by the five parameter curve 
fitting in Luminex100 ISSoftware.
Transcriptome	analysis
Five mice per experimental group were selected for transcriptome analysis. The selection 
of animals was performed one day before sacrife and based on weight loss only. The 
average weight loss of the mice selected for transcriptome analysis was representative for 
all mice in each of the experimental groups. Total RNA was isolated from frozen colon tissue 
using TRIzol reagent (Invitrogen, Breda, The Netherlands) according to manufacturer’s 
instructions. RNA was treated with DNAse and purified using a nucleospin RNAII Total RNA 
Isolation kit (Macherey-Nagel, Düren,Germany). Concentrations and purity of RNA samples 
were determined with a NanoDrop ND-1000 spectrophotometer (Isogen, The Netherlands). 
RNA integrity was checked employing an Agilent 2100 bioanalyzer (Agilent Technologies, 
Amsterdam, The Netherlands) with 6000 Nano Chips according to the manufacturer’s 
instructions. RNA integrity numbers (RIN) were above 8.
BiotinylatedcRNA was prepared using the IlluminaTotalPrep RNA Amplification Kit (Ambion, 
Inc., Austin, TX, USA) according to the manufacturer’s specifications starting with 500 ng 
total RNA. Per sample, 750ng of cRNA was used to hybridize to the Sentrix MouseRef-8 
BeadChips (Illumina, Inc., San Diego, CA, USA). Each BeadChip contains eight arrays 
and each of the arrays harbors 25697 probes. Hybridization and washing were performed 
according to the Illumina standard assay procedure. Scanning was performed on the 
IlluminaiScanner (Illumina, Inc., San Diego, CA, USA). Image analysis and extraction of raw 
and background subtracted expression data were performed with IlluminaBeadstudio v3 
Gene Expression software using default settings.
GeneSpring GX 11.0 was used for quantile normalization of the probe-level, background 
subtracted expression values. After normalization, unexpressed probes were removed from 
the subsequent analyses. Probes were considered to be expressed, if the probe was present 
(detection p-value >=0.99) in at least 3 out of 20 samples in the dataset.
After this filtering procedure, 13551 probes remained in the analysis. All expression values 
below 5 (2.322 on log2 scale) were floored to 5. Differentially expressed probes were 
identified using the limma package of the R/Bioconductor project, applying linear models and 
moderated t-statistics that implement empirical Bayes regularization of standard errors(10). 
The statistical analyses were performed through The Remote Analysis Computation for 
gene Expression data (RACE) suite at http://race.unil.ch(11). p-values below 0.05 were used 
as a threshold for significance of the differential expression. Pathway analysis software 
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Metacore(V6.2), a highly curated Web-based application for identification of gene ontology 
processes in input genesets, was used to identify biological processes (GeneGo Inc., St. 
Joseph, MI, USA).
RT-qPCR
Three genes encoding chemokines, which were upregulated during colitis, were selected 
for validation with RT-qPCR. 500 ng of RNA was used for single-stranded cDNA synthesis 
using a High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad,CA, USA) 
according the manufacturer’s protocol. RT-qPCR was performed on an Applied Biosystems 
7500 Fast Real-Time PCR system. Primer sequences used were as follow; CCL2 5’- 
TAGGCTGGAGATCTACAAGAGG-3’ (S) and 5’- AGTGCTTGAGGTGGTTGTGG-3’ (AS), 
CCL11 5’- GGCTGACCTCAAACTCACAGAAA-3’ (S) and 5’- ACATTCTGGCTTGGCATGGT-3’ 
(AS), CCL24 5’- GCAGCATCTGTCCCAAGG-3’ (S) and 5’- GCAGCTTGGGGTCAGTACA -3’ 
(AS). Each reaction contained 25ngcDNA, 0.3μM sense and antisense primers, and Sybr 
Green Master Mix (Applied Biosystems, Carlsbad, CA, USA) under the following thermal 
conditions: 50°C for 1 minute, 95°C for 10 minutes, and 40 cycles of 15 seconds at 95°C 
and 1 minute at 60°C, followed by a dissociation stage. Relative mRNA expression was 
normalized to β-actin and was expressed using the ΔΔCt method.
Immunohistochemisty
Colon fragments adjacent to those used for RNA isolation were fixed in 4% buffered 
formaldehyde and embedded in paraffin, or embedded in Tissue-Tek and snap-frozen in 
liquid nitrogen.
From paraffin-embedded tissue,5 µm sections were stained with either toluidin blue and 
counterstained by hematoxylin-eosin, in order to assess numbers of mast cells or with 
hematoxylin-eosin-safran for microscopical evaluation.
Six μm cryo-sections from frozen colon fragments were fixed in ice-cold acetone for 
10 minutes and air-dried. Sections were blocked for endogenous peroxidase (Peroxidase 
Blocking Agent, Dakocytomation, Glostrup, Denmark), avidin/biotin (SP-2001, Vector 
Laboratories, Peterborough, UK), and 5% BSA for non-specific antibody binding. Slides were 
incubated overnight at 4 °C with the following rat anti-mouse monoclonal antibodies (BD 
Biosciences, San Diego, CA, USA) in appropriate dilutions: CD4 (clone H129.19) and CD8-
bio (clone 53-6.7), IgG2a isotype (clone R35-95); CD11b-bio (clone M1/70), FcRεI-bio, (clone 
MAR-1), IgG2b-bio isotype (clone A95-1). Bound primary antibody was detected via goat 
anti-rat-biotin and/or peroxidase-labeled streptavidin (SA-5004, Vector Laboratories). Slides 
were developed with Novared substrate (SK-4800, Vector Laboratories) and counterstained 
with haematoxylin. Three non-serial colon sections per mice were used for quantification, by 
counting immunopositive cells at a 400x magnification, which were normalized against the 
mucosal area.
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Mice were subjected to oral treatment with probiotics during the development of colitis or 
treatment with PBS (p.o.), starting 2 weeks before the first rectal TNBS challenge. During 
the experimental period, healthy control mice which were left untreated showed gain of 
bodyweight as compared to baseline (109.0±3.7%). In contrast, mice subjected to colitis 
induction showed a transient weight loss for 3 days immediately following each TNBS 
instillation (Figure 1A).At endpoint (day 28) mice subjected to colitis induction showed less 
gain in bodyweight (104±4.0%; p<0.01) as compared to the healthy controls. Although also 
the mice treated with L. plantarum or VSL#3 showed transient weight loss after each TNBS 
challenge, they showed less weight loss over the entire follow-up period compared to vehicle-
treated mice challenged with TNBS (Figure 1A; repeated measurements ANOVA, p<0.001 
and p<0.01 for L. plantarum and VSL#3, respectively).
Seven days after the third TNBS challenge (i.e. on day 28),mice were sacrificed and colons 
were evaluated macroscopally. Colons of vehicle-treated mice showed an increased weight/
length ratio compared to healthy mice (Figure 1B; p<0.001). Colitis was also evident from 
thickening of the rectal part of the colon (p<0.01; data not shown).Although hemorrhages (as 
shown by histological evaluation) and the absence of solid stool are a hallmark during the 
acute phase following each rectal TNBS instillation, these features were less pronounced on 
day 28 and are therefore not included in the evaluation of treatment effects. Adhesions of the 
colon were only sporadically observed.
VSL#3 treated mice showed a less pronounced increase in the colon weight/length ratio as 
compared to vehicle-treated mice(Figure 1B; p <0.05) without having a significant effect on 
the colon thickness (data not shown). L. plantarum did not show effects on the macroscopic 
score. In a separate time-course experiment, VSL#3 was shown to be most effective after 
the second and third challenge (Figure 1D).
Histopathological evaluation of the rectal part of the colons was performed to establish a 
composite score as described before (12),based on mucosal architecture, cellular infiltration, 
muscle thickening, goblet cell depletion and crypt abscess formation. On day 28, in particular 
cellular infiltration and loss of mucosal architecture contributed to the score in mice with 
colitis compared to healthy controls (Figure 1C). Both VSL#3 and L. plantarum showed 
a modest inhibitory effect on this semi-quantitative score. As will be discussed below, 
significant inhibitory effects of probiotics were demonstrated after quantification of discrete 
subsets of cells.
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Figure	1.	
(A) Body weight development in the recurrent 
TNBS colitis model. Body weights were 
normalized against the body weight on day 
-1. Colon weight/length (B) is a parameter 
reflecting changes in colon morphology 
(n = 10-12 mice / group). (D) Histological 
score of the colon. (D) Development of colon 
weight/length ratio in time (n = 8 mice per 
group). Panel A, B and D are representative 
for 2 independent experiments. Mann-
Whitney U-test; * p<0.05, *** p<0.001.
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vehicle Vehicle1 L. plantarum2 VSL#32
G-CSF 53±42 45±19 42±20 26±10*
GM-CSF 185±42 214±43† 182±31† 169±29*
IFN-γ 530±240 763±184 † 643±242 463±170**
IL-10 63±51 196±101 * 126±49 † 121±73
IL-17 77±55 149±68 * 92±54 * 64±30 **
IL-1α 237±91 273±60 219±69 † 179±81*
IL-1β 1004±379 1499±547 † 1078±521 † 887±271 *
IL-3 11±5 19±16 10±3 * 15±4.3 *
IL-9 193±43 267±185 187±73 152±66 *
MCP-1 560±243 878±291 * 712±254 542±185 *
MIP-1α 1593±434 1929±399 1583±346 1348±268 **
Serum of individual mice, collected at endpoint on day 28, was assayed by multiplex analysis as 
described in material and methods.Results represent mean + SD of 6 to 10 mice per group.
1 Mann-Whitney U-test as compared to healthy mice
2 Mann-Whitney U-test as compared to vehicle-treated mice with colitis† p<0.10, * p<0.05, ** p<0.01





α-defensin Fold	change p Fold	change p
defensin related cryptdin 20 (Defcr20)) -9.7 0.006 -1.9 0.38
defensin related cryptdin 26 (Defcr26) -5.0 0.009 -1.8 0.48
defensin related cryptdin 4 (Defcr4) -5.4 0.026 -1.6 0.62
defensin related cryptdin 5 (Defcr5) -4.8 0.031 -1.8 0.44
defensin related cryptdin 6 (Defcr6) -11.2 0.002 -2.7 0.21
defensin related cryptdin, related 
sequence 10 (Defcr-rs10)
-4.8 0.069 -1.4 0.77
defensin related cryptdin, related 
sequence 7 (Defcr-rs7)
-5.0 0.031 -1.3 0.74
defensin related sequence cryptdin 
peptide (Defcr-rs1)
-13.8 0.004 -2.4 0.28
defensin, alpha 1 (Defa1) -12.5 0.006 -2.3 0.34
Fold change is defined as the ratio of the signal of mice treated with TNBS and probiotic to that of 
mice treated with TNBS + vehicle.
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Genome	wide	gene	expression	analysis
To gain insight into colitis-associated processes modulated by L. plantarum and VSL#3, 
RNA from colonic tissue was isolated 7 days after the last TNBS challenge, and subjected 
to genome wide screening. Microarray analysis identified 831 probes that were differentially 
expressed between healthy mice and mice with colitis. Post-genomic validation of microarray 
data with RT-qPCR for 6 genes showed a strong correlation between both techniques (data not 
shown). The complete list of differentially expressed genes is provided in Supporting Table 1. 
The effect of probiotic treatment on TNBS colitis was visualized by principal component 
analysis (PCA) on the set of 831 probes that differed between healthy mice and mice with 
Figure	2.
Two-dimensional visualization of principal component analysis (PCA) constructed with the set of 
831 differentially expressed genes in the colon upon colitis induction, and position of colitis mice 
treated with L. plantarum or VSL#3 in this space. Each dot represents the expression profile of an 
individual mouse. 
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colitis (Figure 2). PCA analysis allows grouping of individual mice with overall similar gene 
expression profiles. Although all these 831 genes contributed to the differentiation between 
healthy control mice and colitis animals, dominant clusters of genes encoded for mast cell 
enzymes, defensin related peptides, as well as other immune related transcripts. This plot 
showed that long-term probiotic administration to mice subjected to colitis induction exhibited 
a profile in between healthy and diseased mice, although still closer to diseased mice. To gain 
insight into disease-related processes that were modulated by probiotics, we next focused on 
genes and gene clusters affected by probiotic intervention during colitis. Gene ontology (GO) 
classification using Metacore pathway analysis was applied on genes that were normalized 
in probiotic treated mice. Cellular processes that were normalized by VSL#3 treatment were 
mainly related to DNA replication and regulation of immune functioning. Each intrarectal 
TNBS challenge was associated with up-regulation of gene clusters involved in remodeling of 
the extracellular matrix and the cytoskeleton; up-regulation of these genes was suppressed 
by VSL#3 treatment in particular two days after the first TNBS challenge.
Another set of genes that was up-regulated in the colons of mice with colitis comprised 
of α-defensins and related antimicrobial peptides. Table 1 shows a list, including the fold-
change and p-values, to illustrate the inhibitory effect of VSL#3 on up-regulation of these 
defensin-related cryptdins. L. plantarum was ineffective in this respect.
At several time points dedicated evaluation of genes encoding TLR or associated pathways 
did not reveal major changes in response to colitis induction and/or probiotics. Yet, as will 




Detailed analysis revealed increased expression of mast cell protease-1, mast cell 
protease-4, chymase-1, chymase-2, carboxypeptidase A3, and FcεRI in mice with colitis. 
Figure 3 shows a heat map of expression profiles of these mast cell related genes in mice 
with colitis compared to healthy controls, as well as expression patterns in mice treated with 
probiotics. Although not all of these genes were comparably induced by colitis induction, the 
overall pattern strongly suggested an increase of mast cells in the tissues, which was not 
observed in mice subjected to treatment with VSL#3 or L. plantarum. As will be discussed 
in the next section these observations were partly reflected by lower numbers of mast cells.
Because local chemokine production is key to the infiltration of the intestine by immune 
cells, we addressed the expression of a set of chemokines during the course of colitis in this 
model. We assessed gene expression profiles of mice treated with VSL#3, two and seven 
days after each TNBS challenge and compared these profiles with vehicle-treated mice. As 
shown in Figure 4A, genes encoding several chemokines involved in the recruitment of mast 
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cell progenitors and other inflammatory cells to the intestinal mucosa were up-regulated2 
days after each TNBS challenge, but not at 7 days post-challenge. RT-qPCR confirmed the 
enhanced expression of chemokines after each TNBS-challenge, this analysis also showed 
that VSL#3 treatment suppressed up-regulation of these chemokines during the first TNBS-
challenge (Figure 4B), but not at later time points (data not shown).
Probiotics	prevent	colitis	associated	influx	of	inflammatory	cells	into	colonic	(sub)
mucosa
As shown in Figure 5A, TNBS-induced colitis was associated with increased infiltration of the 
lamina propria and the submucosa by mast cells. Although treatment with probiotics resulted 
Figure	3.
Heat map of gene expression of mast cell-associated enzymes (red indicates up-regulation, blue 
indicates down-regulation)
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in a lower expression of mast cell associated enzymes, this was only in part reflected by 
lower numbers of mast cells, visualized by toluidin blue or specific staining with anti-FcεRI.
Also numbers of other inflammatory cells including CD4+ T cells, CD8+ T cells and CD11b+ 
innate immune cells confirmed as macrophages by F4/80 staining were significantly increased 
after TNBS-colitis induction. Mice treated with L. plantarum or VSL#3 showed significantly 
lower numbers of these cells (Figure 5B).
To study whether these inflammatory processes were reflected in serum at endpoint, we 
performed a multiplex analysis and evaluated a panel of 23 cytokines and chemokines. 
Table 2 displays only those cytokines and chemokines that were modulated in mice treated 
with probiotics. Colitis induction was associated with increased levels of several (pro)-
inflammatory cytokines and chemokines (GM-CSF, IFN-γ, IL-10, IL-17, IL-1β, and MCP-1). 
Mice treated with VSL#3 showed significantly decreased levels of IFN-γ, IL-17, GM-CSF, IL-
1α, IL-1β, MCP-1 and MIP-1α as compared to vehicle controls. In this respect, L. plantarum 
treatment was less effective with a trend towards down-regulation of several of these 
cytokines and only significant inhibition of IL-17 and IL-3.
Figure	4.
(A) Chemokine expression in the TNBS colitis model at various time points (B) Effect of VSL#3 
treatment on gene expression profiles of chemokines involved in the recruitment of mast cells on 
day 9.
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Discussion
Relapsing colitis in BALB/c mice was mimicked by weekly intrarectal administrations of low 
dose TNBS in ethanol. The model is characterized by the initial production of Th1 cytokines 
followed by a Th17- like profile after 3 weeks (9). We confirmed increased levels of IFN-γ, 
IL-17 and several chemokines in serum samples, collected three weeks after the first rectal 
TNBS challenge, in conjunction with a gradual increase of inflammatory cells in the colon.
Because it has been suggested that probiotics may modulate local immune response by 
affecting regulatory T cells and/or T cell differentiation(13),we choose for this intermediate 
time-point with developing pathology to evaluate the effects of probiotic treatment. Likewise, 
we selected a time-point of 7 days after the third intrarectal challenge, to avoid the acute 
phase directly following each rectal challenge. Therefore, our results reflect effects of 
probiotics on a gradually developing process of inflammation, characterized by the influx of 
T cells and macrophages with moderate pathology as an aspect of IBD, rather than effects 
on disease with high severity.
In the present study, we have shown that this model is sensitive to prophylactic treatment 
with probiotics, evident from less intestinal inflammation and normalized colonic gene 
expression profiles. Beneficial effects of probiotics were previously reported for L. plantarum 
NCIBM8826 and VSL#3 in spontaneous (14;15) and chemical induced (16-18) models of 
experimental colitis. Here, we confirm that probiotics significantly affect the host, rendering 
the mice largely resistant to the development of disease in response to multiple challenges 
with TNBS. Moreover, we substantiated these effects by genome wide mRNA profiling. In our 
experiments, both L. plantarum and VSL#3attenuated the development of clinical features 
of colitis, with favorable effects on gain of bodyweight and slight improvement of colon 
morphology.
Both in UC and CD, the colonic mucosa is infiltrated by neutrophils, macrophages, and 
lymphocytes. This feature of human IBD is reflected in the relapsing TNBS colitis model by 
the infiltration of CD4+, CD8+ T cells, macrophages and mast cells in the intestinal mucosa 
after 3 repetitive colitis inductions. Influx of these inflammatory cells was reduced in mice 
treated with either L. plantarum or VSL#3, and this might be due to local down regulation of 
chemokines. Indeed, various chemokines key to the recruitment of inflammatory cells were 
less up-regulated after the first TNBS challenge, in mice treated with VSL#3. At endpoint, 
diminished levels of MIP-1α, G-CSF, GM-CSF, and MCP-1were demonstrated in serum. The 
beneficial effects of probiotics in this study were also evident from an overall reduction of 
inflammatory serum cytokines. Seven days after the last TNBS challenge untreated mice 
with colitis showed increased levels of several cytokines, including IL-1α, IL-1β, IFN-γ, MIP-
1α and IL-17. These cytokines are suggestive for an involvement of macrophages and a 
mixed Th1/Th17 population (19;20)(21). These observations are of importance, since CD has 
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recently been characterized as a Th1/Th17 driven inflammatory disease (22). Importantly, 
also these cytokines were significantly lower in serum of mice treated with VSL#3.
There is strong evidence for an involvement of mast cells in the pathogenesis of IBD (23). 
This is of interest since the relapsing colitis model involves a mast cell component, evident 
from progressively elevated mRNA levels of transcripts encoding mast cells (Kremer, et al 
2012). However, the exact role of mast cells in intestinal inflammation is topic of debate. Mast 
cells were shown to protect from colitis by enhancing the barrier function of epithelial cells 
and by limiting spontaneous development of colitis in susceptible IL-10-/- mice(24). However, 
mast cells have also been shown to increase epithelial barrier permeability (25) and the 
recruitment of inflammatory cells to the site of infection by the release of cytokines and several 
pro-inflammatory mediators like trypases and chymases (26;27). In the TNBS colitis model 
the pathology is mast cell dependent, since colitis could not be induced in mast cell deficient 
mice(28). Furthermore mast cell stabilizers (29;30) reduce symptoms of colitis. In our study, 
VSL#3 was able to reduce up-regulation of mast cell related genes in acute phases of colitis. 
During the first acute phase, following the first rectal challenge, this was accompanied by 
suppression of up-regulation of MCP-1 (CCL2), Eotaxin-1 (CCL11), and Eotaxin-2(CCL24). 
These chemokines have been implicated in the recruitment of mast cells (31;32) and can be 
produced by intestinal epithelia cells or leukocytes in the colonic mucosa. Recently, studies 
in the DSS colitis model demonstrated that Ly6ChighCCR2+ inflammatory macrophage are 
the major source of CCL11(33). It might therefore be that the anti-inflammatory effects of 
VSL#3 are partly due to a direct effect on these cells, thereby limiting mast cell recruitment. 
Strategies to modulate mast cell infiltration may bea therapeutic strategy in human IBD, since 
increased numbers of mast cells are found in both inflamed and non-inflamed tissue in UC 
and CD patients (34).
Although several genes downstream TLR, including cytokines and chemokines were 
modulated by probiotics, we did not observe differential expression of all 13 known mouse 
TLR. Also Metacore analysis did not reveal significant enrichment of genes involved in TLR 
signaling. Possibly, such effects require a more dedicated analysis of specific cell type rather 
than a heterogeneous population of cells as present in the intestinal mucosa.
In view of the anti-inflammatory effects of VSL#3 treatment, it was surprising to observe that 
VSL#3 reduced colitis associated upregulation of α-defensin mRNA levels in the inflamed 
colon. α-defensins are predominant antimicrobial factors involved in the host defense against 
bacteria, fungi, protean, and viruses(35). In the intestines these anti-microbial peptide are 
mainly produced by Paneth cells. Until recently, these α-defensins were not considered to 
be produced in the colon of mice(36;37). However, this idea was based on normal colon 
in homeostatic conditions and more recently α-defensins producing Paneth cells were 
described to play a role under inflammatory conditions in the colon(38). Our observations 
are of interest because an increased expression of human defensin A5 and A6 (DEFA5 
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&DEFA6) was also observed in the colon of (pediatric) IBD patients(39;40), which was largely 
due toPaneth cell metaplasia. It has been suggested that the anti-microbial peptides are 
produced as a mucosal defense mechanism to counteract a bacterial attack, induced by 
tissue damage. Therefore, we speculate that reduced α-defensin gene expression in VSL#3 
treated mice, is due to less excessive inflammation and consequently less involvement of 
metaplastic Paneth cells.
The recurrent TNBS colitis model comprises several features of IBD and due to the cytokine 
profiles and histopathological features during the early stages it has similarities with Crohn’s 
disease. These results may be surprising because in human clinical trials probiotics have 
been shown effective in prolonging the remission phase of ulcerative colitis, but not in Crohns’ 
disease (41). However, it should be taken into account that the recurrent TNBS model is 
rather a more generalized model of colitis, with shifting cytokine profiles. Moreover, it should 
be taken into account that our studies reflect the prophylactic activity of probiotic treatment 
whereas in patients treatment was initiated during ongoing disease. In view of our data it is 
tempting to speculate that the primary effect of probiotics is to down-regulate chemokines 
and thereby control the severity of inflammation. Likewise, evaluation of probiotic treatment 
initiated after the induction of colitis may help to reveal which mechanisms are relevant to the 
efficacy of probiotics in this model.
Further studies addressing the effect of probiotics on local chemokine expression and 
underlying mechanisms in colitis may open new avenues for the treatment of IBD
Acknowledgements:
We are grateful to Nicole Worms and Sabine Mourits for excellent technical assistance. This 
study was partly performed in the framework of the Dutch Top Institute Pharma project D1-
101
Mariman.indd   61 21-2-2014   10:01:55
62  |  Chapter 3
Reference	List
1.  Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 
2010;28:573-621.
2.  Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 
2007;448:427-434.
3.  Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J 
Gastroenterol. 2010;45:571-583.
4.  Guandalini S. Update on the role of probiotics in the therapy of pediatric inflammatory bowel 
disease. Expert Rev ClinImmunol. 2010;6:47-54.
5.  Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for 
development of spontaneous colitis and immune system activation in interleukin-10-deficient 
mice. Infect Immun. 1998;66:5224-5231.
6.  Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev 
Immunol. 2010;28:623-667.
7.  Boirivant M, Amendola A, Butera A. Intestinal microflora and immunoregulation. Mucosal 
Immunol. 2008;1 Suppl 1:S47-S49.
8.  Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic 
applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585-1596.
9.  Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1-dependent 
tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol. 2007;178:5859-
5870.
10.  Smyth GK. Linear models and empirical bayes methods for assessing differential expression 
in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
11.  Psarros M, Heber S, Sick M, et al. RACE: Remote Analysis Computation for gene Expression 
data. Nucleic Acids Res. 2005;33:W638-W643.
12.  Santiago C, Pagan B, Isidro AA, et al. Prolonged chronic inflammation progresses to dysplasia 
in a novel rat model of colitis-associated colon cancer. Cancer Res. 2007;67:10766-10773.
13.  Boirivant M, Strober W. The mechanism of action of probiotics. CurrOpinGastroenterol. 
2007;23:679-692.
14.  Pagnini C, Saeed R, Bamias G, et al. Probiotics promote gut health through stimulation of 
epithelial innate immunity. Proc NatlAcadSci U S A. 2010;107:454-459.
15.  Reiff C, Delday M, Rucklidge G, et al. Balancing inflammatory, lipid, and xenobiotic signaling 
pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 
Inflamm Bowel Dis. 2009;15:1721-1736.
16.  Uronis JM, Arthur JC, Keku T, et al. Gut microbial diversity is reduced by the probiotic VSL#3 
and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis. 2011;17:289-297.
17.  Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier 
by maintaining tight junction protein expression and preventing apoptosis in a murine model of 
colitis. Am J PhysiolGastrointest Liver Physiol. 2009;296:G1140-G1149.
18.  Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the 
anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 
2004;126:520-528.
19.  Palmieri O, Latiano A, Salvatori E, et al. The -A2518G polymorphism of monocyte 
chemoattractant protein-1 is associated with Crohn’s disease. Am J Gastroenterol. 
2010;105:1586-1594.
20.  Noguchi M, Hiwatashi N, Liu ZX, et al. Increased secretion of granulocyte-macrophage 
colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion. 
2001;63 Suppl 1:32-36.
21.  Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles 
of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15:341-352.
Mariman.indd   62 21-2-2014   10:01:55
Gene expression profiling identifies mechanisms of protection  |  63 
22.  Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological 
and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 
2009;58:1152-1167.
23.  He SH. Key role of mast cells and their major secretory products in inflammatory bowel 
disease. World J Gastroenterol. 2004;10:309-318.
24.  Chichlowski M, Westwood GS, Abraham SN, et al. Role of mast cells in inflammatory bowel 
disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoSOne. 
2010;5:e12220.
25.  Santos J, Yates D, Guilarte M, et al. Stress neuropeptides evoke epithelial responses via mast 
cell activation in the rat colon. Psychoneuroendocrinology. 2008;33:1248-1256.
26.  He SH. Key role of mast cells and their major secretory products in inflammatory bowel 
disease. World J Gastroenterol. 2004;10:309-318.
27.  Hamilton MJ, Sinnamon MJ, Lyng GD, et al. Essential role for mast cell tryptase in acute 
experimental colitis. ProcNatlAcadSci U S A. 2011;108:290-295.
28.  Rijnierse A, Koster AS, Nijkamp FP, et al. Critical role for mast cells in the pathogenesis 
of 2,4-dinitrobenzene-induced murine colonic hypersensitivity reaction. J Immunol. 
2006;176:4375-4384.
29.  Rijnierse A, Redegeld FA, Blokhuis BR, et al. Ig-free light chains play a crucial role in murine 
mast cell-dependent colitis and are associated with human inflammatory bowel diseases. J 
Immunol. 2010;185:653-659.
30.  Xu X, Weksler-Zangen S, Pikarsky A, et al. Mast cells involvement in the inflammation and 
fibrosis development of the TNBS-induced rat model of colitis. Scand J Gastroenterol. 
2002;37:330-337.
31.  Zimmerman NP, Vongsa RA, Wendt MK, et al. Chemokines and chemokine receptors in 
mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. 
Inflamm Bowel Dis. 2008;14:1000-1011.
32.  Hallgren J, Gurish MF. Pathways of murine mast cell development and trafficking: tracking the 
roots and routes of the mast cell. Immunol Rev. 2007;217:8-18.
33.  Waddell A, Ahrens R, Steinbrecher K, et al. Colonic Eosinophilic Inflammation in Experimental 
Colitis Is Mediated by Ly6Chigh CCR2+ Inflammatory Monocyte/Macrophage-Derived CCL11. 
J Immunol. 2011;186:5993-6003.
34.  He SH. Key role of mast cells and their major secretory products in inflammatory bowel 
disease. World J Gastroenterol. 2004;10:309-318.
35.  Tecle T, Tripathi S, Hartshorn KL. Review: Defensins and cathelicidins in lung immunity. Innate 
Immun. 2010;16:151-159.
36.  Patil A, Hughes AL, Zhang G. Rapid evolution and diversification of mammalian alpha-
defensins as revealed by comparative analysis of rodent and primate genes. Physiol 
Genomics. 2004;20:1-11.
37.  Mastroianni JR, Ouellette AJ. Alpha-defensins in enteric innate immunity: functional Paneth 
cell alpha-defensins in mouse colonic lumen. J Biol Chem. 2009;284:27848-27856.
38.  Wada R, Yamaguchi T, Tadokoro K. Colonic Paneth cell metaplasia is pre-neoplastic condition 
of colonic cancer or not? J Carcinog. 2005;4:5.
39.  Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy 
colon is dysregulated in ulcerative colitis. Gut. 2008;57:1398-1405.
40.  Zilbauer M, Jenke A, Wenzel G, et al. Intestinal alpha-defensin expression in pediatric 
inflammatory bowel disease. Inflamm Bowel Dis. 2010.
41.  Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis. 2008;14:1597-1605.
Mariman.indd   63 21-2-2014   10:01:55





Rob Mariman1,2, Esther Reefman1, Carla Persoon-Deen1, Koen van de 
Mark1, Nicole Worms1, Frits Koning2 and Lex Nagelkerken1
Affi	liations
1 TNO, Metabolic Health Research, Leiden, the Netherlands
2 Leiden University Medical Centrum, Department of Immunohematology and Bloodtransfusion, 
Leiden, the Netherlands
Submitted for publication
Mariman.indd   65 21-2-2014   10:01:56
66  |  Chapter 4
Abstract
Genetic predisposition and environmental factors including the gut microbiota have been 
suggested as major factors in the development and progression of atopic dermatitis. 
Hyperlipidemic human APOC1+/+ transgenic mice display many features of human atopic 
dermatitis, along with a disturbed skin barrier function. Cytokine analysis of serum shows an 
increase of various pro-inflammatory cytokines, but lower levels of IFN-γ. These mice also 
display aspects of colitis evident from macroscopic and histological abnormalities. Genome-
wide transcriptome analysis of the intestine shows upregulation of several genes associated 
with mast cells and eosinophils and this observation was confirmed by demonstrating 
increased numbers of IgE+ and FcRε+ mast cells in the colon and in the skin. Oral treatment 
with L. plantarum resulted in decreased numbers of mast cells in the colon and less severe 
skin pathology, suggesting that modulation of intestinal immune homeostasis contributes to 
the suppression of atopic dermatitis.
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Introduction
Atopic Dermatitis (AD) is a chronic relapsing skin disease characterized by intense pruritus 
and the development of inflammatory lesions[1].The exact etiology, pathophysiology and 
pathogenesis of AD are not fully understood, although multiple genetic and environmental 
factors have been implicated [2]. The incidence of AD in the Western world has dramatically 
increased during the past decades, currently affecting 20% of young schoolchildren and 6% 
of the total population[3]. Atopic diseases, such as rhinitis, asthma and AD, are the result of 
an inflammatory reaction triggered by type 2 T helper (Th2) cell-mediated immune responses 
against ‘innocuous’ antigens (allergens) in susceptible individuals [4]. Environmental 
changes associated with a Western lifestyle are thought to be involved in the increased 
incidence of atopic diseases. According to the hygiene hypothesis [5,6] reduced exposure 
to pathogenic and nonpathogenic microbes with concomitant decreased cellular immunity 
enables enhanced Th2 responses [7].
The intestinal microbiota plays a key role in immune homeostasis and distinct enterotypes 
may be associated with established and developing allergic disease [8-11].Epidemiological 
data showed that the intestinal flora of atopic children differs from that in healthy children 
[9]. Interestingly, Lactobacillus and Bifidobacteriumspp are more frequently found in the 
intestinal flora of non-allergic children compared with allergic children [12]. Accordingly, 
probiotic bacteria have been suggested for the treatment of AD[13]. Both animal and clinical 
studies have shown promising effects of probiotic bacteria by modulating allergic responses 
[14,15].Although the mode of action of probiotic bacteria is still unclear, part of their beneficial 
effects in AD patients may be explained by the induction of regulatory cytokines [16].
Interestingly, L. rhamnosus has been shown to improve barrier integrity of the small intestine 
in children with AD [17]. This observation is in line with the notion that the intestinal microbiota 
and probiotic bacteria may exert effects by contributing to intestinal immune homeostasis 
and barrier function [18].
Recently, we demonstrated that probiotic treatment inhibits the induction of colitis, largely 
by reducing the local pro-inflammatory milieu [19]. Because the gut-associated mucosal 
immunesystem is considered as a key regulator of inflammatory diseases [20], we wished 
to evaluate intestinal inflammation in human APOC1+/+ transgenic mice and study effects 
of treatment with probiotic bacteria .Previously, we demonstrated that these mice have a 
disturbed lipid profile [21] and develop skin pathology that resembles several aspects of 
human atopic dermatitis [22,23]. As compared to other mouse models of atopic dermatitis, 
the APOC1 mouse model has the advantage that it combines skin inflammation with 
a disturbed skin barrier integrity [24]. In the present study, we show that these mice with 
a genetic predisposition to develop strong Th1 immunity, show Th2-type inflammation of 
the colon. Treatment with L. plantarum not only reduced intestinal inflammation but also 
ameliorated features of AD in these mice.
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In this study we wished to evaluate the integrity of the intestine in human APOC1+/+ transgenic 
mice. Previously, we reported that these mice show hyperlipidemia and the development of 
AD [21,22]. Accordingly, the mice in this study showed increased levels of triglycerides and 
cholesterol compared to their heterozygous littermates (Figure 1A). Furthermore, lipoprotein 
fractionation by FPLC on plasma of 4-hour fasted mice showed that the total cholesterol was 
mainly composed of VLDL (Figure 1B). These mice displayed a variable severity of AD, based 
Figure	1.	Disturbed	serum	lipid	levels	and	symptoms	of	atopic	dermatitis	in	human	APOC1	
transgenic	mice.
(A) Plasma triglycerides and total cholesterol are elevated in APOC1 homozygous (APOC1 +/+) 
(B) 4-hour fasted mice were bled, and plasma was pooled per group (n=8-12 / group). The distribution 
of cholesterol over the individual lipoproteins was determined after separation by fast protein liquid 
chromatography. 
(C) Increased transepidermal water loss (TEWL) was observed in the upper dorsal area of 15-week-
old APOC1+/+. Values are means ± SD (n = 8-12 per group. *p <0.05, ** p<0.01, ***P<0.001)
(D) In a separate cohort of 28 APOC1 +/+ mice (♂/♀ n = 28), TEWL was correlated to the severity of 
dermatitis according to the TIS score as well as to skinfold thickness. 
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on three parameters: 1) the clinical appearance2) thickening of skin and 3) trans-epidermal 
water loss (TEWL). APOC1+/+ mice displayed increased TEWL(Figure1C),indicative for 
loss of integrity of the skin barrier. As shown in Figure 1D, these TEWL-values were highly 
correlated both with the three-item severity score (r2= 0.90, p<0.0001) and the thickness 
of the skin (r2= 0.68, p<0.0001). No obvious correlation between serum lipids and AD 
parameters were observed at endpoint.
Apart from the skin pathology, these APOC1+/+ mice displayed intestinal abnormalities. As 
shown in Figure 2A, stool in APOC1+/+ was soft as compared to wild-type animals. In the 
distal part of the colon soft feces was observed in >90% of APOC1+/+ mice (n=16), but not in 
wild-type mice. These abnormalities in stool consistency were accompanied by macroscopic 
and histopathological changes of the colon. APOC1+/+ had an increased colon length (Figure 
2B) and showed increased thickening of the distal colon (Figure 2C).Furthermore, APOC1+/+ 
mice displayed increased inflammation of the colon (Figure 2D).
Figure	2.	Changes	in	colon	morphology	of	human	APOC1	transgenic	mice
Overexpression of human APOC1 is associated with soft feces in the distal part of the colon (A). 
Colons of these mice show a significantly increased length (B), thickness (C) and histological score 
(D). Bars represent group averages, error bars represent SD. Mann-Whitney U-test; * p<0.05, 
** p<0.01, *** p<0.001.
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Genome-wide	gene	expression	profiling	of	the	colon	ofAPOC1	transgenic	mice
To gain further insight into the abnormalities observed in the colon ofAPOC1 +/+ mice, we 
evaluated genome-wide gene expression in colon and small intestine. Principal Component 
Analysis (PCA) was performed using all 26,000 probes on the microarray. This unsupervised 
approach separated the APOC1+/+ mice from the wild-type mice. Figures 3A and 3B show 
PCA plots illustrating differential gene expression patterns between APOC1+/+ and wild-
type mice for colon and small intestine. Statistical analysis between ApoC1+/+ and wild-type 
mice identified 1,252 genes and 1,001 genes that were differentially expressed (fold change 
>1.5, pBayes< 0.05) in the colon and small intestine, respectively. To further elucidate the 
processes associated with these differentially expressed genes, MetaCore™ software was 
applied to identify enriched process networks. The ten most significant processes are depicted 
in Figure 3C. Five out of 10 and 3 out of ten of these processes were related to immune 
function in small intestine and colon, respectively. In view of the observed changes in colon 
morphology, we further focused on processes in the colon. Detailed analysis of immune 
function revealed elevated levels of mast cell related transcripts including cpa3,cma2, mcpt-
1, mcpt-4, and mcpt-9 in colons of APOC1+/+ mice compared to wild-type mice (Figure 4A). 
Immunohistochemical staining of FcεRI+ and IgE+ cells confirmed the presence of large 
numbers of mast cells in the lamina propria of APOC1+/+ mice as shown in Figure 4B and 4C, 
respectively. The expression of several genes encoding pro-inflammatory chemokines 
Figure	3.	Genome	wide	gene	expression	profiling	of	the	intestines	of	APOC1	transgenic	mice.
Two-dimensional visualization of principal component analysis (PCA) constructed with all genes on 
the microarray, discriminating APOC1+/+ mice form wild-type C57BL/6 mice. Each dot represents 
the expression profile of an individual mouse for colon (3A) and small intestine (3B). Top ten enriched 
process networks are depicted (3C).
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Figure	4.	APOC1	transgenic	mice	have	increased	levels	of	mast	cells	in	the	colonic	mucosa
(A) Gene expression levels of mast cell-associated enzymes in wild-type C57BL/6 and APOC1+/+ 
mice. Mean ± SEM was based on 6 mice / group
(B) Colon tissue was immunostained with anti-IgE, anti-FcεR1 and counterstained with hematoxylin. 
Quantification of positive cells was based on 4-5 non-serial colon sections. Results are depicted as 
mean ± SEM for all individual mice per group. Statistical significance was calculated using the Mann-
Whitney U test. *, P < 0.05; **, P < 0.01.
Figure	5.	Reduced	IFN-γ	and	IL-10	levels	in	the	serum	of	APOC1+/+	mice.
Serum samples of APOC1+/+ and C57BL/5 mice were evaluated using a 23-plex bead assay as 
indicated in Material & Methods. Only cytokines that showed significant differences between the 
groups are depicted.
Bars represent group averages, error bars represent SD. Mann-Whitney U-test; * p<0.05, ** p<0.01, 
*** p<0.001
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associated with the recruitment of mast cells [25] were also up-regulated in APOC1+/+ mice 
compared to wild-type controls. These include Ccl-5, Ccl-11 and CXCL-14; enhanced mRNA 
expression of these chemokines was accompanied by increased expression of eosinophil 
associated transcripts like RNAse2 and Ear2, -8, 10 (see supplementary Table). In contrast, 
Cxcl-9 and Cxcl-10 as well as IL-18 were down-regulated in APOC1+/+ mice compared to 
wild-type mice.
Several pro-inflammatory cytokines, including IL-12p40, IL-6 and IL-1α, were increased 
in serum of APOC1+/+ mice (Figure 5). Th2 cytokines (IL-4, IL-5, IL-13) were below the 




APOC1+/+ mice (12 mice per group) were treated from an age of 8 weeks onwards and sacrificed after 
8 weeks of treatment with vehicle,VSL#3 or L. plantarum. Trans-epidermal water loss (A), skinfold 
thickness (B) and excoriations (C) were evaluated during the treatment period for each individual 
mouse compared to baseline levels. Repeated measurement ANOVA, *p < 0.05, **p < 0.01. After 
sacrifice, colons were histological evaluated after staining with toluidine blue and assessed in a semi-
quantitative fashion(D). Results are depicted as mean ± SEM. *Mann-Whitney U-test, p < 0.05.
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Decrease	inflammation	of	colon	and	atopic	dermatitis	in	APOC1+/+	mice	treated	with	
L.	plantarum
Recently, we demonstrated that probiotic treatment affects intestinal gene expression and 
renders BALB/c mice resistant to the induction of colitis [19]. We were therefore interested 
whether oral administration of probiotics would have a favorable effect on the development of 
intestinal and skin inflammation. Eight-week-old APOC1+/+ mice with established symptoms 
of AD were randomized over 3 groups (12 mice / group) and treated with VSL#3, L. plantarum 
or vehicle during a period of 8 weeks. As shown in Figure 6A, L. plantarum treatment 
delayed the loss of the skin barrier integrity as measured by TEWL (repeated-measures 
ANOVA P < 0.001). Furthermore, L. plantarum treated mice did not show progression of skin 
thickening, in contrast to VSL#3, which was ineffective in this respect (RM ANOVA P < 0.001) 
(Figure 6B). Although L. plantarum treatment did not affect the three-item severity score, 
combining three different parameters, it showed a favorable effect on the development of 
excoriations as shown in Figure 6C (repeated-measures ANOVA P < 0.01).
Moreover, mice treated with VSL#3 or L. plantarum displayed less inflammation of colon, 
evident from decreased infiltration by mast cells as shown in Figure 6D.
Discussion
The largest body of immune cells is found in the gastro-intestinal tract and referred as gut-
associated lymphoid tissue (GALT). The GALT is continuously exposed to intestinal bacteria, 
which are recognized by intestinal epithelial cells and dendritic cells, thereby shaping the 
immune system [26,27]. An uncontrolled immune response against the commensal microbiota 
has been linked to several (chronic) intestinal disorders, such as Crohn’s disease, ulcerative 
colitis and celiac disease [28,29]. Moreover, perturbations in the gut microbiota have been 
linked to dysregulated immune responses and inflammatory diseases at peripheral tissue 
sites [30].A strong association between the development of allergic disorders like asthma 
and atopy and the composition of the fecal microbiota of infants has been reported [31,32].
In this study, we showed that human APOC1+/+ transgenic mice that show human AD-
like features also show inflammation of colon and substantial changes in intestinal gene 
expression. Furthermore, oral administration of L. plantarum resulted in amelioration of both 
colon and skin pathology in these mice.
Genome wide associated studies identified only one common gene (C11Orf30 ) on susceptible 
loci in AD and inflammatory bowel disease (IBD) patients [33,34]. However, epidemiological 
studies showed an increased prevalence of AD and IBD patients [35,36]. Recently, a large 11-
year prospective study demonstrated an association between ulcerative colitis - a Th2 driven 
intestinal inflammation – and AD. Additionally, patients with AD appear to have an increased 
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intestinal permeability [37][17]. Herein, we showed that AD-prone humanAPOC1+/+ mice 
have colon abnormalities evident from altered macroscopic features and stool consistency. 
Unsupervised analysis of the transcriptome data set also revealed several genes in the 
small intestine related to barrier and host defense, such as anti-microbial peptides, that were 
down-regulated (data not shown). Reports on macroscopic and histological features of the 
large intestine in patients with atopic dermatitis are scarce. To our knowledge, only one 
study by Arisawa et al describes pathological examination of the colon of these patients 
[38]. They concluded that AD patients might have a latent chronic inflammation in the large 
intestine, marked by increased eosinophilic infiltration in the intestinal mucosa, as compared 
to healthy individuals [8]. Interestingly, transcriptome analysis of the colon of APOC1+/+ mice 
also implicated a role for eosinophils and mast cells.
C57BL/6 is a prototypeTh1 mouse strain with high expression of IFN-γ and low levels of IL-4 
[39]. However, human APOC1+/+ mice have decreased serum levels of IFN-γ and IL-10, 
whereas general inflammatory mediators such as IL-12p40, IL-6 and TNF-α were increased. 
In the colon, expression of Cxcl-9,Cxcl-10, Il-18 – formally depicted as IFN-γ inducing factor 
– was decreased in APOC1+/+ compared to wild-type mice controls. These findings together 
with the infiltration of IgE and FcRε+ cells suggest a Th2-driven inflammation in the colonic 
mucosa of APOC1+/+ mice.
Epidemiological studies have indicated that the incidence of allergies, including atopic 
dermatitis, has increased during the past decades in many western countries [40]. This 
increased disease incidence seems to be associated with a variety of environmental 
factors: the extended hygiene hypotheses, antibiotic use, lifestyle changes or a western 
type diet [6,41]. According to this hypothesis, commensal gut bacteria might induce an anti-
inflammatory response by inducing regulatory T cells [42]. It might also be that a lack of 
pro-inflammatory stimuli due to increase hygiene results in a decreased Th1 response and 
an increased Th2 response causing allergic diseases [43]. Therefore modulating intestinal 
immune homeostasis by oral administration of selected probiotics have been proposed as a 
strategy to treat or prevent atopic dermatitis. In this study L. plantarum diminished Th2 type 
inflammation in the colon, i.e. decreased numbers of mast cells, along with favorable effects 
on aspects of atopic dermatitis. Failure of the probiotic mixture VSL#3 in ameliorating skin 
pathology, despite favorable effects on colon inflammation, suggests that different strains 
may act differently in diverse pathological conditions.
In conclusion, our data suggest that over-expression of human APOC1 results in a Th2-
type inflammatory response in intestine and skin, despite a Th1-type background. Because 
inflammation of both tissues is improved by oral administration of probiotic bacteria it is 
tempting to speculate that ensuring intestinal immune homeostasis contributes to the control 
of atopic dermatitis.
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Materials	&	methods
Mice
Human APOC1(+/+) transgenic mice were generated on a C57BL/6 background as described 
previously [21]. Wild-type C57BL/6 mice were purchased from Charles River and housed 
under the same conditions. All studies were performed in the animal facility of TNO with 
a 12h light/dark cycle. Mice had free access to standard mouse chow (SSNIFF R/M-H, 
Bioservices B.V., Uden, the Netherlands) and water. Animal experiments were approved by 
the institutional ethical committee on animal care and experimentation.
Probiotic treatment
VSL#3 (Ferring Pharmaceuticals, Berkshire, UK) was purchased as a commercially 
available probiotic mixture containing freeze-dried bacteria (Bifidobacterium longum, 
B. breve, B. infantis, Lactobacillus acidophilus, L. plantarum, L. casei, L. bulgaricus, and 
Streptococcus thermophilus).
L. plantarum NCIMB8826 was grown until mid-exponential growth phase (OD600nm = 1) as 
described previously [19].
Assessment	of	dermatitis
Mice were monitored regarding the progression of dermatitis with the use of a Three-Item-
Score (TIS) score comprising the following items: 1) scaling, 2) papules and lichenification, 
3) excoriations, as described previously [23]. Each of the items were graded from 0 (normal) 
to 3 (severe), and included in a TIS scale ranging from 0 to 9. Thickness of a fold of skin 
in the upper dorsal area was measured employing a digital caliper (Mitutoyo, Veenendaal, 
The Netherlands). TEWL was measured by placing a 12-mm detection probe of a skin 
evaporative water recorder (Tewameter® TM 300, Courage &, Khazaka, Cologne, Germany) 
on the upper dorsal skin area of each individual mouse.
Transcriptome	analysis
Total RNA was isolated from frozen colon or small intestine using TRIzol reagent (Invitrogen, 
Breda, The Netherlands) according to the instructions of the manufacturer. RNA was treated 
with DNAse and purified using a nucleospin RNAII Total RNA Isolation kit (Macherey-
Nagel, Düren, Germany). RNA integrity was checked employing an Agilent 2100 bioanalyzer 
(Agilent Technologies, Amsterdam, The Netherlands) with 6000 Nano Chips, according to 
the instructions of the manufacturer. RNA integrity numbers were above 8.7.
Microarray studies were performed as described previously [44].In short, biotinylated cRNA 
was prepared using the IlluminaTotalPrep RNA Amplification Kit (Ambion, Inc., Austin, TX, 
USA) starting with 500 ng total RNA. Per sample, 750 ng of cRNA was used to hybridize to 
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the SentrixMouseRef-8 BeadChips (Illumina, Inc., San Diego, CA, USA). Each BeadChip 
contains eight arrays and each of the arrays harbors 25697 probes. GeneSpringGX 11.0 
was used for quantile normalization of the probe-level, background subtracted expression 
values. Differentially expressed probes were identified using the limma package of the R/
Bioconductor project, applying linear models and moderated t-statistics that implement 
empirical Bayes regularization of standard errors. The statistical analyses were performed 
through The Remote Analysis Computation for gene Expression data (RACE) suite at 
http://race.unil.ch [45]. p-values below 0.05 were used as a threshold for significance of the 
differential expression. Pathway analysis software Metacore (V6.2), a highly curated Web-
based application for identification of gene ontology processes in input gene sets, was used 
to identify biological processes (GeneGo Inc., St. Joseph, MI, USA).
Histological	assessment	of	the	colon
Following the assessment of macroscopic parameters, colons were dissected and fragments 
were fixated in 4% buffered formalin and embedded in paraffin. Sections of 5 µm were 
stained with hematoxyllin-eosin-saffron. Inflammation was scored in a blinded manner in 4 to 
6 non-sequential sections per colon fragment at a 400× magnification, according to a semi-
quantitative scoring system with a scale from 0 to 4, based on the presence of inflammatory 
infiltrates and mucosal damage.
Immunohistochemisty
Colon fragments were fixated in 4% buffered formaldehyde and embedded in paraffin, or 
embedded in Tissue-Tek and snap-frozen in liquid nitrogen. From paraffin-embedded tissue, 
5 µm sections were stained with toluidin blue and counterstained by hematoxylin-eosin, to 
enable the assessment of mast cells in semi-quantitative fashion. Immunohistochemistry 
was performed on 6 µm cryo-sections with antibodies specific for IgE (R35-118) and FcεRI 
(MAR-1) (both obtained from BD Biosciences San Diego, CA, USA). Positive cells were 
counted at a 400× magnification.
Lipid	and	lipoprotein	analysis
After a 4-hour fasting period, EDTA-plasma was collected. Total plasma cholesterol and 
triglyceride levels were measured (Roche Diagnostics). Lipoprotein profiles were obtained 
by FPLC, as described previously [46].
Cytokine	and	chemokine	quantification	in	serum
Cytokine concentrations in serum obtained at each sacrifice were determined by Multiplex 
analysis using a Bio-Plex Pro 23-Plex Panel, including IL-1α, -1β, -2, -3, -4, -5,-6, -9, -10, 
-12(p40), -12(p70), -13, -17, IFN-γ, TNF-α, RANTES, MIP-1α and -1β, MCP-1, KC, G-CSF, 
GM-CSF, and eotaxin (Bio-Rad Laboratories, Hercules, CA, USA) .
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Abstract
Probiotic bacteria express a wide range of molecular structures that bind to receptors on 
innate immune cells and mediate health-promoting effects in the host. We have recently 
demonstrated in a colitis model that favorable effects of the probiotic mixture VSL#3 may 
in part be due to suppression of intestinal chemokine expression. To obtain more insight 
into the underlying mechanisms, we studied modulation of bone marrow derived dendritic 
cells (BM-DC) from BALB/c (Th2 biased) versus C57BL/6 (Th1 biased) mice. Our data show 
that VSL#3 differed from pure TLR ligands by inducing higher levels of various cytokines, 
including IL-12p70, IL-23 and IL-10.Dedicated TLR-arrays were employed to profile mRNA 
from BM-DC cultured with LPS, VSL#3, or a combination of both. This approach identified (I) 
a cluster of genes that was up-or down-regulated, irrespective of the stimulus, (II) a cluster 
of genes that was synergistically up-regulated by LPS and VSL#3 in BM-DC from C57BL/6 
mice, but not from BALB/c mice, (III) a cluster of LPS-induced genes that were suppressed 
by VSL#3, in particular chemokines. These data show therefore that this probiotic mixture 
has both pro- and anti-inflammatory effects on BM-DC, and suggest that their immune-
modulating properties in vivo may depend on the genetic background of the host.
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Introduction
Dendritic cells (DC) are bone marrow derived antigen-presenting cells capable of inducing 
protective adaptive immune responses or tolerance. DC are equipped with Toll-like receptors 
(TLR) and C-type lectin receptors that activate different signalling pathways in response to 
microorganisms [1].TLR expressed on the cell surface predominantly bind bacterial products, 
such as lipopeptides and peptidoglycan (TLR1, -2 and -6), lipopolysaccharide (LPS, ligand 
ofTLR4) and flagellin (TLR5). TLR3, -7, -8 and -9 reside in intracellular organelles and 
recognize microbial nucleic acids [2]. In the intestinal mucosa, various subsets of DC are in 
close contact with the intestinal microbiota and continuously migrate from the lamina propria 
to the mesenteric lymph nodes, ensuring a balance between immunity and tolerance [3]. 
Lamina propria DC can be divided into two major classes: CD103- DC induce Th1 and Th17 
responses, whereas CD103+ DC rather induce regulatory T cells [4]. Different types of DC 
develop from bone marrow progenitors and therefore immature bone marrow derived DC 
(BM-DC) are widely used in in vitro studies. Such studies contribute to a better understanding 
of the mechanism by which microorganisms modulate immune responses in vivo. Although 
not identical to intestinal DC, it has been demonstrated that splenic DC from Th1-prone 
C57BL/6 mice and Th2-prone BALB/c mice respond differently to microbial stimuli [5-7]and 
this may in part be explained by differences in TLR expression. BALB/c mice express higher 
levels of TLR2, -4, and -5 mRNA, whereas C57BL/6 mice express more TLR9 mRNA [8]. In 
addition, the expression of the macrophage mannose receptor on BM-DC is mouse-strain 
specific, and this phenomenon may influence antigen-uptake by such cells [9].
Probiotic bacteria modulate DC via surface expression and/or secretion of products which 
function as ligands for TLR and C-type lectin receptors. The expression of these ligands 
depends on bacterial species, growth phases and available nutrients, and this explains in 
part that different species and strains of probiotics vary in their ability to induce cytokines 
and chemokines. [10][11][12]
Recently, we demonstrated that treatment of BALB/c mice with a mixture of probiotic bacteria 
(i.e. VSL#3) has profound effects on gene expression in the colons of mice subjected to colitis 
induction, with favorable effects on the development of disease [13]. However, substantial 
variability in the response of human subjects to probiotic interventions has been found [14], 
suggestive for an influence of genetic and environmental factors.
To gain more insight into the influence of genetic background, we choose to study BM-DC 
from two genetically distinct mouse strains and evaluate their response to the probiotic 
mixture VSL#3in vitro, as compared to ultrapure TLR ligands. Our results, obtained by 
dedicated gene expression profiling of genes related to TLR-signalling and by studying 
cytokine production, suggest that VSL#3 may display both pro- and anti-inflammatory 
effects, dependent on mouse strain.
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Materials and methods
Mice
Seven- to eleven–week-old C57BL/6 mice (Charles River, Maastricht, Netherlands) and 
BALB/c mice (Janvier, St. Berthevin, France) were used in this study. All animal experiments 
were conducted with the approval of the Institutional Animal Welfare Committee, filed as 
number DEC2661, in compliance with European Community specifications regarding the use 
of laboratory animals.
Isolation	and	culture	of	BM-DC
BM-DC were isolated as described previously[15], with slight modifications. Briefly, bone 
marrow was flushed from femur and tibia. Cells were passed through nylon mesh to obtain 
a single cell suspension. After a single wash step, cells were cultured in RPMI 1640 medium 
containing 10% foetal bovine serum (Lonza, Verviers, Belgium), 2mM L-glutamine, 100 U/ml 
streptomycin, 100 μg/ml penicillin (Gibco, San Diego, CA, USA), 50μM β-mercaptoethanol 
(Sigma Adrich, Zwijndrecht, The Netherlands) in the presence of 20 ng/ml recombinant mGM-
CSF (Peprotech, Rocky Hill, NJ, USA). Cells were cultured (106 cells/ml) at 37oC. Twothirds 
of the culture medium were refreshed on days 3 and 6. After 8 days of culture non-adherent 
and loosely adherent BM-DC were collected and used for stimulation experiments. Viability 
of cells (>95%) was assessed by trypan blue dye exclusion. Cells were cultured at a cell 
density of 106/ml and stimulated with TLR-ligands and/or probiotic bacteria at concentrations 
indicated in the figure legends.
Reagents
Pam3CSK4, poly I:C,LPS E. coli K12, Flagellin S.typhimurium, CpGODN1826, Imiquimod and 
Peptidoglycan from E. coli 0111:B4were purchased from Invivogen (San Diego, CA, USA). All 
of these ultra-pure TLR ligands were endotoxin free(<0.001 endotoxin units/μg), except for 
peptidoglycan which contained <125 endotoxin units /ml.
VSL#3, a mixture containing freeze-dried B.longum, B.breve,B. infantis, L.acidophilus, 
L.plantarum, L.casei, L.bulgaricus and S.thermophilus, was purchased fromFerring 
Pharmaceuticals (Berkshire, UK). L. plantarum NCIMB8826andB.animalis ssp. lactisBB-82 
weregrown at 37 oC in Mann-Rogusa Sharpe (MRS) broth (Scharlau Chemie, Barcelona, 
Spain) until mid-exponential density (OD600nm = 1). Bacteria were washed twice in phosphate-
buffered saline (PBS, pH 7.4). Lyophilized bacteria were prepared by freezing bacterial pellets 
(-80oC) before overnight lyophilisation in a freeze-dryer under vacuum (40 mBar). Lyophilised 
bacteria were stored at -20oC until use.
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RNA	isolation	and	RT-qPCR
Total RNA from 106 cells was isolated using an RNAEasy Kit (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s instructions. Five hundredng RNA werereverse transcribed 
into single stranded cDNA using a High Capacity RNA-to-cDNA kit (Applied Biosystems 
(AB), Carlsbad, CaliforniaUSA) and incubated for 60 minutes at 37oC and 5 minutes at 95oC. 
cDNA was amplified employing a 7500 Fast Thermal cycler (AB, USA) using SYBRgreen 
PCR master mix (AB, USA). Thermal cycling parameters consisted of 1’ at 50oC, 10’ at 95oC, 
followed by 40 cycles of 15’’ at 95oC s and 1’at 60oC. Primer pairs were for Il12p35: 5′-CTG 
GAG CAT CCG AAT TGC A-3′ (sense, S) and 5′-CAT CCT CTG AGA TTT GAC GCT TT-3′ 
(anti-sense, AS); Il23p19: 5′-GGC AAC TTG GAC CTG AGG AG-3′ (S) and 5′-CAT GGG CTC 
TCG GTC CAT AG-3′ (AS); Cxcl9: 5′-CCT AGT GAT AAG GAA TGC ACG ATG-3′ (S) and 
5′-CTA GGC AGG TTT GAT CTC CGT TC-3′ (AS); Cxcl10: 5′-ATC ATC CCT GCG AGC CTA 
TCC T-3′ (S) and 5′-GAC CTT TTT TGG CTA AAC GCT TTC-3′ (AS); B2m: 5′- acc gtg aaa 
aga tga tga ccc ag-3′ (S) and 5′- agc ctg gat ggc tac gta ca-3′ (AS); ); Il12p40: 5′-GGA AGC 
ACG GCA GCA GAA TA-3′ (S) and 5′-AAC TTG AGG GAG AAG TAG GAA TGG-3′ (AS). 
Gene expression levels were quantified according to the formula: 2-(Cti-Cta) where Cti is the 
cycle threshold of the gene of interest and Cta is the cycle threshold value for β-actin.
PCR	array
Expression of genes involved in TLR pathways was studied by using the RT2-ProfilerPCR 
Array (Mouse TLR-Signaling Pathway) from SABiosciences (Frederick, MD, USA).This 
array combines the quantitative performance of SYBR Green-based real-time PCR with the 
multiplegene profiling capabilities of a microarray. 96-well plates containing gene-specific 
primer sets for 84 relevant TLR pathway genes, 5 housekeeping genes, and 2 negative 
controls were used. For each experimental condition, RNA was isolated as described above. 
Gene expression was normalized to internal controls (housekeeping genes) to determine the 
fold change in gene expression between test and control samples by ΔΔCt (SA Bioscience).
Cytokine/chemokine	analysis
Cytokines were measured in the supernatants of BM-DC cultures 24 hours after cell 
stimulation using commercially available ELISA kits for IL-12p70, IL-12p40, IL-23p19, IL-10, 
IL-6, and TNF-α (Ebioscience, San Diego, CA, USA). Chemokines (CXCL-9 and CXCL-
10) were quantified using a multiplex immunoassay (Invitrogen). Assays were performed 
according to the manufacturer’s instructions.
Flowcytometryanalysis
BM-DC were phenotypically characterized before and after 24 hours of stimulation. Cells 
were collected and washed with PBS. 2 x 105 cells were incubated (30 min, 4oC, protected 
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Figure	1.	Flowcytometry	and	gene	expression	profiling	reveals	phenotypic	differences	
between	BM-DC	from	C57BL/6	and	BALB/c	mice
A)	Immature BM-DC generated in the presence of GM-CSF were stained with PE-labelled anti-
CD103 and APC-labelled anti-CD317 and evaluated by flowcytometry. Filled histograms show the 
fluorescence intensity for each marker. Dotted lines reflect staining with isotype control antibodies. 
The percentage of cells expressing these markers is indicated in each panel.
B)	mRNA isolated from immature BM-DC was used to evaluate the expression of genes involved in 
TLR signaling. Results (i.e. an algorithm expressing Ct of the gene of interest relative to the Ct of the 
housekeeping gene) for C57BL/6 BM-DC (Y-axis) were plotted against results for BALB/c BM-DC 
(X-axis). Genes that showed at least a 3-fold difference in expression between C57BL/6 or BALB/c 
BM-DC are indicated.
C)	Differences in TLR gene expression between BM-DC from C57BL/6 and BALB/c mice. mRNA 
isolated from immature BM-DC was amplified by quantitative RT-PCR and Ct-values for each 
transcript were normalized to a panel of six housekeeping genes. These normalized Ct values are 
inversely correlated to the level of mRNA expression. Bars represent the normalized Ct values ± SD 
for BM-DC from 3 individual mice. Student’s t-test: * p<0.05, ** p<0.01, *** p<0.001.
Mariman.indd   84 21-2-2014   10:02:04
The probiotic mixture VSL#3 mediates  |  85 
from light) with monoclonal antibodies. The following dye-conjugated antibodies CD11c-
PerCP/Cy5.5 (N418), CD86-FITC (B7-2GL-1), CD80-Pacific Blue (16-10A1), MHCII-PE 
(M5/114.15.2), CD317-APC (927), CD103-PE(2E7) were purchased fromBD Biosciences (San 
Diego, CA, USA). Flowcytometric analyses were performed with a fluorescence-activated cell 
sorter (FACSCanto II, BD Biosciences) and analyzed with FACSDiva Software 6.1.2.Gating 
of positive cells was based on the results obtained with isotype control antibodies.
Statistical	analysis
Statistical analyses were performed with the Mann-Whitney U-test or Student’s t test if the 




BM-DC from BALB/c and C57BL/6 mice were generated by 8 days of culture under identical 
conditions in the presence of GM-CSF. As shown in Figure 1A, BM-DC from BALB/c mice 
showed a higher expression of CD103 and CD317 as compared to BM-DC from C57BL/6mice. 
Moreover, gene expression profiling of transcripts involved in TLR-signalling showed higher 
expression ofTlr3and Ifnb in cells from BALB/c mice (Figure 1B).BM-DC from BALB/c mice 
also showed significantly higher levels of mRNA encoding TLR5, -6 and -9, as compared to 
BM-DC from C57BL/6 mice (Figure 1C).
Before studying the response of these cells to probiotic bacteria we first evaluated their 
response to ultrapure TLR ligands. Flowcytometric analysis of the stimulated BM-DC 
confirmed similar up-regulation of CD80, CD86 and MHC class II expression, regardless 
of mouse strain or TLR-ligand (data not shown). However, BM-DC from BALB/c and 
C57BL/6mice showed a different cytokine response to several TLR-ligands, as shown in 
supportive Figure 1.In particular, the IL-12p70 production in response to LPS or CpG was 
higher in C57BL/6 BM-DC. These data indicate that the genetic background strongly 
influences the phenotype and response of BM-DC to pure TLR ligands.
The	probiotic	mixture	VSL#3	and	LPS	synergistically	induce	IL-12p70	and	IL-23	
production	in	BM-DC	from	C57BL/6mice
Probiotic bacteria are far more complex than ultrapure TLR ligands and therefore we studied 
to what extent the genetic background of BM-DC would influence their response to VSL#3.
We therefore stimulated BM-DC with increasing numbers of bacteria, in the absence 
or presence of LPS. Figure 2A shows the production of TNF-α, IL-6 and IL-12p70upon 
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Figure	2.	BM-DC	from	C57BL/6	and	BALB/c	mice	differ	in	their	response	to	probiotic	bacteria	
and	pure	TLR	agonists.
(A) Production of IL-6, TNFα, and IL-12p70 by BM-DC from C57BL/6 mice, stimulated with various 
VSL#3 concentrations (CFU/ml) in the absence or presence of 1 µg/ml LPS.
(B) Synergistic induction of IL-12p70 and IL-23 depends on the genetic background of the bone 
marrow donor mouse. IL-12p70 and IL-23 secretion by BM-DC from C57BL/6 mice (white bars) or 
BALB/c mice (hatched bars) stimulated with bacteria, LPS or a combination of both, is shown as a 
percentage of cytokine levels secreted in response to LPS alone (C57BL/6: 138 pg/ml IL-12p70 and 
117 pg/ml IL-23; BALB/c: 14 pg/ml IL-12p70 and 258 pg/ml IL-23) . Results represent the mean ± SD of 
3 mice per group. Mann-Whitney U test: * p<0.05, ** p<0.01, *** p<0.001. Data are representative for 2 
to 3 independent experiments.
(C) Relative Il12p35and Il23p19 gene expression by C57BL/6 BM-DC after stimulation with LPS (1 
µg/ml), CpG (5 µg/ml), Pam3CSK4 (100 ng/ml) and poly I:C (50 ng/ml). Results are expressed as a 
percentage (mean ± SD of 3 individual mice) of mRNA expression, induced by stimulation with VSL#3 
alone. Synergistic induction was only found with the combination of VSL#3 and LPS. Results were 
evaluated statistically using the Mann-Whitney U test; * p<0.05.
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Figure	3.	Differences	in	gene	expression	between	BM-DC	from	C57BL/6	mice	and	BALB/c	
mice.
Clusterogram showing the supervised hierarchical clustering of genes related to TLR-signaling after 
stimulation of BM-DC with medium, LPS (1 μg/ml), VSL#3 (107 CFU/ml), or a combination of both. 
Relative expression levels for each individual gene are presented as minimum (green) and maximum 
(red). Columns represent gene expression profiles of BM-DC from C57BL/6 and BALB/c mice, 4 hours 
after stimulation (3 individual mice per strain and experimental condition). 
Mariman.indd   87 21-2-2014   10:02:09
88  |  Chapter 5
stimulation of C57BL/6 BM-DC. All of these cytokines were stimulated by VSL#3 in a dose-
dependent fashion. Simultaneously, VSL#3 strongly induced IL-10 production (supportive 
Figure 1). The combination ofVSL#3 and LPS resulted in an additive effect on the secretion 
of all of these cytokines. However, at a VSL#3:DC ratio of 10:1 a synergistic induction of IL-
12p70 was observed.
Figure 2B shows that BM-DC from C57BL/6 mice showed a synergistic increase of IL-12p70 
and IL-23in response to VSL#3 and LPS, whereas such an effect was not observed with BM-
DC from BALB/c mice. This difference in response of BM-DC from C57BL/6 and BALB/c mice 
was confirmed for IL-12p70 with L. plantarum, one of the constituents of VSL#3 (Figure 2B).
Recently, it has been shown that TRIF- and MyD88-dependent TLR ligands act in synergy 
to induce the release of IL-12p70 in BM-DC[16].However,VSL#3 did not show synergy with 
the MyD88-coupled TLR-ligands CpG and Pam3CSK4, or the TRIF-coupled TLR ligand poly 
I:Cwith regard to the induction of IL-12p70 and IL-23p19(Figure 2C). Synergy in IL-12p70 and 
IL-23 induction was hence specific for the combination of VSL#3 and LPS, and only found 
with BM-DC from C57BL/6 mice.
TLR	gene	array	analysis	of	BM-DC	identifies	stimulating	and	blocking	activities	of	
VSL#3
To identify mechanisms by which probiotic bacteria may modulate the innate immune 
response, we analyzed mRNA expression of 84 genes implicated in TLR signaling. A time 
course study, revealed peak levels of mRNA encoding IL-12p35, IL-12p40, and IL-23p19 
after 4 hours of stimulation with VSL#3 and LPS (data not shown). Therefore, RNA was 
isolated from BM-DC after 4 hours of culture with or without LPS, VSL#3, or a combination 
of both. Figure 3 shows the relative gene expression in BM-DC from C57BL/6 and BALB/c 
mice. Results of three individual mice per stimulus are each shown as a column in this 
heatmap. Hierarchical clustering of transcripts in C57BL/6BM-DC revealed genes that are 
co-regulated. In BM-DC derived from both mouse strains, LPS and VSL#3 down-regulated 
a cluster of genes encoding TLR, e.g.Tlr5, Tlr4 and Tlr8. Moreover, both VSL#3 and LPS 
induced a set of pro-inflammatory gene transcripts, such as Tnf, Il1a and Il6, regardless of 
mouse strain.
In addition to the synergistic induction of IL12 and IL23(Figures 2B and 2C), the TLR signaling 
array revealed that the combination of VSL#3 and LPS also synergistically induced the 
expression of several other genes involved in innate immunity. In Figure 4, it is shown that 
3 representatives of this cluster - Lta, Ifng and Ifnb–are synergistically induced in C57BL/6 
BM-DC, but not in BALB/c BM-DC.
Importantly, a set of LPS-induced gene transcripts was suppressed by VSL#3 both in BALB/c 
BM-DC and in C57BL/6BM-DC.In this cluster Myd88, Cxcl9 and Cxcl10 were the most 
important representatives.
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The expression level (i.e. Ctvalues 
obtained from Figure 3) of Lta (top), 
Ifnb (middle) and Ifng (bottom) in BM-
DC from C57BL/6 or BALB/c mice 
was determined after stimulation with 
VSL#3 (107 CFU/ml), LPS (1 µg/ml) 
or a combination of both. Bar graphs 
represent the fold induction compared 
to unstimulated C57BL/6 BM-DC. 
Statistical evaluation was performed 
with the Student’s t-test; * p<0.05, 
** p<0.01, *** p<0.001.
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Figure	5.	Suppression	of	LPS-induced	chemokine	
induction	by	VSL#3	and	L. plantarum.
(A)	mRNA expression level for Cxcl9 and Cxcl10 in BM-
DC from C57BL/6 mice after stimulation with VSL#3, 
in the absence or presence of LPS (1 µg/ml). Data are 
presented relative (mean ± SD of three individual mice) 
to unstimulated cells. For statistical evaluation the Mann-
Whitney U-test was used. * p<0.05, ** p<0.01, *** p<0.001. 
Data are representative for 3 independent experiments.
(B)	CXCL-10 production after 24 hours of stimulation 
was determined by multiplex assay.Mean concentrations 
± SD measured in culture supernatants of BM-DC from 
3 individual mice are presented. Mann-Whitney U-test; 
*** p<0.001.
(C)	Effect of L. plantarum and B. lactis on LPS-induced 
expression of Cxcl9 and Cxcl10 in BM-DC from C57BL/6 
mice. Data represent mean fold change ±SD of three 
individual mice, compared to unstimulated cells. Results 
were evaluated statistically using the Mann-Whitney U 
test. * p<0.05, ** p<0.01, *** p<0.001.
(D)	CXCL-10 production after 24 hours of stimulation was 
determined by multiplex assay. Mean concentrations ± SD 
in culture supernatants corresponding with three individual 
mice are presented. Mann-Whitney U-test; ** p<0.01.
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The suppressive effect of VSL#3 on LPS-induced Cxcl9 and Cxcl10 expression was verified 
by quantitative RT-PCR (Figure 5A).Down-regulation was also confirmed on the protein level 
for CXCL-10 (Figure 5B);levels of CXCL-9 were below the detection limit.
VSL#3 is composed of different members of two lactic acid genera, i.e. Lactobacilli and 
Bifidobacteria. We therefore studied effects of representative members, i.e. L. plantarum 
and B. lactis. Whereas L. plantarum suppressed LPS-induced CXCL-10 both at the mRNA 
and protein level and CXCL-9 at the mRNA level, B. lactis failed in this respect (Figure 5C).
Discussion
Probiotic bacteria and prebiotic supplements have successfully been applied in the treatment 
of various inflammatory disorders, including allergies and intestinal disorders [17]. However, 
results of clinical trials are not consistent and variation in efficacy most likely depends on 
numerous factors, including type of bacterial strain (single strain versus a mixture of strains), 
dosing regimen, delivery method and host factors, such as genetics, age, diet, and disease 
state [18]. Several trials have shown beneficial effects of lactobacilli, bifidobacteria and 
E.coli Nissle 1917 in the induction of remission as well as the maintenance of remission in 
patients with Ulcerative Colitis [19]. However, the efficacy in Crohn’s disease appears less 
evident [20]. In the underlying study, we employed a simplified model system to evaluate 
the effects of VSL#3 - a complex mixture of TLR ligands - on BM-DC and identified both 
pro- and anti-inflammatory effects. These apparently contradictory findings may be due to 
the simultaneous presence of eight probiotic strains. On the other hand, similar contradictory 
effects were observed with L. plantarum, i.e. one single probiotic strain. In fact, even individual 
TLR ligands may induce a quick and transient production of pro-inflammatory cytokines such 
as IL-12, followed by the production of anti-inflammatory cytokines such as IL-10, as part of 
a suppressive mechanism essential to limit the extent of inflammation. The balance between 
(the levels) of these cytokines may differ between individuals and represents a major 
determinant for the severity of the subsequent inflammation process. Besides, probiotic 
bacteria may mediate additional mechanisms in vivo that control the extent of inflammation, 
e.g. the enhancement of intestinal barrier function, altered epithelial signaling, competition 
with pathogens and secretion of short chain fatty acids like acetate, propronate and butyrate, 
and have also effects on immune cells distinct from DC [21-23].
Although we allowed bone marrow progenitors from BALB/c versus C57BL/6 mice to 
differentiate in vitro into immature DC under controlled and identical conditions, we observed 
that VSL#3 and several TLR-ligands induced a more pronounced pro-inflammatory response 
in C57BL/6 mice , whereas BALB/c rather showed more IL-10 production. These observations 
are consistent with differences between the two mouse strains in terms of cellular and 
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humoral immune responses to different pathogens [24-26]. Our study did not show that levels 
of TLR gene expression could explain these differences. Moreover, we observed in BM-DC 
from C57BL/6 mice, but not from BALB/c mice, that VSL#3 augmented the induction of IL-
12p70 and IL-23 by LPS in a synergistic fashion. Furthermore, several other genes involved 
in cellular immunity, were synergistically up-regulated after combined stimulation with VSL#3 
and LPS. This suggests that this mixture of probiotic bacteria carries the potential to amplify 
inflammatory responses dependent on the genetic background of the host.
In parallel studies employing human DC, we demonstrated that LPS-induced phosphorylation 
of STAT-1 was inhibited by VSL#3, whereas phosphorylation of NF-κB was not influenced 
(Mariman et al., submitted for publication). A similar mechanism could explain the inhibition 
of chemokines, such as CXCL-9 and CXCL-10 by VSL#3, along with a robust induction of 
IL-12 and IL-23.
It should be noted that effects of VSL#3 are not representative for individual probiotic strains, 
as was shown by comparing L. plantarum and B. lactis in our in vitro studies.
Our findings may also explain that certain probiotic strains were ineffective in vivo or 
even displayed adverse effects during ongoing inflammation [27,28]. On the other hand, 
our extensive characterization of gene expression during the induction of TNBS-colitis in 
BALB/c mice [8] did not reveal that VSL#3 enhanced IL-12 p40 or IL-23p19 mRNA levels 
in colon tissue (even not in acute phases of the model). As mentioned above, this might 
be due to simultaneous induction of anti-inflammatory cytokines, or dampening of the local 
inflammatory response through mechanisms distinct from TLR-signaling.
Importantly, in this in vitro study we confirmed that probiotic bacteria may down-regulate the 
production of chemokines in agreement with our in vivo findings in the recurrent TNBS colitis 
model, where we also showed less recruitment of inflammatory cells and a lower disease 
severity[29].
Altogether, our data suggest that the net effect of probiotic bacteria in vivo depends on a 
complex of factors that vary between individuals and may depend on their genetic background 
and health status.
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Supporting	Figure	1.	BM-DC	from	C57BL/6	and	BALB/c	mice	respond	differently	to	TLR-
ligands.
Induction of key polarizing cytokines depends on the genetic background of the bone marrow donor 
mice. BM-DC were stimulated for 24 hours with 100 ng/ml Pam3CSK4, 50 μg/ml peptidoglycan (PG), 
100 µg/ml poly I:C, 1 μg/ml LPS, 500 ng/ml Flagellin (Flag), 1 μM Imiquimod (Imiq), 5 μg/mlCpG or 107 
CFU/ml VSL#3. Supernatants were evaluated by ELISA with regard to cytokine secretion for C57BL/6 
mice (white bars) or BALB/c mice (hatched bars). Means concentrations ± SD of 3 individual mice are 
presented. Mann-Whitney U test: * p<0.05, ** p<0.01, *** p<0.001. 
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Abstract
Probiotic bacteria represent a complex of microbe-associated molecular patterns by 
which they are suggested to mediate health promoting effects on the host. We recently 
demonstrated in a mouse model of colitis that such effects may in part be due to suppression 
of chemokine expression in the colon. Moreover, in vitro studies implicated a role for probiotic 
bacteria in the suppression of LPS-induced chemokine production by mouse bone marrow 
derived dendritic cells. Herein, we studied modulation of human monocyte-derived DC by a 
mixture of probiotic bacteria in response to the TLR-4 agonist LPS and evaluated chemokine 
mRNA expression and protein secretion. This approach revealed differences in gene 
expression by LPS or VSL#3, a mixture of probiotic bacteria. Moreover, a set of LPS-induced 
chemokines was identified that was suppressed by VSL#3. In silico approaches identified 
STAT-1 as a dominant regulator of this cluster, and this was confirmed by demonstrating that 
phosphorylation of this transcription factor was inhibited by VSL#3.These data indicate that 
probiotic bacteria may contribute to the control of inflammation by selective suppression of 
chemokines.
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Introduction
The gastrointestinal tract is continuously exposed to foreign antigens – mainly derived from 
the commensal microflora and/or food antigens [1]. Immune responses in the intestinal 
mucosa need to be tightly regulated by activating pro-inflammatory pathways for appropriate 
host defense against pathogenic microorganisms while remaining unresponsive to symbiotic 
bacteria [2,3].Under homeostasis conditions little or no inflammation occurs in the gut 
associated lymphoid tissue (GALT). However, genetic defects and impairment of barrier 
integrity may cause exaggerated immune responses driven by the microflora resulting in 
the development of intestinal inflammation [4].Specific lactobacilli and bifidobacteria have 
been shown efficient in modulating intestinal immunity in homeostasis [5]and conditions of 
chronic intestinal inflammation like inflammatory bowel disease [6]. Several modes of action 
of probiotic bacteria have been identified, including restoration of microbial homeostasis 
through microbe-microbe interactions, pathogen inhibition, enhancement of barrier integrity, 
or via direct modulation of immune responses [7].
In the gastro-intestinal tract, probiotic bacteria may be recognized by a plethora of pattern 
recognition receptors, including toll-like receptors, C-type lectin receptors and NOD-like 
receptors on epithelial cells and innate immune cells, such as dendritic cells (DC) [8,9]. 
Maturation of DC after contact with antigen or inflammatory stimuli is accompanied by 
functional and phenotypic changes. Dependent on the stimulus, DC can secrete chemokines 
and cytokines, thereby inducing naïve T cell proliferation and polarization towards Th1, Th2, 
Th17 effector cells or regulatory T cells[10].Accordingly, much attention has focused on the 
impact of DC priming by probiotic bacteria to modulate adaptive immune responses. Recently, 
we demonstrated that treatment with VSL#3 has profound effects on gene expression in the 
colon of mice subjected to colitis induction, with favorable effects on disease development 
[11]. These data were suggestive for a role of probiotic bacteria in the modulation of innate 
immunity, in particular chemokines. Moreover, in vitro studies with mouse bone marrow 
derived DC implicated a role for VSL#3 by blocking the ability of LPS to induce various 
chemokines DC (Mariman et al, submitted for publication).
In this study, we examined human monocyte derived DC and the modulation of cytokine and 
chemokine expression by VSL#3, employing dedicated PCR arrays and multiplex protein 
profiling. By this approach we identified a cluster of LPS-induced genes that were suppressed 
by VSL#3. STAT-1 was identified as a dominant regulator of this cluster, and potential target 
of probiotic bacteria.
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Material and methods
DC cultures
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy 
donors (Sanquin, Leiden, the Netherlands) by Histopaque (Sigma Diagnostics St.Louis, MO, 
USA) density gradient centrifugation. Human monocytes were purified from PBMC by positive 
selection using anti-CD14-conjugated magnetic microbeads (StemCell Technologies, 
Grenoble, France). The recovered cells were 95% to 99% CD14+ as determined by flow 
cytometry. Monocytes were cultured at 2 × 106/ml in RPMI1640 supplemented with 100U/
ml penicillin, 100μg/ml streptomycin, 10μMultraglutamin and 5% (v/v) FBS (Lonza, Verviers, 
Belgium). In order to stimulate their differentiation into DC, cells were cultured in the presence 
of GM-CSF (50 ng/ml) and IL-4 (40 ng/ml). After 5 days of culture, immature DC were washed 
and seeded at 106/well in 24-well plates. Stimuli – all in culture medium – were added to these 
DC and after 48 hours of culture supernatants were harvested for cytokine and chemokine 
profiling. For RNA profiling, RNA was isolated after 4 hours of culture.VSL#3, a mixture 
containing 8 different lactic acid bacteria, was purchased from Ferring Pharmaceuticals 
(Berkshire, UK). Freshly reconstituted bacteria from lyophilized stocks were added to DC 
cultures at a bacteria – DC ratio of 10 to 1. Ultrapure LPSE. coli K12 (final concentration 1μg/
ml) was purchased from Invivogen (San Diego, California, USA).
RNA	isolation	and	transcription	profiling	using	PCR	array
Total RNA was isolated from 106 cells using a RNAEasy Kit (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s instructions. 500 ng RNA was used for single stranded 
cDNA synthesis using a High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad, 
CA USA) and incubated for 60 min at 37 oC and 5 minutes at 95 oC.cDNA was used for 
PCR-array analysis by using the RT2-ProfilerPCR Array (human cytokine & chemokine array) 
from SuperArray Bioscience (Frederick, MD, USA). The PCR array combines the quantitative 
performance of SYBR Green-based real-time PCR with the multiple gene profiling capabilities 
of microarray. 96-well plates containing gene-specific primer sets for 84 chemokines and 
cytokines, 5 housekeeping genes, and 2 negative controls were used. For each experimental 
condition, cDNA from 6 individual donors was analyzed. Gene expression was normalized 
to internal controls (housekeeping genes) to determine the fold change in gene expression 
between test and control samples by ΔΔCt (SuperArray Bioscience).
Chemokine	profiling
Multiplex analysis was performed on the supernatants of DC for profiling of secreted 
chemokines (Invitrogen, human 10-plex)according to the manufacturer’s instructions. The 
beads were read on a LiquiChip 200, (Qiagen, Hombrechtikon, Switzerland), and data 
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were analyzed by the five parameter curve fitting in Luminex100 IS Software. Chemokine 
concentrations are presented as pg/ml.
NF-κB	and	STAT-1	phosphorylation	assay
STAT-1 transcription factor activity was quantitatively detected by TransAM STAT family 
transcription factor assay (Active Motif, Carlsbad, CA) according to the manufacturer′s 
recommendations. In short, cell nuclei were prepared from DC using a nuclear extraction kit 
(Active Motif). Nuclear lysates (derived from 15*106 cells) were incubated in 96-well dishes 
containing immobilized oligonucleotides containing a STAT consensus DNA-binding site 
(5′-TTCCCGGAA-3′). The specific primary antibody and the secondary antibody conjugated 
to horseradish peroxidase were incubated with the nuclear extracts following the vendor’s 
manual. The colorimetric reading (at 450 nm) was determined on a VERSAmaxmicroplate. 
Nuclear extracts from COS-7 cells (treated with IFN-γ) were included as positive controls for 
STAT1α. Phosphorylation assay for NF-κBp65 was performed as described for STAT-1, with 
slight modifications. Instead of TMB substrate, a chemiluminescent substrate was used to 




We previously identified the modulation of chemokines as a major mechanism in the 
protective effect of probiotic bacteria in colitis[11]. These effects could be partly mimicked in 
vitro employing mouse bone marrow derived DC. Consequently, we wished to study if and 
how probiotic bacteria would modulate inflammatory responses in human DC. Therefore, 
we evaluated modulation of TLR-4 induced signaling pathways in human DC by probiotic 
bacteria. DC from 6 individual donors were generated by culturing CD14+ monocytes in the 
presence of GM-CSF and IL-4. After 5 days of culture cells were washed and stimulated with 
LPS, the probiotic mixture VSL#3 or a combination of both.
Consistent with previous publications [12-14],the mixture of lactic acid bacteria as well as 
LPS were able to induce DC maturation, evident from the enhanced expression of HLA-DR, 
CD86, and CD83 (data not shown).
To assess the expression of chemokine and cytokines, RNA was isolated from DC left 
unstimulated or stimulated with LPS, VSL#3, or a combination of both, and subsequently 
analyzed with the use of a dedicated PCR gene array. A complete list of all measured 
transcripts and their fold induction relative to unstimulated DC is depicted in supportive 
Table 1. Transcripts of a large number of pro-inflammatory mediators were induced compared 
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Supportive	Table	1	mRNA expression levels of 84 chemokines and cytokines after 4 hours of 
stimulation with LPS, VSL#3 or a combination of both, as determined by qPCR arrays. Data for each 
gene were normalized to a panel of housekeeping transcripts and compared to unstimulated DC. 
Results represent the mean of 6 individual donors.
Up–regulation	(as	compared	to	medium	control)
Fold	change
Chemokine/Cytokine LPS VSL#3 VSL#3	+	LPS
ADIPOQ 1.4  1.2  1.4  
BMP2 3.5  2.4  8.4  
BMP4 1.1  1.9 * 1.7 *
BMP6 3.6  14.4 ** 52.3 **
BMP7 -1.0  1.4  1.4  
C5 -1.4  -1.8  -1.1  
CCL1 762.7 ** 210.8 * 234.3 *
CCL11 1.6  1.8  2.7 **
CCL13 2.0  -1.3  -1.1  
CCL17 2.9 ** 1.9  2.3 *
CCL18 1.0  -1.0  1.1  
CCL19 45.7  4.4 ** 18.0  
CCL2 45.6 ** 19.1 * 16.2 **
CCL20 954.5 *** 755.3 * 1657.4 ***
CCL21 1.3  -1.1  1.1  
CCL22 5.6 ** 8.1 ** 8.8 **
CCL24 1.2  1.4  1.0  
CCL3 47.7 *** 105.2 ** 159.5 ***
CCL5 412.7 ** 127.9 * 476.7 **
CCL7 6.8 * 4.4  3.1  
CCL8 145.8 ** 7.8  13.2 ***
CD40LG -2.1  -2.7 * -1.3  
CNTF -1.4 * -1.4  -1.3  
CSF1 14.9 ** 23.0 ** 26.9 **
CSF2 182.0 *** 687.2 * 2049.1 ***
CSF3 50.9  51.1  233.0  
CX3CL1 4.5 * 3.2  2.6  
CXCL1 589.9 ** 403.5  1060.3 **
CXCL10 8118.3 *** 217.6 ** 1488.8 ***
CXCL11 30832.8 ** 294.6 *** 7989.2 **
CXCL12 1.8  1.3  1.7  
CXCL13 1.4  -2.7 * -1.7  
CXCL16 1.4 * 2.0 ** 2.2 ***
CXCL2 153.5 *** 452.8  1088.3 **
CXCL5 4.1 * 7.9 * 6.5 *
CXCL9 4136.7 * 42.5 ** 602.7 **
FASLG 7.1  4.8 ** 10.2 *
GPI -1.4  -1.6 * -1.5 *
IFNA2 -1.0  1.1  1.5  
IFNG 41.5 * 36.2  94.0 *
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Up–regulation	(as	compared	to	medium	control)
Fold	change
Chemokine/Cytokine LPS VSL#3 VSL#3	+	LPS
IL10 13.8  20.2  69.6  
IL11 1.8 * 2.3  3.7 *
IL12A 73.4  1591.1 * 3385.0 *
IL12B 1817.4 * 9130.1 * 5194.7 **
IL13 3.5 * 4.9 * 12.0 ***
IL15 14.6 * 2.7 * 9.7 ***
IL16 -10.6 *** -6.2 *** -8.2 ***
IL17A -1.0  1.4  1.3  
IL17F 2.0 * 1.5  2.4 **
IL18 -2.7 * 1.7 * -1.5  
IL1A 691.8 * 925.2 * 1771.6 ***
IL1B 567.1 * 895.1 * 1560.5 **
IL1RN 8.4 * 19.8 *** 25.2 ***
IL2 2.1 * 3.6 * 3.5 *
IL21 1.3  -1.0  2.0 **
IL22 1.8  1.1  2.3  
IL23A 34.1 * 104.4 *** 300.6 *
IL24 -1.2  1.3  1.3  
IL27 127.6 * 27.5  144.4  
IL3 -1.0  -1.2  1.4  
IL4 1.4  1.2  1.7  
IL5 1.1  -1.4  1.4  
IL6 2184.1 ** 1657.6  3885.9  
IL7 142.2 * 86.0  199.7 *
IL8 323.6 *** 632.7 * 1090.3 **
IL9 -1.2  4.7  2.2  
LIF 33.2 *** 246.7  284.0  
LTA 57.2 *** 168.4 *** 157.7 ***
LTB 1.0  1.1  1.2  
MIF 1.1  1.1  1.2  
MSTN -1.4  -1.9 * -1.3  
NODAL -2.4 * -2.3 * -2.5 *
OSM 4.3 *** 7.4 ** 13.2 *
PPBP -1.4  -1.2  -1.2  
SPP1 1.2  6.5 *** 4.6 **
TGFB2 -3.1 *** -2.5 *** -1.6 *
THPO 1.1  -1.1  -1.1  
TNF 50.4 *** 206.5 * 248.0 ***
TNFRSF11B 9.6 * 18.0 * 32.3 ***
TNFSF10 137.5 *** 6.9 * 18.2 ***
TNFSF11 1.3  1.3  1.4  
TNFSF13B 1.2  -3.6 ** -1.9  
VEGFA 2.8  7.7 * 12.5 *
XCL1 -1.5  1.5  1.9  
Results were statistically evaluated by Student’s t-test, comparing the replicate 2^(- delta Ct) values 
for each gene in the control group and treatment groups.
* p<0.05, ** p<0.01, and *** p<.0001.
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to immature DC, irrespective of the stimulus. However, the magnitude of induction or 
inhibition was gene-and stimulus-specific. Therefore, hierarchical clustering was applied to 
identify clusters of co-regulated genes. A heatmap showing the clustering of the expression 
patterns of 6 individual donors is depicted in Figure 1. In this heatmap, minimum (green) and 
maximal (red) fold inductions as compared to unstimulated DC are shown for each gene. 
Two major cluster could be identified as indicated in Figure 1.Cluster I comprise genes that 
are moderately induced by LPS, compared to the mixture of bacteria. These include Il1α, 
Figure	1.
Chemokine	and	cytokine	expression	by	stimulated	DC.
Clusterogram showing the supervised hierarchical clustering of relative expression levels for all 
samples and all genes included in the real-time PCR arrays. Data for each gene were normalized to 
a panel of housekeeping transcripts and compared to unstimulated DC. Relative expression levels for 
each individual gene are presented as minimum (green) and maximum (red). Rows represent gene 
expression profiles of individual samples, 4 hours after stimulation (6 donors for each experimental 
condition).
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Il1β,Ccl3, Csf2, Cxcl2, Il12a, Il12b.Moreover, the co-incubation of human DC with VSL#3 
and LPS synergistically induced IL-23A and IL12A transcripts. Together with IL-12B, these 
subunits form IL-23 and IL-12p70, respectively. Secretion of these cytokines by DC may 
polarize naïve T-cells into Th17 and Th1 cells. Robust responses with respect to IL-12, but also 
IL-10 are in line with previous reports in human and mouse DC [15,16], and are related to high 
bacterial doses.
Interestingly, cluster II comprises LPS-induced genes that were suppressed by VSL#3.
Cluster II comprisedTnfsr10 and a number of chemokines, including Cxcl-9, Cxcl-10, Cxcl-
11, Ccl1, Ccl2, Ccl8, and Ccl19. Supernatants of replicate cultures harvested after 48 hours 
were subjected to multiplex analysis and this confirmed diminished protein levels of CXCL-9, 
CXCL-10, CCL-2 and CCL-8 as shown in Figure 2. It is known that LPS can bind to TLR4 
and thereby inducing both pro – and anti-inflammatory effects [17]. At the level of the plasma 
membrane, LPS activated TLR-4 binds to sorting adaptor (TIRAP), which then recruits the 
signaling adaptor myD88 to trigger production of pro-inflammatory mediators. However, 
Figure	2.	
LPS-induced	chemokine	production	of	human	DC	is	suppressed	by	VSL#3
A set of genes representing cluster II was confirmed at the protein level. Supernatants were harvested 
from replicate DC cultures after 48 hours and performed in parallel with the cultures used for mRNA 
profiling. Levels of various cytokines and chemokines were determined by multiplex bead array 
technology. Results are expressed as pg/ml ± SD. 
Rank-Wilcoxon paired test: * p<0.05, ** p<0.01, *** p<.0001
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activated TLR-4 in the endosomes engages the adaptor molecules TIRAP and TRAF to 
induce IFN-β and the anti-inflammatory IL-10 [18]. It has been reported that involvement of 
these two signaling pathways in LPS induced chemokine expression varies considerably 
depending on the kind of chemokine [19]. CCL-2, CCL-7, CCL-8, CXCL-2, CXCL-3, and 
CXCL-9 largely rely on myD88, whereas CCL-5, CXCL-10 and CXCL-13 are regulated by 
myD88 independent pathways. Since in this study VSL#3 inhibited both expression of 
myD88-dependent (CXCL9 and CCL8) and myD88-independent chemokines (CXCL10), it is 
tempting to conclude that VSL#3 does not interfere at the level of myD88-or TRIF-coupled 
TLR-signaling.
The observed effect on the modulation of LPS-induced chemokines might be partly beyond 
the level of transcriptional regulation. Recently, it was demonstrated that L. plantarum 
mediates degradation of CXCL-10 by the production of lactocepins [20]; these proteinases 
are derived from lactococci and lactobaccili and have substrate specificity for a class of 
chemokines, including CXCL-9 and CXCL-10, but not CCL5[21].
Figure	3.
VSL#3	inhibits	LPS-induced	phosphorylated	STAT-1
(A) LPS-induced genes, significantly suppressed by VSL#3, were analyzed by using Metacore 
Network analysis (Transcription factor). STAT-1 was predicted to be a key driver of this cluster. 
(B) DC were stimulated for 3 hours, and STAT-1 and NF-κB p65 phosphorylation was quantified in 
nuclear extracts using the Trans-am assay. Absorbance values (mean ± SD) of 5 individual donors are 
shown. Rank-Wilcoxon paired test: * p<0.05, ** p<0.01.
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However, our study shows that probiotic bacteria also selectively suppress expression of 
genes encoding these chemokines.
VSL#3	inhibits	LPS-induced	phosphorylation	of	STAT-1
Since only a distinct subset of LPS-induced genes was suppressed by VSL#3, we aimed 
to identity a common regulator for this cluster. In silico analysis using MetaCore software 
was used to identify transcription factors regulating genes in this cluster. Compared to the 
reference list of all 84 genes measured on the array, LPS-induced genes suppressed by 
VSL#3 were highly enriched for the transcription factor STAT-1 (z-score 173, p-value 1.3*10-
26) as depicted in Figure 3A. To validate the role of STAT-1 in the suppression of LPS-induced 
gene expression found by out bioinformatics approach, an additional experiment was 
performed to measure phosphorylated STAT-1 in the nucleus upon stimulation. Therefore, 
DC were stimulated for 45 and 180 minutes before the isolation of nuclear proteins. Nuclear 
extract from 107 DC was analyzed by TRANSamTM. This ELISA-based assay allows detection 
and quantification of DNA-binding activity of transcription factors, in this case pSTAT-1α and 
pNF-κBp65. Irrespective of the stimulus, NF-κB was already activated after 45 minutes 
of incubation (data not shown). In contrast, 3 hour after stimulation, pSTAT-1 levels were 
increased in nuclear extracts of LPS-stimulated DC, but not of VSL#3 stimulated cells 
(Figure3B). In line with the in silico prediction, migration of STAT-1 to the nucleus upon 
phosphorylation was blocked in the presence of VSL#3. Further studies are needed to 
elucidate how phosphorylation of this specific transcription factor is regulated by probiotic 
bacteria, although induction of SOCS1 might play a role in this respect[22]. Phosphorylation 
of NF-κB was not inhibited by VSL#3, which explains the robust induction of IL-12p70. This 
suggests that VSL#3 can reduce production of specific chemo-attractants in vitro by selective 
inhibiting of STAT-1 induced transcription regulation.
STAT-1 deficiency reduced the intensity of spontaneous and chemical induced colitis [23,24]. 
Furthermore, a recent report showed that selective regulation of STAT-1 signaling in T-cells 
by fusaruside resulted in reduced production of pro-inflammatory cytokines and improved 
TNBS induced colitis [25]. Therefore, our previous studies showing that probiotic bacteria 
have a favorable effect on the development of colitis may be explained by modulation of 
transcriptional regulation of chemokines and cytokines.
A better understanding of how MAMPs present on probiotic bacteria modulate intracellular 
signaling induced by pathogenic bacteria may be helpful to identify mechanisms by which 
probiotic bacteria contribute to the control of inflammation. In addition, our approach with 
emphasis on chemokine expression by DC may help to select probiotic strains with distinct 
properties tailored to suppress inflammation in autoimmune or allergic disorders.
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Conclusion
We showed that probiotic bacteria interfere with STAT-1 phosphorylation in human DC in 
conjunction with the modulation of chemokine expression and secretion. This finding may 
contribute to a better understanding of the mechanisms by which probiotic bacteria exert 
anti-inflammatory effects.
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Abstract
Probiotic bacteria may render mice resistant to the development of various inflammatory 
and infectious diseases. For a better understanding of the underlying mechanisms by which 
probiotic bacteria may influence intestinal immune homeostasis, the effect of long- and 
short-term treatment with a mixture of 8 probiotic bacteria (i.e. VSL#3) was evaluated in 
non-inflammatory conditions. To this end, we studied the effect of VSL#3 in BALB/c and 
C57BL/6 mice, as mouse strains with dominant humoral or cellular immunity, respectively. 
VSL#3 administration resulted in an increase of B cells and a decrease of CD4+ T cells in the 
Peyer’s patches (PP) and mesenteric lymph nodes (MLN) of both mouse strains. However, 
genome wide gene expression profiling using micro-arrays revealed that oral administration 
of VSL#3 to BALB/c and C57BL/6 mice was associated with host-specific modulation of 
gene expression in colon and small intestine. Whereas VSL#3 treatment resulted in down-
regulation of Il13 and Epx, and up-regulation of Il12rb1, Ccr5, Cxcr3 and Cxcl10 in BALB/c 
mice, such effects were not observed in C57BL/6 mice. In BALB/c mice, a 2-fold increase 
in CD103+ CD11c+ dendritic cells was found both in PP and in MLN, 18 hours after the first 
treatment with VSL#3. Possibly as a consequence of this modulation of the innate immune 
response, prolonged treatment with VSL#3 was associated with increased numbers of Th17 
cells and Foxp3+ regulatory T cells in the MLN of these mice.
In conclusion, these experiments in healthy mice show that probiotic bacteria may alter the 
immunological phenotype of the host; the nature of these effects is dependent on mouse 
strain.
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Introduction
Directly after birth, the (human) gastro-intestinal tract is colonized by a complex community 
of micro-organisms termed the “microbiota” (1). The community structure of this microbiota 
directly contributes to a variety of physiological and metabolic processes that are important 
to host function (2, 3). Moreover, interactions between microbes and the host are of critical 
importance in orchestrating the (mucosal) immune system (4). For example, the absence of 
intestinal bacteria in germ-free mice results in defects in the development of gut associated 
lymphoid tissue (5) reflected by reduced IgA production by plasma cells (6), fewer Peyer’s 
Patches (PP) and mesenteric lymph nodes (MLN) as well as impaired development of 
isolated lymphoid follicles (7). Likewise, the induction of either regulatory or effector T 
cell responses in the mucosa depends on the bacterial species present (8). For example, 
segmented filamentous bacteria induce effector Th17 responses, which provide protection 
against gut pathogens (9, 10). In addition, certain Clostridium species and Bacteroides 
fragilis favor the induction of Foxp3+ regulatory T cell (T reg) responses (11). These T reg 
cells can prevent systemic and tissue-specific autoimmunity and inflammatory lesions at 
mucosal interfaces and are thereby essential for the maintenance of immune homeostasis. 
In turn, the intestinal immune system shapes the composition of the gut microbiota (12-
14). In view of the interplay between the host and the intestinal microbiota, also probiotic 
bacteria may have favorable effects and contribute to intestinal immune homeostasis (15)
(16). Beneficial effects of probiotic bacteria have been observed in patients with ulcerative 
colitis in remission and in patients with atopic disease (17, 18). Several mechanisms of 
action have been proposed, including modulation of innate and adaptive immune responses, 
effects on the composition of the gut microbiota, strengthening of the mucosal barrier and the 
prevention of microbiological translocation (19, 20). These mechanistic studies mostly rely 
on in vitro assays or animal models for inflammation (21-23). However, immunomodulation 
by probiotic bacteria in a simplified in vitro system or in an established inflammation model in 
vivo does not reflect effects in conditions of homeostasis. Only few studies have addressed 
the effects of probiotic bacteria in healthy subjects (24-27) and substantial variability in the 
response of human subjects to probiotic intervention were found (28, 29).
We previously demonstrated that prophylactic treatment with probiotic bacteria renders 
BALB/c mice largely resistant to the induction of colitis (30). Therefore, probiotic bacteria may 
represent important nutritional ingredients that contribute to intestinal immune homeostasis 
and protection against inflammatory disease. To gain insight into the underlying mechanism 
of protection, we evaluated the effect of a mixture of probiotic bacteria in healthy mice. To 
account for the variation among individuals, we studied this probiotic mixture not only BALB/c 
mice but also in C57BL/6 mice, because these mice have an established bias for Th2 and 
Th1 type immune responses, respectively. In this study, we show by transcriptome profiling, 
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in conjunction with immune cell characterization, that probiotic bacteria have differential 
effects on immunological processes, dependent on mouse strain. 
Material and methods
Mice
9-week old C57BL/6 mice (Charles River, Maastricht, Netherlands) and BALB/c mice 
(Janvier, St. Berthevin, France) were used in this study. Mice were conventionally housed 
with free access to standard mouse chow (SSNIFF R/M-H, BioServices B.V., Uden, The 
Netherlands) and acidified tap water. Animal experiments were approved by the Institutional 
Animal Welfare Committee of The Netherlands Organization for Applied Scientific Research 
(TNO), approval number DEC2981 and DEC3288, in compliance with European Community 
regulations regarding the use of laboratory animals.
Study	design
VSL#3 (Ferring Pharmaceuticals, Berkshire, UK) was purchased as a commercially available 
probiotic mixture containing freeze-dried bacteria (Bifidobacterium longum, B. breve, B. 
infantis, Lactobacillus acidophilus, L. plantarum, L. casei, L. bulgaricus, and Streptococcus 
thermophilus). To study the effect of long-term probiotic administration, mice were gavaged 
with PBS or 3 x 108 CFU VSL#3 suspended in 200 μl PBS, 3 times a week, for a period of 
4 weeks. In a follow-up study, also short-term administration of probiotics was examined by 
sacrificing mice 18 hours after one single oral dose of VSL#3.
Flow	cytometry	analysis
Spleen, MLN and PP were isolated and passed through a 70-µm nylon cell strainer (BD 
Biosciences, San Jose, CA, USA) to prepare single-cell suspensions. Cells were stained 
with different rat-anti-mouse antibodies obtained from Biolegend/BD Biosciences: CD3–
FITC (145-2c11), CD4–PerCp (DM4-5), CD8–PerCp-Cy7 (53-6.7), CD25-APC (PC61.5), 
CD45-PerCp-Cy5 (30-F11), CD19–V450 (ID3), IFN-γ–FITC (XMG1.2), IL-17–PE (TC11-
18H10), CD11c–Pe-Cy7 (N418), CD103–PB (2E7) and F4/80–APC(BM8). Where needed, 
isotype-matched controls were included.
For intracellular cytokine staining, cells were cultured in RPMI-1640, supplemented with 10% 
FCS, and stimulated with 40 nM phorbol-12-myristate-13-acetate (PMA) and 2 nM calcium 
ionomycin (Sigma Aldrich). Brefeldin A (3 µM) was added to allow for intracellular cytokine 
accumulation.. Cells were stimulated for four hours at 37°C. Fixation and permeabilization 
reagents (Caltag Laboratories, Burlingame, CA, USA) were used for intracellular staining 
according to the instructions of the manufacturer. In short, 1×106 cells were incubated for 
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30 minutes with a cocktail of primary antibodies and 1% normal mouse serum to prevent 
non-specific antibody binding. Subsequently, cells were fixated, washed and incubated (30 
minutes) with permeabilization buffer containing the intracellular cytokine antibody cocktail..
Unstimulated cell suspensions were used for regulatory T cell staining. Intranuclear Foxp3 
staining was performed using eBioscience T reg staining kit using PE-conjugated Foxp3 
(FJK-16s). Flowcytometric analyses were performed on a fluorescence-activated cell sorter 
(FACSCanto II, BD Biosciences) and results were analyzed with FACSDiva Software 6.1.2.
Transcriptome	Analysis
Total RNA was isolated from frozen intestinal tissue using TRIzol reagent (Invitrogen, Breda, 
The Netherlands) according to the manufacturer’s instructions. RNA was treated with DNAse 
and purified using Nucleospin RNAII Total RNA Isolation kit (Macherey-Nagel, Düren, 
Germany), according to the instructions of the manufacturer.
The quality control of RNA samples, RNA labeling and hybridization were performed at 
ServiceXS (Leiden, The Netherlands). The RNA concentration was assessed using a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, U.S.A). 
The RNA quality and integrity was determined using Lab-on-Chip analysis on an Agilent 
2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, U.S.A.). The RNA integrity 
numbers (RIN) of all RNA samples had values above 8.7. Biotinylated cRNA was prepared 
using the IlluminaTotalPrep RNA Amplification Kit (Ambion, Inc., Austin, TX, U.S.A.) according 
to the manufacturer’s specifications starting with 500 ng total RNA. Per sample, 750 ng 
cRNA was used to hybridize to the Sentrix MouseRef-8 BeadChips (Illumina, Inc., San Diego, 
CA, U.S.A.). Each BeadChip contains eight arrays and each of the arrays harbors 25,697 
probes. Hybridization and washing were performed according to the Illumina standard assay 
procedure. Scanning was performed on the IlluminaScanner (Illumina, Inc., San Diego, CA, 
U.S.A.). Image analysis and extraction of raw and background subtracted expression data 
were performed with IlluminaBeadstudio v3 Gene Expression software using default settings. 
The data discussed in this publication have been deposited in NCBI’s Gene Expression 
Omnibus (31) and are accessible through GEO Series accession number GSEXXXX (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSEXXXX). GeneSpring GX 11.0 was used 
for quantile normalization of the probe-level, background subtracted expression values. 
After the normalization, unexpressed probes were removed from the further analyses. All 
expression values below 5 (2.322 on log2 scale) were floored to 5. Differentially expressed 
probes were identified using the limma package of the R/Bioconductor project, applying 
linear models and moderated t-statistics that implement empirical Bayes regularization of 
standard errors (32). The statistical analyses were performed through The Remote Analysis 
Computation for gene Expression data (RACE) suite at http://race.unil.ch (33). p-bayes 
values < 0.05 was used as threshold for significance of the differential expression.
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The effects of treatment with a mixture of probiotic bacteria on gene expression in colon and 
small intestine was evaluated in BALB/c and C57BL/6 mice. We first analyzed differences 
between both mouse strains with respect to gene expression in the small intestine and 
colon. Figure 1A shows for individual untreated mice an unbiased analysis approach using 
all 25,697 genes on the array for principal component analysis (PCA). This PCA-plot reveals 
two distinct clusters of colon and small intestine related genes (component 1), whereas 
component 2 reveals differences in gene expression between the two mouse strains. We 
next identified differentially expressed genes (fold change >1.5 and p-bayes< 0.05) between 
BALB/c and C57BL/6 mice for both tissues. A complete list of all differentially expressed 
genes can be found in Supportive Table 1. Metacore analysis revealed that overlapping 
genes were predominantly related to the immune response, and include MHC haplotype 
variation. Moreover the expression of a variety of antimicrobial peptides differed between 
the two mouse strains, especially in the small intestine. These antimicrobial proteins include 
lactoperoxidase, lysozyme and a set α-defensins. We also analyzed the expression of key 
regulators involved in the differentiation of CD4+ T cells. As shown in Figure 1B, the Th2 
regulator GATA3 was increased in the small intestine of BALB/c mice as compared to C57BL/6 
mice. In contrast, RORγ (key regulator of Th17 cells) was preferentially expressed increased 
in colon and small intestine of C57BL/6 mice. In view of these differences, immune modulating 
effects of probiotic bacteria might be different in these mice. We therefore determined the 
effect of VSL#3 on gene expression in both mouse strains. To this end, wild-type BALB/c and 
C57BL/6 mice were treated three times a week for a period of 4 weeks, by oral administration 
of 3x108 colony forming units of VSL#3 or vehicle. Probiotic supplementation did not affect the 
development of body weight (data not shown). The numbers of differentially expressed genes 
(fold change >1.5, p-Bayes < 0.05) between VSL#3- and vehicle-treated mice are indicated 
in Table 1. A complete list of differentially expressed genes is provided in Supportive Table 2.
To gain insight into the processes that are associated with these differently expressed 
genes after administration of VSL#3 to mice, significantly overrepresented Pathway Maps 
were created with MetacoreTM Software. This unbiased approach was applied to map the 
differentially expressed genes into clusters with common biological functions. Table 2 shows 
all significant pathway maps, including the number of genes with the according p-values. 
This table shows profound effects of VSL#3 on genes related to the immune response. To 
visualize expression patterns of these immune-related genes, a heat map was constructed 
including all of these modulated genes in the small intestine and colon (Figures 2A and 2B, 
respectively). For the small intestine of BALB/c mice, these genes were further subdivided 
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into genes related to the innate and adaptive arm of the immune system. Supportive Figure 1 
shows an interactome chart of these genes, where up-regulated genes are indicated in red 
and down-regulated genes in blue. Innate immune transcripts up-regulated upon VSL#3 
administration include Nos2 and Nod2. In BALB/c mice we also observed modulation of 
adaptive immune cells, as suggested by an increased expression of Il-12rb1, Ccr5 and 
Cxcr3, as well as the chemokine Cxcl-10. On the other hand, Il-13 and Epx were down-
regulated in the small intestine of these mice. Remarkably, colons of BALB/c mice showed 
down-regulation of Il17a and Foxp3.
In C57BL/6 mice, significant immunomodulatory effects were present both in small intestine 
and colon, but these could not be linked to a defined immunological process.
Figure	1.	Gene	expression	profiles	in	the	intestine	of	BALB/c	and	C57BL/6	mice
A. Two-dimensional visualization of principal component analysis (PCA) constructed with all 27,000 
genes on the array. Each dot represents the expression profile of an individual mouse.
B. Expression of transcription factors T-bet, GATA-3, RORγ and Foxp3 were compared between the 
two mouse strains.
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Figure	2.	Effect	of	oral	administration	
of	VSL#3	on	the	expression	of	genes	
related to immune function
A heat-map of immune-related genes with 
significantly different expression in VSL#3-
treated mice compared to PBS-treated 
mice. Relative expression levels for each 
individual gene are presented as minimum 
(blue) and maximum (red). Columns 
represent gene expression profiles of 
individual mice for the small intestine (A) 
and colon (B).
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Probiotic	bacteria	modulate	local	innate	and	adaptive	immune	cells	in	
healthy	BALB/c	mice
As shown above, treatment with VSL#3 influenced the intestinal expression of a variety 
of genes related to the immune response Moreover, we showed previously that prolonged 
treatment with VSL#3 rendered BALB/c mice resistant to the induction of colitis (30). 
Therefore, we evaluated the effect of prolonged treatment on innate and adaptive immune 
cells in healthy BALB/c mice.
As shown in Figure 3, prolonged treatment with VSL#3 was associated with decreased 
numbers of CD4+ T cells (p<0.01), in conjunction with increased numbers of CD19+ B cells 
(p<0.05), in PP and MLN, but not in spleen. CD8+ T cells were unaffected. Similar results 
were obtained in C57BL/6 mice (p<0.01, data not shown).
Figure	3.	Prolonged	administration	of	VSL#3	alters	B	and	T	cell	frequencies	in	PP	and	MLN
Single cells suspension of Peyer’s Patches and mesenteric lymph nodes were prepared from BALB/c 
mice 18 hours after one single dosage of VSL#3, or after a treatment period of 4 weeks. Cells from 
untreated mice served as a control.
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For BALB/c, we also evaluated effector and regulatory T cells. Figure 4 shows that prolonged 
VLS#3 treatment was associated with an increase of IL-17+ Th17 cells (p<0.05) as well as 
of Foxp3+ T reg cells (p<0.01), whereas numbers of IFN-γ+ Th1 cells remained unchanged. 
At early time points, i.e. 18 hours after one single dosage of VSL#3, no such effects were 
observed.
Evaluation of innate cells showed an increase of CD11c+ cells in PP (p<0.01) and an increase 
of F4/80+ macrophages (p <0.01) in MLN after prolonged exposure to VSL#3 (Figure 5). 
Remarkably, a subset of CD11c+ cells expressing CD103 - and reported to induce regulatory 
T cells (34, 35) was transiently increased both in PP an MLN (p<0.05 and p<0.001, 
respectively), 18 hours after the first single dosage of VSL#3.
Figure	4.	Effect	of	VSL#3	treatment	on	the	development	of	effector	T	cells
MLN cells from BALB/c mice were analyzed after 4 weeks of treatment with VSL#3. Cells were 
stained for CD3 and CD4, fixated and permeabilized prior to detection of intracellular IL-17 and IFN-γ. 
A representative FACS plot of cells stained for intracellular cytokines is shown in Figure 4A. IFN-γ+, IL-
17+ and Foxp3+ cells are depicted as a percentage of CD4+ cells in MLN and spleen (Figures 4B and 4C, 
respectively). Results are depicted as mean ± SD for 8 individual mice per group. Statistical significance 
compared to vehicle treated mice was calculated using the Mann-Whitney U test. *, p < 0.05; **, p < 0.01.
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Figure	5.	VSL#3	treatment	
has immediate effect on 
CD103+	DC
Single cells suspension of 
Peyer’s Patches and mesenteric 
lymph nodes were prepared 
from BALB/c mice, 18 hours 
after one single dosage of 
VSL#3 or after a treatment 
period of 4 weeks. Cells from 
untreated mice served as a 
control. Cells were analyzed 
by flowcytometry. F4/80+MF 
and CD11c+ DC are expressed 
as a percentage of CD45+ 
mononuclear cells. CD103+ DC 
are expressed as a percentage 
of the total CD11c+ population. 
Results of individual mice are 
shown. Mann-Whitney U test, * 
p < 0.05, ** p < 0.01.
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Discussion
In a previous study we showed that prophylactic treatment of mice with the probiotic 
supplement VSL#3 renders BALB/c mice resistant to the induction of colitis (30). Moreover, 
VSL#3 and various related Lactobacillus and Bifidobacteria species have been shown to 
alter phenotype, cytokine and chemokine release in both human and mouse DC (36, 37). 
We recently showed that VSL#3 inhibits LPS-induced activation of mouse and human 
DC especially by dampening the expression and secretion of chemokines (Mariman et 
al, submitted for publication). Modulation of chemokines by probiotics may thus result in 
a diminished recruitment of immune cells to the intestines under inflammatory conditions. 
Here, we show that this probiotic mixture also modulates immune cells in conditions of 
homeostasis.
The intestinal microbiota contributes to the development of the immune system, and 
conversely, the immune system influences the composition of the microbiota (38, 39). Paneth 
cell derived defensins, innate antimicrobial peptides that contribute to the mucosal host 
defense, play a role in this respect by affecting the composition of the intestinal bacterial 
microbiota (40, 41).
We observed that BALB/c and C57BL/6 mice differed with respect to gene expression in 
colon and small intestine; differentially expressed genes comprised genes related to immune 
regulation as well as anti-microbial peptides. These findings may not only be due to the 
genetic background and polarized immune response of these two mouse strains but also 
to a different composition of the intestinal microbiota of these mice. The assessment of the 
exact contribution of each of these phenomena therefore requires further studies in germfree 
animals.
Regardless of these differences in gene expression between the two mouse strains, we 
observed significant effects of treatment with VSL#3, with emphasis on immune-related 
processes. Whereas these effects in C57BL/6 could not be linked to a defined immunological 
process, treatment of BALB/c mice with VSL#3 showed up-regulation of Il12rb1, Ccr5, Cxcr3 
and Cxcl10 and down-regulation of Il13 and Epx. This suggest a shift from a Th2 to a Th1 
phenotype in BALB/c mice. These data therefore suggest that probiotic treatment may be 
favorable to control immune responses under polarized conditions.
To verify the effects of probiotic treatment at the level of innate and adaptive immune cells 
we evaluated such cells in PP, MLN and spleen. Irrespective of the mouse strain studied, 
the number of CD19+ B lymphocytes in the PP and MLN were significantly increased after 
long term administration of VSL#3. Most B cells in the intestine are plasma cells that secrete 
IgA into the lumen (38, 42). IgA is a predominant immunoglobulin in mucosal secretions 
which serves as a first line of humoral defense at all mucosal surfaces, where binding of 
IgA to microorganisms reduces their motility and adhesive properties within the mucosal 
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lumen and its surface (43). Previous studies linked beneficial effects of specific Lactobacillus 
species to increased CD19+ B lymphocytes in the ileal mucosa (44) and increased levels of 
IgA-producing cells in the lamina propria (45, 46). Therefore, it is tempting to speculate that 
increased B cell frequencies observed in our study contribute to the beneficial effects of 
VSL#3 via IgA-mediated mechanisms.
Interestingly, prolonged treatment of BALB/c mice with VSL#3 also resulted in an increase 
of CD4+CD25+Foxp3+ T reg cells locally in the MLN, but not in the spleen. It has been shown 
that the induction of CD4+CD25+Foxp3+
 T reg cells in MLN depends on CD103+ DC in the lamina propria (34, 35). Therefore, our 
observation that this CD103+CD11c+ DC subset increased in the PP and MLN of BALB/c 
mice, 18 hours after the first treatment with VSL#3, may explain the increased numbers of T 
reg cells we found at a later stage in the MLN.
On the other hand, the increase of T reg cells and Th17 cells in MLN may in part be due to 
migration from the intestine, in view of the decreased expression of Foxp3 and Il17a in the 
colon.
Recently, we demonstrated by transcriptome profiling of colons that inflammation in the 
recurrent TNBS colitis model is mediated by a gradual involvement of mast cells (47) and T 
cells immune processes that are suppressed by treatment with VSL#3 (30). Collectively, our 
data suggest that VSL#3 treatment has favorable effects in this model by modulating local 
inflammation through the induction of T reg cells.
The variation between the two mouse strains under investigation i.e. BALB/c versus 
C57BL/6, was more profound than the effect of the intervention by VSL#3. This is in line with 
observations in human subjects, where duodenal biopsies were taken before and after intake 
of a probiotic supplement (48). In this study, transcriptome profiles clustered per person and 
not per intervention, showing that person-to-person variation in gene expression was the 
largest determinant of differences between the transcriptomes. Our present data in BALB/c 
and C57BL/6 mice substantiate these observations. Therefore, a full appreciation of the 
health benefits of probiotic bacteria with emphasis on translational value should take both 
genetic and microbial factors into account. 
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The microbiota present in the gastrointestinal (GI)-tract has a fundamental role in the 
maintenance of host homeostasis [1]. Host-microbiota interactions are of critical importance 
for tissue formation, metabolism, and the development and function of innate and adaptive 
immunity [2]. Shifts in the composition of the microbiota induced by improved hygiene, 
antibiotic treatment, dietary changes or (invasive) pathogens can perturb immune-regulatory 
networks [3]. Due to these environmental changes many individuals in industrialized 
countries are no longer exposed to the microbiota of our evolutionary past [4]. The rapid 
increase in prevalence of immune mediated disorders - autoimmune diseases, inflammatory 
bowel disease (IBD) [5,6] and allergies [7,8]- in western societies is thought to be mediated 
in part by disturbances in host-microbiota interactions [9]. Restoring immune homeostasis by 
modulating host-microbiota interactions with probiotic bacteria has been demonstrated to be 
effective in chronic intestinal diseases and allergies [10,11]. Therefore, a better understanding 
of the mode of action of probiotics may help to advance the development of nutritional and 
pharmaceutical intervention strategies that may help to reverse the current rise of immune-
related disorders. This thesis aimed to provide insight into the role of probiotic bacteria in the 
regulation of mucosal and systemic immune responses and contribution to suppression of 
inflammatory diseases. This thesis shows that probiotic bacteria have favorable effects in a 
model of IBD and provides evidence regarding the underlying mechanism.
Immune	regulation	in	Inflammatory	Bowel	Disease
IBD patients are currently treated with anti-inflammatory and immunosuppressive drugs, 
antibiotics, surgery and/or biologicals such as anti-TNF[12]. Monoclonal antibodies directed 
against TNFα have substantially improved therapy, although a considerable proportion 
of the patients is non-responder, develops neutralizing antibodies after prolonged use, or 
experiences serious side effects [13-16]. Classical immunosuppressive drugs and antibiotics 
have rather limited efficacy, and show adverse side effects. So there is a clear medical need 
to develop novel anti-inflammatory treatments for IBD patients; this may include the use of 
probiotic bacteria. Probiotics with potential health promoting effects could most probably be 
validated through the use of proper animal models.
One of the key issues with respect to animal models is their translational value for patients. 
Chapter 2 describes a model based on the previous published recurrent TNBS-induced colitis 
model [17,18]. We characterized the processes associated with the early stages of colitis by 
genome-wide transcriptome analysis of colon tissue. TNBS-induced colitis has originally 
been positioned as a model for Crohn’s disease (CD), based on histopathological features 
like transmural cellular infiltrations and local production of Th1/Th17 cytokines [19,20]. When 
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compared with recently published gene expression data from inflamed biopsies from ulcerative 
colitis (UC) [21] and CD [22] patients, the recurrent TNBS colitis model overlapped respectively 
18 and 16 percent. This overlap is comparable with other genome-wide transcription studies 
aimed to identify genes and biological processes affected in experimental colitis, i.e. acute 
TNBS colitis model in rats [23], murine DSS colitis [24], IL-10-/- colitis [25], and CD4CD45Rbhi 
T-cell transfer colitis [26].Yet, pathway analysis identified major processes important for IBD 
i.e. tissue morphogenesis, wound healing, immune/inflammatory response, cell adhesion 
and angiogenesis. The model therefore represents several aspects of mucosal inflammation 
in UC and CD patients. Indeed, expression of α-defensins and chemokines as well as the 
influx of macrophages, T-lymphocytes and mast cells in the intestinal mucosa represents 
aspects of mucosal infiltration in UC and CD. Moreover, local budesonide treatment, a 
corticosteroid used to treat IBD patients[27,28],partly reduced colitis features in this model.
A hallmark of chronic inflammatory intestinal disorders is the rapid recruitment of leucocytes, 
in particular T cells, to the site of inflammation [29]. Mediators that facilitate these processes 
include adhesion molecules and chemokines [30], and these were induced in the model 
particularly 2 days after each TNBS challenge. Recent studies indicate that targeting these 
molecules may be promising for the treatment of IBD [31-33]. Novel compounds evaluated in 
this respect include Natalizumab(anti-α4) [31,34,35], Vedolizumab (anti-β7 ) [36,37] , ISIS2302 
(anti-ICAM1) [38], and CCX282-B (anti-CCR9). However, targeting these leucocyte migration 
markers, which are not gut specific, may also raise safety issues [39]. Since the microbiota 
is involved in shaping the intestinal immune system, i.e. by targeting leucocytes and their 
migration mediators, modulating the microbiota might be a new treatment approach/ strategy 
in individuals susceptible for intestinal inflammation. The study described in chapter 3 shows 
that recurrent TNBS colitis model is sensitive to probiotic bacteria. Possible mechanisms 
underlying these beneficial effects will be discussed in the next paragraph.
Modulating	mucosal	immune	responses	by	probiotic	bacteria
To gain insight into the anti-inflammatory potential of probiotic bacteria the probiotic mixture 
VSL#3 versus a single strain-L.plantarum-, were evaluated by studying their effect on 
gene expression profiles in the colon. In contrast to studies with these probiotic bacteria 
in immune compromised mice such as the IL-10-/-[25]and T cell transferred Rag2-/- colitis 
model [40], our results in the recurrent TNBS colitis model reflect immune modulation in mice 
with a fully functional immune system. Probiotic treatment reduced colitis associated influx 
of T-lymphocytes, mast cells and macrophages. This was accompanied by suppression 
of chemokines like MCP-1,eotaxin-1, and eotaxin-2. These chemo-attractants have been 
implicated in the recruitment of a variety of innate and adaptive immune cells [30,41] and 
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can be produced by intestinal epithelial cells or innate immune cells in the colonic mucosa. 
Therefore, it is tempting to speculate that probiotics ameliorate experimental colitis in this 
model by interfering with these chemokine-secreting cells which consequently results in 
reduced influx of inflammatory cells.
The induction of regulatory T cells (Treg) represents another potential mechanism by which 
oral administration of VSL#3 may render mice resistant to TNBS induced colitis. As described 
in chapter 7, prolonged administration of VSL#3 drives the induction of these FoxP3+Treg 
locally in the MLN of healthy BALB/c mice. Such cells have the capacity to migrate from a 
secondary lymphoid organ like the MLN to the inflamed mucosa and suppress T effector cell 
responses [42].
In IBD, dysregulated T cell responses perpetuate the disease and the vicious cycle of chronic 
inflammation [43]. It is unknown whether overabundance of T effector cell responses in IBD 
are the result of reduced numbers of Treg, dysfunction of Treg or resistance of T effector cells 
for suppression. Apart from a small sub-population of IBD patients with reduced Treg activity 
caused by a mutation in FoxP3 [44,45], most IBD patients have normal numbers of these cells 
in the inflamed mucosa [46]. Some reports even show an increase in numbers of Treg cells 
during inflammation [47-49] possible as a compensation mechanism in an attempt to control 
inflammation. Since the induction of Treg by probiotic bacteria is considered as a mechanism 
by which they induce anti-inflammatory effects, prophylactic and therapeutic treatment 
may have different outcomes. Treg can prevent disease development in spontaneous and 
chemical induced colitis [50,51]. In immune-compromised mice, adoptive transfer of Treg 
has also been shown to be efficient in amelioration of an established inflammation [52]. 
In contrast to chemical-induced colitis models, were Treg lost their potency to suppress 
colitis when these cells were transferred to mice with established colitis [51]. This might 
be related to environmental factors, since Treg cells have reduced suppressive capacity 
if pro-inflammatory cytokines or co-stimulatory signals are present in the inflamed site as 
shown in various experimental models for autoimmune diseases. [53-55].This implicates that 
induction of Treg by probiotics could be effective in a prophylactic setting but would fail in 
IBD patients during periods of active inflammation. Although this is beyond the scope of 
this thesis, it would be interesting to evaluate the therapeutic potential of probiotics in the 
recurrent TNBS colitis model.
Modulation	of	cytokine	and	chemokines	release	by	probiotics
In chapters 3 and 7it is shown that probiotic bacteria modulate expression patterns 
of inflammatory mediators like cytokines and chemokines in vivo under conditions of 
inflammation and homeostasis. Probiotic bacteria have been shown to interact with innate 
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immune cells and intestinal epithelial cells via binding to pattern recognition receptors 
[56], thereby modulating inflammatory signaling pathways[57]. In chapter 5, in vitro studies 
with bone marrow derived dendritic cells (BM-DC)were employed to evaluate the effects 
on probiotics on the expression and release of these inflammatory mediators. Studies 
described in this chapter showed that immune modulating capacities of probiotics on DC 
depend on host genetics and the presence of other stimulatory signals. DC derived from 
the bone marrow of two polarized mouse strains i.e. C57BL/6 and BALB/c mice responded 
differently to ultrapure Toll-like receptor ligands that mimic microbe-associated molecular 
patterns(MAPS) on bacteria, fungi, and viruses. Host specific responses of BMDC stimulated 
with these ultrapure ligands that trigger one single receptor, underline the impact of genetic 
factors on MAMP responses in the gut, but underestimate the complex environment of 
the gut. DC in the lamina propria(LP) integrate signals simultaneously received from the 
commensal microbiota and (potential) pathogenic microorganisms. Moreover, during active 
intestinal inflammation that is often accompanied by impaired barrier function, intestinal DC 
are exposed to an enormous load of Gram-negative bacteria that reside in the lumen [58]. 
In chapter 5 it is shown that probiotic bacteria synergistically enhance the production of IL-
12p70 and IL-23 in DC from C57BL/6 mice induced by LPS (as a representative component 
of Gram-negative bacteria). Previous studies have shown that simultaneous activation of 
TRIF and MyD88 coupled TLR (by bacteria and/or pure ligands) induces a robust induction 
of IL-12p70 [59]. It is therefore tempting to speculate that Gram-positive probiotic bacteria 
may induce robust Th1 and Th17 responses in individuals with established inflammation. This 
implies a risk of probiotics use under these conditions, because steering the immune system 
towards a Th1/Th17 inflammatory response could be harmful to patients suffering from Th1/
Th17-mediated (autoimmune) disease such as CD.
Apart from this pro-inflammatory effect, probiotic bacteria induced anti-inflammatory 
effects with respect to chemokine expression and release. Irrespective of the mouse strain, 
VSL#3 and L .plantarum suppressed LPS induced up-regulation of CXCL-9 and CXCL-10. 
These chemokines target the CXCR3 chemokine receptor that is expressed on Th1 cells, 
CD8+ T cells and DC [60]. Both chemokines have been shown to play a role in a variety 
of autoimmune diseases and infectious diseases by recruitment of inflammatory cells to 
the site of inflammation [61-65]. Moreover, therapy with anti-CXCL-10 antibody reduced 
experimental colitis in IL-10-/- mice by interfering with recruitment of T effector cells [66,67]. 
Chapter 6 describes comparable in vitro studies with human monocyte derived DC. With the 
use of dedicated PCR arrays for cytokines and chemokines, the gene expression signature 
of human DC in response of LPS and VSL#3 was identified. This unbiased approach, not 
focusing on one single inflammatory mediator, identified a cluster of LPS-induced genes that 
was suppressed by VSL#3. Chemokines present in this cluster did not target a single receptor, 
but a diversity of chemokine receptors including CCR8, CCR1, CCR3, CCR7 and CXCR3. 
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Consequently, this reduced chemokine expression may potentially dampen attraction of a 
broad panel of immune cells including T cells, NK-cells, DC, B cells, eosinophils, basophils 
and mast cells [68]. In silico analysis of transcription factors appeared a powerful approach 
to identify a common regulator of LPS-induced genes that were blocked by probiotics. 
Transcription factor analysis could be used because a large panel of chemokines and 
cytokines was under investigation in this study. The majority of these inflammatory mediators 
was not affected by probiotic treatment and could therefore be used as a reference set. 
STAT-1 was predicted as a dominant driver of LPS-induced genes that were suppressed 
by VSL#3, which was confirmed by demonstrating that phosphorylation of this transcription 
factor was inhibited by probiotic bacteria. This suggests that VSL#3 can reduce production 
of specific chemo-attractants in vitro by selective inhibiting of STAT-1 induced transcription 
regulation. STAT-1 is relevant in intestinal disease, since STAT-1 deficiency reduced the 
intensity of spontaneous and chemical induced colitis [69,70]. Furthermore, a recent report 
showed that selective regulation of STAT-1 signaling in T-cells by fusaruside resulted in 
reduced production of pro-inflammatory cytokines and improved TNBS induced colitis [71].
Understanding how MAMPs present on probiotic bacteria modulate intracellular signaling 
induced by pathogenic bacteria could be helpful to identify mechanisms by which probiotics 
promote health in vivo. Accordingly, a better knowledge of the molecular mechanisms of 
induced signaling pathways could allow selection of probiotic strains with distinct properties, 
leading to more specific and efficacious therapeutic strategies in the prevention or treatment 
of allergic and autoimmune diseases.
Probiotics	modulate	immune	responses	outside	the	gut
Commensal bacteria influence local immune responses in the gastrointestinal mucosa 
under inflammatory and homeostatic conditions[10]. However, immune modulation by the 
GI-microbiota is not restricted to the intestine and may influence immune responses in 
peripheral tissues as well [8]. Epidemiological studies found strong correlations between 
altered fecal microbiota and atopic diseases. Atopic diseases, such as asthma and AD are 
the result of an inflammatory reaction triggered by a Th2 cell mediated immune response.
In chapter 4,it is shown that there is an association between gut inflammation and atopic 
dermatitis (AD) in human ApoC1+/+ transgenic mice. Interestingly, transcriptome profiling of 
the colon further indicated that these mice have reduced intestinal chemokines and cytokines 
that are associated with Th1 immune responses along with increased allergic markers like 
IgE+ and FcεRI+ cells, suggesting a Th2 driven inflammation in the intestine.
Recent evidence shows that the commensal microbiota programs many aspects of the 
adaptive immune system, including T cell responses [75]. Environmental changes such as 
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antibiotics, diet and infant feeding regimes have been shown to influence the composition 
of the microbiota [76-79]. It is hypothesized that these changes in the gastrointestinal 
microbiome composition contribute to the increase in prevalence of immune mediated 
disorders. Studies in experimental models for rheumatic arthritis [80], experimental 
autoimmune encephalomyelitis [81]and various animal colitis models demonstrate that the 
commensal microbiota contributes to autoimmune and allergic disorders at sites distal to 
the intestinal mucosa[82]. Exacerbation of arthritis and EAE is likely the consequence of 
pathogenic Th17 cells that traffic out the LP to their target tissue [80,81,83]. Other studies 
also indicate that T-cell activation in the intestinal mucosa by microorganisms influences 
systemic immunity[75]. For example B. fragilis PSA affects the nature of systemic T cell 
responses evident from increased circulating Th1 cells in mice colonized with this bacterial 
strain[84].Likewise, it has been shown that Clostridium IV and XIV in the GI-tract not only 
induce expansion of Treg in the LP, but also in the periphery[85,86].
Interestingly, oral administration of L. plantarum result in amelioration of skin pathology in the 
human ApoC1+/+ transgenic mice model for atopic dermatitis (AD) as shown in chapter 4. This 
might be due to the induction of local inflammatory responses by this specific L. plantarum 
strain as observed in an ex vivo study employing human colon explants [87]. Moreover, oral 
administration of this lactobacillus strain to healthy mice increased the frequency of IFN-γ 
positive T cells locally in the mesenteric lymph nodes, as well as in peripheral immune tissue 
like the spleen [88]. The beneficial effect of probiotics intervention in this mouse model was 
not limited to the skin. L. plantarum also reduced the number of mast cells in the intestinal 
mucosa. Therefore, it is tempting to speculate that L. plantarum exerts the beneficial effect 
in this mouse model for AD by balancing Th1/ Th2 responses. Failure of the probiotic mixture 
VSL#3 in preventing skin pathology suggests that different strains may act differently in 
diverse pathological conditions. This implicates a careful selection of probiotic strains for 
therapeutic use is required, based on the type of inflammation.
Concluding	remarks
A better understanding of host-microbiota interactions in the pathogenesis of (auto)-immune 
and infectious diseases may contribute to new treatments of inflammatory diseases. 
Manipulating the enteric microbiota with fecal microbiota transplantation and probiotics 
might have great potential for treating IBD[89-91]. However, to fully benefit from the potential 
of such strategies deeper understanding of the immune-modulating mechanisms of these 
interventions is required.
We and others have shown that oral administration of specific probiotic strains reduce the 
severity of intestinal inflammation and atopic dermatitis in experimental animal models. 
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However, to improve the application of probiotics in healthy and diseased individuals it is 
important to define the proper probiotic bacterial strains for a specific therapeutic application. 
In addition, we showed in chapter 4 and 7 that effects of probiotics on immune related gene 
expression in the intestine largely depend on host genetics. This is in line with clinical studies, 
where human biopsies from healthy volunteers taken before and after probiotic intervention 
also showed large intra-individual differences in their response to probiotics. Therefore, 
it seems doubtful that all individuals experience similar physiological benefits of a certain 
probiotic strain. Current probiotics have not been selected for specific treatment purposes 
but they rather are “all purpose” probiotics. The development of a new generation of probiotic 
strains for disease specific application therefore may benefit from detailed knowledge of 
their immune modulating properties. Design of probiotic therapies should be based on 
the abnormalities in the microbial composition, the underlying genetic defect and desired 
biological response.
Due to their long history of use in food formation, the FDA has designated most probiotics to 
be generally recognized as safe (GRAS-status). However, it should be noted that a concern 
regarding the safety of using probiotics has recently been raised due to increased risk of 
mortality in patients with severe acute pancreatitis [92]. We showed that the involvement 
of other immune activating signals could also affect the innate immune responses towards 
probiotics. This implicates that patients with an established intestinal inflammation may 
respond differentially to probiotic intervention than healthy individuals. Consequently, it will 
be necessary to monitor safety issues when probiotics are used to treat IBD patients.
In conclusion, it was shown that immune-modulating properties of probiotic bacteria are 
strain specific and depend on host genetics and environmental factors. This illustrates the 
likelihood that personalized probiotic therapies for individuals should be designed, that are 
based on host genetic polymorphism and the desired biological response rather than non-
discriminating heterogeneous patients with a single approach. Improved knowledge about 
the working mechanisms of probiotics will contribute to proper strain selection for a specific 
prophylactic or therapeutic application, ultimately leading to more personalized medicine.
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Alle verschillende micro-organismen in onze darm, worden samen het “darm-microbioom” 
genoemd. Het aantal bacteriën in onze darmen is meer dan 10 keer zo groot dan het totale 
aantal cellen in het menselijk lichaam. Het darm-microbioom beïnvloed diverse processen in 
de gastheer waaronder fysiologische en immunologische processen.
Veranderingen in de samenstelling van het darm-microbioom in onze huidige samenleving 
kunnen worden veroorzaakt door een verbeterende hygiëne, het gebruikt van antibiotica 
en een veranderd dieet. Door deze veranderingen in onze leefomgeving worden we niet 
langer blootgesteld aan hetzelfde microbioom als onze voorouders. Er wordt gesteld dat 
de toename van diverse immuun gerelateerd ziekten, waaronder auto-immuun ziekten, 
chronische darmontsteking (IBD) en allergieën deels wordt veroorzaak door de verstoring 
van de interacties tussen de gastheer en het microbioom. Het herstellen van de balans in 
het immuunsysteem door het moduleren van deze interactie tussengastheer en microbioom 
door middel van probiotische bacteriën is effectief gebleken in de behandeling van Colitis 
ulcerosaen allergieën. Probiotica zijn door de Wereldgezondheidsorganisatie gedefinieerd 
als “Levende micro-organismen, die wanneer in voldoende hoeveelheden toegediend, een 
gunstig effect hebben op de gastheer”.
In dit proefschrift is gepoogd een beter inzicht te krijgen in de rol van microbioom-gastheer 
interacties in de regulering van het immuun systeem.
In hoofdstuk 2 wordt een muismodel voor IBD geïntroduceerd, het zogenaamde TNBS-
colitis model. Door in de tijd te kijken naar het expressieprofiel van meer dan 27.000 genen 
zijn onderliggende pathologische processen in dit colitis model gekarakteriseerd. 
Hieruit bleek dat dit model wordt gekenmerkt door zowel acute ontsteking als chronisch 
processen van celinfiltratie, angiogenese en fibrose, welke allen relevant zijn voor humane 
pathologie. Daarnaast is ook aangetoond dat immuun-suppressieve medicijnen de ernst van 
dedarmontsteking verminderen, wat het model geschikt maakt voor het testen en ontwikkelen 
van nieuwe medicijnen.
In hoofdstuk 3 is dit in vivomodel gebruikt om te evalueren of probiotische bacteriën een 
gunstig effect hebben op ontsteking in de darm. Muizen behandeld met de probiotsche 
stam Lactobacillusplantarumof de commercieel beschikbare mix van probiotische bacteriën 
VSL#3 waren deels beschermd tegen de inductie van ziekte. Een mogelijk verklaring voor 
dit gunstige effect is gelegen in het feit dat VSL#3 de gen-expressie van chemokines- 
signaalstoffen verantwoordelijk voor de rekrutering van immuuncellen - onderdrukt.
Diverse studies met proefdieren tonen aan dat voeding met probiotische bacteriën een 
allergische reactie in de huid kan verminderen. Daarom is in hoofdstuk 4 gekeken naar de 
relatie tussen immunologische processen in de darm en de huid. Hiervoor zijn transgene 
ApoC1 muizen gekozen, die in de huid spontaan atopische dermatitis (atopisch eczeem) 
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ontwikkelen. In vergelijking met normale muizen hebben deze transgene muizen in de dikke 
darm meer Mest-cellen en een verhoogd aantal cellen die de allergische markers IgE en 
FcεRI+ tot expressie brengen. Toediening van de probiotische stam Lactobacillus plantarum 
verlaagde het aantal Mest-cellen in de dikke darm en verminderde de symptomen van 
atopische dermatitis. Dit suggereert dat beïnvloeding van het immuun systeem in de darm 
kan bijdragen aan het onderdrukken van atopische dermatitis in de huid.
Om meer inzicht te krijgen in de manier waarop probiotische bacteriën het immuun-
systeem beïnvloeden is gebruikt gemaakt van celkweek systemen met dendritische 
cellen. Deze dendritische cellen zijn onderdeel van het aangeboren immuunsysteem en 
herkennen bacteriën, virussen en andere micro-organismen via speciale receptoren op het 
celoppervlak. Door het opnemen en presenteren van antigenen dirigeren ze het adaptieve 
immuunsysteem waaronder T-cellen. Hoofdstuk 5 worden studies met dendritische cellen 
uit muizen beschreven. Deze laten zien dat de probiotische mix VSL#3 zowel pro- and anti-
inflammatoire eigenschappen kan hebben op dendritische cellen, en dat de genetische 
achtergrond van de gastheer hierin een belangrijke rol speelt. Vergelijkbare studies met 
dendrische cellen van humane origine, gepresenteerd in hoofdstuk 6, tonen dat deze 
effecten gevonden in de muis vertaalbaar zijn naar zijn de mens. In deze studie werd verder 
aangetoond dat de probiotische mix VSL#3 de fosforyleringvan STAT-1 blokkeert, waardoor 
de productie van specifieke groep chemokines wordt geremd.
Concluderend, in dit proefschrift werd aangetoond dat het effect van probiotica op het 
immuunsysteem afhankelijk is van zowel de probiotische stam, het genotype van de 
gastheer alsmedeomgevingsfactoren. Dit impliceert dat voor een succesvolle toepassing van 
probiotica in de kliniek rekening dient te worden gehouden met de genetische achtergrond 
van de gastheer en de gewenste immunologische verandering. Uiteindelijk zal een verbeterd 
inzicht in de interactie tussen probiotische bacteriën en gastheer kunnen leiden tot de 
selectie van de juiste probiotische stam(men)voor specifieke profylactischeentherapeutische 
toepassingen.
Mariman.indd   143 21-2-2014   10:02:22
Mariman.indd   144 21-2-2014   10:02:22
Curriculum Vitae  |  145 
Curriculum Vitae
Rob Mariman werd geboren op 22 december 1983 in Tilburg. In 2002 behaalde hij zijn VWO 
diploma (profiel Natuur & Techniek en Natuur & Gezondheid) aan het Theresia Lyceum in 
Tilburg. Vervolgens startte hij in september 2002 met de studie Life Science and Technology 
aan de Technische Universiteit Delft en de Universiteit van Leiden.
In het kader van zijn Masteronderzoek voerde hij zijn eerste onderzoeksstage uit in het 
laboratorium van dr. E. Vreugdenhil aan het Leiden Amsterdam Centre for drug Research. 
Hier deed hij onderzoek naar de rol van microRNAs op de expressie van de glucocorticoïde 
receptor in de hersenen. Ter afsluiting van zijn Master deed hij een bedrijfsstage bij Chiral 
Vision BV, gericht op de toepassing van enzymen in de organische synthese. Na het voltooien 
van deze stage behaalde hij zijn Master diploma cum laude.
Na zijn afstuderen werd Rob in september 2008 aangesteld als promovendus bij de afdeling 
Immunohematologie en Bloedtransfusie van het LUMC. Voor zijn promotie onderzoek 
werd hij gedetacheerd op de afdeling Metabolic Health Research van TNO in Leiden onder 
supervisie van Dr. L. Nagelkerken. Het promotie onderzoek, waarvan de resultaten zijn 
beschreven in dit proefschrift, heeft hij afgerond in 2013.
Momenteel is Rob aangesteld als post-doctoraal onderzoeker aan de vakgroep Animal 
Genomics aan de Universiteit van Luik, waar hij onderzoek doet naar de rol van microbiota 
bij het ontstaan van de ziekte van Crohn.
Publications
– Mariman R, Kremer B, Koning F, Nagelkerken L. Dualistic nature of probiotic 
bacteria:	 identification	of	concomitant	pro-	and	anti-inflammatory	effects	on	
mouse dendritic cells. (submitted)
– Mariman R, Reefman E, Persoon-Deen C, Koning F, Nagelkerken L. Probiotics 
modulate	 intestinal	 mast	 cells	 and	 atopic	 dermatitis	 in	 human	 ApoC1+/+	
transgenic	mice.	(submitted)
– Mariman R, Kremer B, Koning F, Nagelkerken L. Probiotics	dampen	TLR-4	mediated	
activation	of	human	dendritic	cells	by	 inhibition	of	STAT-1	phosphorylation.	
(submitted)
Mariman.indd   145 21-2-2014   10:02:22
146  |  Curriculum Vitae
– Kremer B, Mariman R, Koning F, Nagelkerken L. Temporal	colonic	gene	expression	
profiling	in	the	recurrent	colitis	model	identifies	early	and	chronic	inflammatory	
processes. PLoS One 2012, 7(11): e50388.
– Liang W, Tonini G, Mulder P, Kelder T, van Erk M, van den Hoek AM, Mariman R, 
Wielinga PY, Baccini M, Kooistra T, Biggeri A, Kleemann R. Coordinated and 
interactive	expression	of	genes	of	lipid	metabolism	and	inflammation	in	adipose	
tissue	and	liver	during	metabolic	overload.	PLoS One 2013, 25;8(9):e75290.
– Mariman R, Kremer B, van Erk M, Lagerweij T, Koning F, Nagelkerken L. Gene 
expression	 profiling	 identifies	 mechanisms	 of	 protection	 to	 recurrent	
trinitrobenzene	sulfonic	acid	colitis	mediated	by	probiotics.	Inflamm Bowel Dis. 
2012, 18(8):1424-33
– Vreugdenhil E, Verissimo C, Mariman R, Kamphuis J, Barbosa J, Champagne D, 
Meijer O, de Kloet ER, Fitzsimons C. MicroRNA	18	and	124a	down-regulate	the	
glucocorticoid	receptor:	implications	for	glucocorticoid	responsiveness	in	the	
brain. Endocrinology 2009, (5):2220-8.
Mariman.indd   146 21-2-2014   10:02:22
Dankwoord  |  147 
Dankwoord
Dan is het “boekje” dus eindelijk helemaal af, maar natuurlijk niet zonder dankwoord. Dit 
proefschrift en de bijbehorende publicaties zouden namelijk niet tot stand zijn gekomen 
zonder de hulp en inzet van vele mensen.
Beste Lex, ik ben je heel veel dank verschuldigd, niet in de laatste plaats met de hulp bij de 
afronding van de artikelen. Ik kijk terug op een leuke en leerzame periode, waarin je mij hebt 
geleerd de juiste vragen te stellen en de focus aan te brengen in het onderzoek.
Beste professor Koning, Frits, al hadden we niet dagelijks overleg over het onderzoek, ik heb 
je begeleiding en positieve instelling als zeer prettig ervaren, dank hiervoor.
Frans, jij hebt mij vanaf de eerste dag geïntroduceerd in het celkweek-werk en hebt mij 
geïnspireerd met je rust en passie voor het werk. Ik kijk met veel plezier terug op onze 
samenwerking, ook op de lange dagen die we hebben gemaakt tijdens de laatste in vivo 
experimenten.
Bas, ik heb veel van je geleerd en veel steun gehad bij het opzetten van mijn eerste studies. 
Bedankt voor je hulp en coaching de eerste jaren.
Tonny, toen ik in 2008 startte met mijn onderzoek had je al veel werk verzet met het 
opzetten van de diverse modellen. Dank hiervoor, en veel succes en plezier met je eigen 
promotieonderzoek waarmee je recentelijk bent gestart.
(Oud)-TNO collega’s van de afdeling Metabolic Health Research hartelijk dank voor de 
samenwerking en de goede werksfeer. Frits en Nico, bedankt voor de gezellige sfeer op de 
kamer in het eerste jaar. Angela, Sabine, Nicole, Wendy en Koen, zonder jullie deskundige 
hulp had ik mijn dierexperimenten niet kunnen uitvoeren. Carla, je hebt mij enorm geholpen 
met je histologische kennis. Marjan, bij TNO in Zeist heb jij mij wegwijs gemaakt in het 
analyseren van microarray data. Kennis waarvan ik tijdens mijn AIO-schap, maar ook in 
mijn huidige baan, nog steeds de vruchten pluk. Teake en Reinout, de discussies over 
wetenschap die we hebben gevoerd in de koffiehoek worden zeker gewaardeerd. Elsbet, 
hartelijk dank voor je hulp met de cholesterolmeting en voor de 1001 andere dingen waarbij 
je als duizendpoot hebt geholpen. Erik, jij zorgde voor de nodige ontspanning en beweging 
op de tennisbaan op de vrijdagmiddag en de zomeravonden. Pascalle, Kirsty, Susanna, 
Marjolein en Renate, dank voor alle goede zorgen voor mijn muizen. Angela, Sabine, Nicole, 
Mariman.indd   147 21-2-2014   10:02:22
148  |  Dankwoord
Herma, Wendy en Koen, zonder jullie deskundige hulp had ik mijn dierexperimenten niet 
kunnen uitvoeren.
Ook de AIO’s op “De” AIO-kamer wil ik bedanken. Lobke, van begin tot eind ben je een 
luisterend oor geweest en heb je achter mijn broek aan gezeten wanneer dat nodig was. 
Susan, ik heb altijd met veel plezier naar je Zuid-Afrikaans accent geluisterd en ik wens je 
heel veel succes met het afronden van je eigen proefschrift. Lob, Suus, ik vind het top dat 
jullie mijn paranimfen willen zijn! Wen, thanks for introducing me to the Chinese cuisine, 
especially the hotpot.
En natuurlijk wil ik mijn (fiets)-vrienden noemen. Fietsend door de polder en bergen waren 
voor mij de momenten waarop ik het hoofd kon leegmaken en ontspannen, wat uiteindelijke 
heeft geleid tot betere prestaties.
Papa en mama, ik wil jullie speciaal bedanken voor alle steun de afgelopen jaren. Bij jullie 
vind ik altijd een veilige thuishaven.
Lieve Petra, jij bent met stip mijn beste herinnering aan TNO. Jij bent de reden dat ik nog zo 
vaak in mijn oude huisje in Leiden ben. Ik ben gek op je!
Mariman.indd   148 21-2-2014   10:02:22
